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In spite of the advances made since the description of willow bark to induce pain relief by 
Hippocrates in ancient Greece, many millions worldwide today still su(er from untreated 
pain. (Verhaak et al., =))>; Dureja et al., :?=@; Breivik et al., :??A) Chronic pain has a 
negative inBuence on an individual’s wellbeing and may be associated with psychiatric 
disorders including mood disorders and anxiety disorders (Tsang et al., :??>). (Racine, 
:?=>) The unmet medical need pushes clinical drug development for the treatment of 
pain into two directions. The 'rst direction is the development of new compounds, which 
can be further subdivided into re'nements of existing and 'rst-in-class compounds. 
This direction is quite rare – especially completely novel concepts – illustrating the 
many challenges that are faced in the development of a novel pain therapy. The second 
direction is to repurpose already marketed pharmacological agents. Some eminent 
examples are the antihypertensive clonidine, the anticonvulsant pregabalin, and the 
tricyclic antidepressant amitriptyline. These two potential avenues in analgesic drug 
development illustrate the spectrum of potential pharmacological targets to treat pain: 
from highly speci'c sodium channels exclusive for the nociceptive system, to largely 
serendipitous e(ects of serotonin and norepinephrine re-uptake blockage and Gamma-
Aminobutyric acid (%898) modulation. This extensive assortment of potential targets 
throughout the central and peripheral nervous system provides many opportunities, but 
is also a peril in 'nding new e(ective and safe treatments against chronic pain. 
Nociception versus pain 
Pain serves an evolutionary purpose as the body’s warning system for any potential 
physical threat. Since the threat of injury may require anticipatory or immediate 
conscious actions, the system is inherently connected to a(ect and cognition. This 
results in di(erent dimensions of pain to be distinguished. The pain cascade is initiated 
within the nociceptive system. 
In =AA@, René Descartes laid the foundation for a mechanical approach to a specialised 
pain system in humans, which was further developed in the nineteenth century as a 
distinct sensory system responding to high intensity sensory input. In the twentieth 
century understanding of the pain system deepened with the introduction of functional 
neurophysiological and neuroimaging techniques including evoked potentials, fCD$ and 
/",. 
This physiological nociceptive mechanism is de'ned by the transduction of a noxious 
signal at the peripheral sensory nerve terminal, generating an action potential after the 
activation threshold is reached. This signal is subsequently transmitted via nociceptors, 
of which there are two main subtypes. Myelinated Aɷ 'bres transmit signals fast and 
respond to weaker stimuli. The unmyelinated C 'bres respond to stimuli of stronger 
intensity and provide slower longer lasting signalling. 
The nociceptive signal is transmitted onto the dorsal horn of the spinal cord where 
the peripheral nerve a(erent synapses into a dorsal horn neuron. From here the signal 
can be transmitted higher up to the central nervous system. At this level, many di(erent 
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neurotransmitters have been identi'ed and implicated to play a role in modulation of 
the action potential; these include excitatory (glutamate) and inhibitory (%898 , glycine) 
neurotransmitters, neuro-active peptides (e.g. Substance P, Calcitonin gene-related 
peptide [.%D/], nociceptin), opioid peptides (enkephalins and dynorphins), and various 
other biogenic amines (serotonin, dopamine, norepinephrine, acetylcholine, 8,/, nitric 
oxide, etc). 
Depending on which type of nociceptor is activated, the pain signal is then transmitted 
supraspinally, predominantly via the ascending pathways in the spinoreticular and 
spinothalamic tracts. These project into the medulla, brain stem, periaqueductal 
grey (/8%) and thalamus; structures that are involved in modulation of nociceptive 
transmission. 
Within the nociceptive system there are two modulatory mechanisms involved 
in transmission, facilitation and inhibition, which are in equilibrium in the healthy 
state. Where facilitation is crucial for early and anticipatory detection of pain signals, 
regulation through descending inhibition is as important for an adaptive sensory system. 
The theoretical framework for this modulatory system was proposed in =)== (Head and 
Holmes, =)==) and experimentally con'rmed in the following years. This framework was 
expanded with the theory of gate control, approximately half a century later. (Melzack 
and Wall, =)A<) Brain regions that have been identi'ed to play a role in pain modulation 
are highly inter-related with the cognitive-a(ective dimensions of pain perception, 
which comprise for example the /8%, amygdala, hypothalamus, components of the 
anterior cingulate cortex, the insula and orbito frontal the dorsolateral prefrontal cortex.
The aggregate of signalling within the sensory-discriminative and cognitive- 
a(ective systems results in pain perception: the subjective experience of becoming 
aware of a signal from the nociceptive system. It is the culmination of sensory and 
emotional input, and involves di(erent cognitive aspects including casual attribution, 
appraisal, attention, context-speci'c meaning making, memory, etc. It is dependent not 
only on factors within the human body, but also on external factors including culture, 
upbringing, situation and numerous other factors.
Clearly, this unpleasant sensation is the most relevant aspect of the entire cascade 
for an individual patient, yet it is the most elusive. 
Pain as symptom or as disease
There is a clear distinction between acute and chronic pain. Where acute pain is typically 
a symptom of an underlying pathophysiological source, chronic pain can to some degree 
be considered to be the disease itself. (Treede et al., :?=)) Chronic pain persists for 
more than six months and results from a dysregulation within the nociceptive system. 
The International Association for the Study of Pain has classi'ed chronic pain for the 
International Classi'cation of Diseases ($.!-==) as a disease or symptom with either 
chronic primary pain syndromes (e.g. 'bromyalgia, complex regional pain syndromes, 
irritable bowel syndromes, non-speci'c low-back pain, chronic migraine), or chronic 
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secondary pain syndromes (cancer-related pain, posttraumatic pain, musculoskeletal 
and neuropathic pain). (Treede et al., :?=))
In the case of neuropathic pain, a lesion secondary to the primary illness develops 
within the nociceptive system. Dependent on the localisation and type of the lesion in 
the nervous system this may induce di(erent symptoms, which are either spontaneous 
(e.g. burning, cold, paraesthesia, hypoesthesia) or an extreme reaction to external 
stimuli. Sensitisation to evoked stimuli can result in the phenomena allodynia or 
hyperalgesia. Allodynia is the sensation of pain resulting from a low intensity stimulus 
due to hyperexcitability and lowered activation thresholds of the nociceptors, which in 
the healthy state would not induce pain. Hyperalgesia is a heightened pain sensation 
to a normally painful stimulus resulting from increased a(erent 'ring after activation of 
a nociceptor. This phenomenon transpires not only in the context of neuropathic pain 
but also during localised inBammation of dermal tissue, for example after sunburn. This 
is known as peripheral sensitisation and results in increased sensitivity to thermal and 
mechanical stimulation at the primary area of injury.
When the lesion within the nociceptive system is located at the level of the dorsal 
horn or higher, central sensitisation may occur. This may not only lead to sensitisation 
in the primary area, but also to referred pain or secondary hyperalgesia or allodynia, 
i.e. sensitisation in an una(ected area. The exact underlying mechanisms are not fully 
understood, but di(erent types of sensitisation occur. The activation thresholds to 
nociceptive a(erents decreases, but also their receptive 'eld increases to a level that 
even non-nociceptive (i.e. Aɴ mechanoreceptors) can activate a nociceptive pathway. 
In the healthy state this protective mechanism ensures that damaged tissue is actively 
protected. However, in the pathological state this may result in (extremely) painful 
sensation to light touch of large body surfaces. 
Precision pharmacology 
Due to its multifaceted character, the treatment of chronic and neuropathic pain is a 
prototype indication where precision pharmacology should be applied. This refers to 
both clinical practice at bedside but also to drug development at large. 
According to the Precision Medicine Initiative, precision medicine is “an emerging 
approach for disease treatment and prevention that takes into account individual 
variability in genes, environment, and lifestyle for each person.” (&$-) As a successor 
to “personalised medicine”, the term precision medicine describes the use of various 
factors to categorise patients into accurate subcategories, thereby enabling evidence-
based decision-making. Reversed, the failure to make the correct distinction between 
individual patients or groups of patients, may lead to errors in the selection of a treatment 
or treatment regimen. 
Precision pharmacology requires an integrated approach that combines mechanistic 
information and clinical pharmacology in order to address inter-individual variability and 
to de'ne subtypes where applicable.
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Complex pain demands complex treatment
In =)>A the World Health Organisation (E-F) introduced the analgesic stepladder 
for cancer pain. (E-F, =)>A) These recommendations have been the blueprint for 
the treatment of cancer pain but also other types of pain. The ladder that is proposed 
is a sequential list of di(erent types of therapies that can be used. If a drug in the 
recommended dose regimen is not e(ective, a drug from the next group should be 
administered. Adjuvant drugs may be used as described. If a drug ceases to be e(ective, 
an alternative that is de'nitely stronger should be used instead. The steps of the ladder 
are as follows:
! Non-opioids (e.g. aspirin, paracetamol, &#8$!#*
" Weak opioids (e.g. codeine, hydrocodone*, oxycodone*, tramadol*,)
# Strong opioids (e.g. morphine, buprenorphine, meperidine, hydromorphone, 
fentanyl, methadone, tapentadol) 
* Not introduced in the initial ladder in !"#$.
Each step may be accompanied with adjuvant treatment (e.g. anticonvulsants, 
anxiolytics, antidepressants, gabapentinoids, &C!8 receptor antagonists, steroids) 
Over time, this ladder, which was intended for terminally ill cancer patients, served as 
a standard to treat other persistent pains as well, even in the absence of evidence that 
this treatment is in fact reducing pain in the long term. For example, the e(ectiveness 
on quality of life of opioid therapy in the treatment of chronic pain is inconclusive (Noble 
et al., :?=?), even though the risks and reduction in quality of life associated with opioid 
use are widely known. Although the ladder provides valid guidance in the treatment 
of acute and end of life pains, this is not necessarily the case for chronic pain, due to 
its unpredictable and capricious disease course. Neuroimaging studies have con'rmed 
the clinical observation that in chroni'cation of pain, plastic changes in cortical-limbic 
structures occur, inducing a shift from a somatosensorial experience to an a(ective 
experience. (Mansour et al., :?=@) These a(ective components express into altered 
mood, anxiety, stress and a subsequent reduction in quality of life and doubling of 
suicide risk. (Racine, :?=>) Consequently, the perception of pain, taking into account not 
only somatosensory but also the a(ective components, is the true target in the treatment 
of chronic pain. 
Developing treatment that targets pain perception 
The treatment of acute pain is characterised by symptom control, but chronic pain 
requires a more re'ned therapeutic approach. Due to the heterogeneity of chronic pain 
conditions and the abundance of potential pharmacological targets that involve most 
of the nervous system from peripheral nerves to higher brain centres, identifying new 
treatments that will be e(ective in large groups of di(erent patients is challenging. It 
has been argued that clinicians today are not much more advanced than they were :? 
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years ago, in their capacity to either e(ectively treat or even diagnose their patients. 
(Vardeh et al., :?=A) Apart from the hiatus in mechanistic understanding of underlying 
pathophysiology, the fact that the potential pharmacological targets are distributed 
throughout the entire nervous system creates a challenge in terms of the occurrence of 
undesirable e(ects resulting from either primary or secondary pharmacological action.
All these factors combined create the framework in which drug development for new 
therapies for chronic and neuropathic pain takes place. This is a complicated area where 
the chance of a “quick win” is minimal. However, given the disease burden of untreated 
and undertreated pain, there is a high need for e(ective analgesic drug development, for 
which the large diversity of targets provides ample opportunity. To treat pain perception, 
especially in the case of chronic neuropathic pain, it is crucial to approach the central 
nervous system in its totality. Although many peripheral causes of pain can be treated 
with single targeted pharmacological interventions, the most e(ective treatments 
for neuropathic pain do not target highly speci'c receptors, but aim to modulate the 
perception of pain at di(erent levels in the cascade. Central pain modulation is the focus 
of this thesis, which mainly deals with two of the most widely distributed targets in the 
central nervous system. Cannabinoid and %898ergic transmission plays an important 
role in pain perception, but also in many other .&# functions, warranting an integrated 
approach. We will now present these two neurotransmitter systems as potential targets 
for the treatment of neuropathic pain, and subsequently proceed with a description of 
methods to measure their diverse e(ects.
$%&&%'(&)(* +,$,-.)+/
The two most important cannabinoid (.9) receptors are .9G and .95. As .95 is 
predominantly found in the immune system, this thesis focuses on the .9G receptor, 
which is distributed throughout the nervous system. These G-protein coupled 
receptors (%/.D) are chieBy expressed in neurons, mostly presynaptical. They function 
in modulating the release of di(erent neurotransmitters including %898 , dopamine, 
noradrenaline, glutamate and serotonin. (Schlicker and Kathmann, :??=)
Anatomically, they are expressed in various brain regions: the cortex, basal 
ganglia, hippocampus, cerebellum, thalamus, amygdala, periaqueductal grey and 
medulla oblongata. Many of these regions are known to play a role in pain perception. 
Furthermore, .9G receptors are found spinally, primarily in the interneurons of the 
dorsal horn. (Mackie, :??<). These receptors have not only been identi'ed centrally, 
but are also expressed in the peripheral nervous system. (Hohmann and Herkenham, 
=))); Veress et al., :?=;) .9G receptors are abundantly present in the sympathetic nerve 
endings and the peripheral nociceptive nerve 'bres, mostly in the myelinated Aɷ 'bres, 
but also in a limited number of C 'bres. (Bridges et al., :??;)
Apart from the two principal endogenous ligands for the cannabinoid receptors, 
anandamide (8"8) and :-arachidonoylglycerol (5-8%), other endocannabinoids include 
noladin ether, virodhamine, and N-arachidonoyldopamine (&8!8). Unlike most other 
neurotransmitters, endocannabinoids are not stored in presynaptic vesicles, but are 
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synthesised and released from the cell membrane responding to physiological or 
pathological stimulation, including noxious stimuli. (Walker et al., :??:; De Petrocellis et 
al., :??@) The main psychoactive ingredient of Cannabis sativa, *)-tetrahydrocannabinol 
(*+-,-.) is the most widely known exogenous ligand for the .9G (and .95) receptors.
The .9G receptor does not only respond to di(erent endogenous ligands, but these 
ligands (8"8 and 5-8%) also have also been reported to interact with other receptors, in 
particular the Transient Receptor Potential (,D/) channel family, of which the ,D/HG is 
widely recognised for its role in (heat) pain sensation and regulation, and pathological 
pain states. (Ahluwalia et al., :??;)
As a result of its widespread distribution, the endocannabinoid system is associated 
with the regulation of a myriad of functions, e.g. learning, memory, mood, appetite, sleep, 
neuroprotection, gastrointestinal motility and pain perception. This wide spectrum of 
functions makes it an interesting and challenging opportunity for the treatment of various 
pathological states. Due to its undisputed association with pain and the modulation 
of pain sensation, this neurotransmitter system is of interest when developing new 
therapies for the treatment of chronic neuropathic pain. 
0%'% +,$,-.)+/
ɶ-Aminobutyric acid (%898) is the major inhibitory neurotransmitter in the Central 
Nervous System. Similar to the cannabinoid receptors, two receptor types have been 
identi'ed for %898 : %898A and %898B. %898A is a pentameric ionotropic receptor, 
mediating fast responses by opening chloride channels in the presence of %898 . 
Over :? combinations of the subunits ɲI-J, ɴλͲξ͕ɶλͲν͕ɷ͕ɸ͕ʍ have been identi'ed, named 
subtypes. This results in a high degree of heterogeneity among the functional e(ects 
exhibited by the di(erent subtypes. %898B, is a %/.D involved in slower cascades of 
second messenger systems. Activation of %898B receptors is associated with activation 
of adenylyl cyclase, opening potassium channels, and inhibiting calcium channels. 
%898 occurs in ;?-@?% of all synapses, and the speci'c types and subtypes of 
%898 receptors are distributed throughout the .&#. For example, the most prevalent 
%898A receptors in the brain consist of a combination of ɲI /ɲK /ɲL /ɲM, and ɴK /ɴL, and ɶI. 
There is only little overlap in localisation of speci'c subtypes, consequently subtypes 
are associated with speci'c neurophysiological functions. Apart from its abundant 
distribution in the brain, %898 receptors are also widely expressed in the spinal cord. 
The highest concentration is found in the dorsal grey and ventral grey matter. In the 
dorsal horn, both %898A receptors and %898B receptors are localised in the presynaptic 
interneurons. (Malcangio and Bowery, =))A) 
Behavioural and pharmacological investigations, ranging from in vitro to preclinical 
and clinical research, have assigned di(erent functional roles to the di(erent receptor 
subunits of %898A . For example, ɲ= agonism is mostly implicated with sedation and 
amnesia. The subtypes containing ɲ: and ɲ; have predominantly been associated 
with anxiolysis (Rudolph et al., =)))). In the last decade however, their role in the 
modulation of pain perception has also been established. (Knabl et al., :??>) Temporal 
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and special memory is processed among others in the hippocampus. Experiments have 
demonstrated that tonic inhibition of glutamatergic input via ɲ< regulates learning and 
memory. (Collinson et al., :??:b) When targeted with an agonist, the loss of inhibitory 
control results in a decrease in cognitive and memory performance.
Parallel to the endocannabinoid system, the %898 system is a comprehensive system 
involved in an extensive range of physiological functions. Based on this physiology, there 
are vast opportunities to intervene, when developing a treatment for neuropathic pain. 
However, both .9G and %898 are important for the 'ne-tuning of neuronal cellular and 
network connections. The challenge for the development of drugs that target these 
neurotransmitters for the treatment of chronic pain is therefore to prevent further 
disruption of any (impaired) balance in pain regulation. Since these pharmacological 
mechanisms play similar regulatory roles in other .&# functions, inhibition can easily 
lead to adverse e(ects. Consequently, cannabinoid or %898ergic drug development 
for chronic pain should always consider the impact on comprehensive pain processing, 
in conjunction with other neurophysiological or psychological systems. This thesis 
contains several chapters where integrated or combined measurements were used for 
dose selection and optimisation, applying multimodal batteries for pain – the PainCart® 
– and for drug-sensitive .&# functions – the NeuroCart®. 
Human evoked pain models as biomarkers for pain 
In the changing landscape of analgesic drug development, the blockbuster model is 
likely to come to an end. With a stronger emphasis on identifying subpopulations of those 
that are likely to respond well to treatment, and those with higher risk of adverse events, 
more e(ective treatments could be developed and potentially with a lower chance of 
failure. This approach is for example precedented in the 'eld of oncology. The concept 
that genotypical, phenotypical and mechanistic understanding is a prerequisite for the 
development of an e(ective therapy of one or more pharmacological interventions is 
now established, on account of the extensive e(orts made to understand underlying 
pathophysiology.
An indispensible feature of e(ective analgesic drug development is to gain 
mechanistic knowledge on the mode of action of the pharmacological agent at each 
step of development. This is the only way to gain true understanding of the drug’s 
pharmacology and the potential bene't and harm for the patient. This can be expected to 
lead to a more eNcient and cost-e(ective development trajectory. In order to implement 
this already in the early clinical phase of research, biomarkers play a crucial role. A 
biomarker is de'ned as “a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacological 
responses to a therapeutic intervention”. (BiomarkersDe'nitionsWorkingGroup, :??=). 
There is an inherent chasm between research in preclinical pain models of pain and 
a clinical, proof-of-concept study in patients with pain (Berge, :?==; Yekkirala et al.), 
strongly contributing to failed clinical trials at this stage.
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Incorporating biomarkers for pain in early phase clinical studies in healthy subjects and 
patients has the potential to bridge this gap to a certain extent. Given the complexity of 
the pathophysiology of pain, it is highly improbable that a single biomarker can represent 
pain in its totality. However, it is achievable to identify mechanism-speci'c biomarkers 
that are: consistent in their response to pharmacological intervention; respond to 
therapeutic doses; demonstrate a dose-response relationship; and are valid in the sense 
that they reBect a plausible relationship with the pathophysiology under investigation. 
These criteria are de'ned as imperative for the selection of a biomarker, in addition to 
validation including an assessment of its sensitivity. (Cohen et al., :?=<) In this light, a 
multi-modal approach, as applied in the battery of evoked pain tasks, referred to as the 
PainCart can play an important role in phase I clinical trials in healthy subjects. Even 
though the clinical presentation of a patient with chronic pain cannot be mimicked 
in any model, the battery of evoked pain tasks could provide valuable information on 
the mechanism of action of an analgesic compound under investigation. If aforesaid 
tool is utilised in a data-intensive phase I or IIa study, in conjunction with frequent 
pharmacokinetic and safety assessments, it is possible to obtain a comprehensive 
understanding of the human pharmacology of a new or already known compound. 
The value of this tool lies within the perception of the researcher or sponsor. Namely, 
where the limited resemblance between a highly heterogeneous chronic pain patient 
and evoking pain in a healthy volunteer in a controlled clinical research setting may be 
perceived as a constraint, it is actually a strong asset for early drug development. A few 
advantages for example are: homogenous study population, standardised stimulus 
modalities, controlled intensity and duration of painful stimuli, quantitative outcomes 
that can be compared over time. (Arendt-Nielsen et al., :??O) Therefore, this type of tool 
allows to thoroughly quantify speci'c elements of a system that is dysregulated in the 
pathophysiological state. 
Gaining information in clinical pharmacology early during clinical development of a 
pharmacological agent provides the context for decision-making in subsequent steps, 
but needs to be interpreted prudently with the correct context. 
Multimodal measurement of pain and central nervous system 
functions: PainCart® and NeuroCart®
Because many types of chronic pain ultimately lead to widespread dysregulations 
within the pain cascade, it is likely that drugs for these conditions will also have an 
impact throughout the central nervous system. To aid in the development of these 
drugs, integrated measurements of pain and other .&# functions should be used to 
determine the pro'le of desired and undesirable e(ects. This approach can help identify 
the optimal therapeutic window, as well as secondary pharmacological e(ects that can 
be used to treat concomitant conditions like insomnia or anxiety. To this end, the Centre 
for Human Drug Research (.-!D) developed two test batteries: the PainCart and the 
NeuroCart. 
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The PainCart is a test battery of human evoked pain tasks, which comprises di(erent 
tasks, associated with di(erent pain modalities. The individual pain tasks have been 
used extensively individually in clinical research. (Okkerse, :?=>) A set of complementary 
tasks has been combined and validated into a composite, multi-modal biomarker. The 
operational characteristics are described in this thesis and elsewhere. (Hay et al., :?=A) 
Initially, the PainCart consisted of four tasks, each targeting di(erent modalities of 
pain in di(erent tissues, localised at di(erent areas of the body. The following modalities 
were included: Pressure pain, Cold pain, Electrical pain and Heat pain. However, the 
test battery did not include a model for hyperalgesia, which is a common symptom of 
neuropathic pain. Therefore the literature review described in Chapter 1 of this thesis 
was performed to identify a model for hyperalgesia in humans that meets the criteria for 
biomarkers in early phase clinical research. 
.%'2, ! Overview of tasks and pharmacodynamics endpoints included in the PainCart® 
described in this thesis 
PainCart Task Endpoints
Cold Pressor (s) /!,, /,,, 8P., H8#
Electrical Stimulation (mA) /!,, /,,, 8P., H8#
./C: Electrical stimulation * (mA) /!,, /,,, 8P., H8#
Pressure Stimulation (kPa) /!,, /,,, 8P., H8#
Normal Heat (°C) /!,
PH9 Heat (°C) /!,
*(Di%erence Pre-Post Cold Pressor) / &'( - Pain Detection Threshold  / &(( - Pain Tolerance Threshold / 
)*+ - Area Under the Curve / ,)- - Post-test Visual Analogue Scale
The tasks in the PainCart are performed consecutively during a measurement round. 
Each measurement round is performed before administration of a treatment, and then 
multiple times after administration of a treatment (active or placebo). To account for 
bias resulting from inter-individual variability in pain reporting, a crossover design is 
recommended, as intra-individual variability is considerably lower. Variability from a(ects 
associated with fear of pain, is reduced by making the subjects themselves responsible 
for starting and ending each pain task. The risk of tissue damage is eliminated, as all pain 
tasks have a maximum safety cut-o(. 
The pain tasks in the battery are complementary in the sense that di(erent elements 
of the nociceptive system are stimulated, resulting in the perception of pain. The 
distinction between the pain tasks arises from various phases of the pain cascade. 
The most obvious di(erence is observed on the level of the peripheral sensory nerve 
endings. Each pain task activates the nociceptive system through a speci'c receptor.
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The Cold pressor task excites the nociceptive cascade through activation of the ,D/C6 
and ,D/8G receptors in the skin (Foulkes and Wood, :??O). Heat on the other hand is 
transduced into an action potential after exciting the ,D/HG receptor. Hyperalgesia, 
when induced for instance by PH9 or a thermode burn, results from a local inBammatory 
reaction in response to tissue damage. In this process, a broad array of inBammatory 
factors are released, including bradykinin, protons (H+), Nerve Growth Factor (&%0) 
and various others, that either modulate or directly activate ,D/HG and ,D/G channels. 
Apart from the peripheral sensitisation that ensues, microglia activated by .8#/2 can 
induce a spinal component to the observed hyperalgesia via sensitisation of nociceptor 
nerve terminals in the dorsal horn (Guan et al., :?=A). Consequently, the activation 
threshold of thermal and mechanical nociceptors decreases in the injured area, causing 
allodynia and hyperalgesia. (Gustor( et al., :??@) The Pressure pain task does not 
activate super'cial cutaneous mechanoreceptors, but reaches deeper high threshold 
mechanoreceptors in the muscle tissue. Muscle pain mainly originates from deep tissue 
group III and IV a(erents. (Graven-Nielsen et al., :??@) In contrast with the other pain 
tasks, the Electrical Pain task bypasses the peripheral receptors and directly stimulates 
the nociceptive nerve. 
.%'2, " Overview of tasks and pharmacodynamics endpoints included in the NeuroCart® 
described in this thesis
NeuroCart Task Endpoints 
Saccadic eye movement Saccadic Peak Velocity (deg/sec)
Smooth pursuit Proportion in smooth pursuit (%)
Adaptive tracking  Average performance (%)
Body sway Anteroposterior movement (mm)
H8# Bond and Lader H8# Alertness (mm)
H8# Mood (mm)
H8# Calmness (mm)
H8# Bowdle H8# Internal perception (mm)
H8# External perception (mm)
H8# ‘Feeling High’ (mm)
Visual Verbal Learning Test (HHQ,) Immediate recall: Number correct
Delayed recall: Number correct
Delayed recognition: Number correct




,)- = Visual Analogue Scale
!"#$%&'#$( '))$))*$"# +, "$-&+.+%"!#!/$, "$-&+012)!+3+%!.'3 '"( 0'!" 0&+.$))!"% !" $'&32 .3!"!.'3 (&-% ($/$3+0*$"# 18
The noxious stimulus is transduced into an action potential that is transmitted via 
nociceptive nerve 'bres. The Aɷ 'bres are responsible for the fast, immediate sensation 
of pain, whereas the C 'bres cause the more dull, prolonged sensation of pain. Aɷ 'bres 
are speci'c for thermal and mechanical stimulation, and C 'bres can also be polymodal. 
Cold pain is known to be mediated via speci'c subpopulations of Aɷ 'bres (Simone and 
Kajander, =))O) and C 'bres, (Campero et al., :??)). Heat pain is initially mediated via Aɷ 
'bres, but hyperalgesia resulting from the PH9 model is thought sensitise both Aɷ 'bres 
and C 'bres, both peripheral and centrally. (Neumann et al., =))A)
The NeuroCart, a multimodal cognitive and neurophysiological test battery, was 
also developed at .-!D. This test battery has been used extensively to characterise the 
speci'c, time- and dose-dependent, neurophysiological and/or neuropsychological 
e(ects of a compound, thereby con'rming whether the compound reaches its 
intended target in the central nervous system. (Groeneveld et al., :?=A) The NeuroCart 
consists of a diverse selection of validated tasks which provide information on various 
functional domains of the central nervous system and the e(ects of pharmacological 
agents thereon. In its full scope, the following functional domains are included in the 
NeuroCart: (visuo)motor coordination, alertness, memory, subjective drug e(ects and 
neurophysiological brain activity (electroencephalography). In this thesis, the test 
battery is limited to the tasks that have previously been demonstrated to be sensitive 
to cannabinoids and %898ergic compounds. Over the years, .-!D has gained 
extensive experience in assessing the pharmacodynamics of these agents with the 
NeuroCart.  
Cannabinoids were the topic of two .-!D dissertations. Lineke Zuurman examined 
a newly developed standardised mode of intrapulmonary administration of *+-,-., 
which was thoroughly investigated with the NeuroCart in healthy subjects. (Zuurman, 
:??>) These studies provided reliable pharmacokinetic-pharmacodynamic models for 
a range of concentration-dependent .&# e(ects, in particular postural instability and 
visual analogue scales for alertness (Bond& Lader) and psychomimetic e(ects (Bowdle), 
but not eye movements or adaptive tracking. In a subsequent thesis, Linda Klumpers 
used these method validations to quantify the inhibitory e(ects of a range of selective 
.9G-antagonists. (Klumpers, :?=@) Klumpers also published the 'rst results with a novel 
oral formulation of *+-,-. (Namisol®) in healthy volunteers. (Klumpers et al., :?=:) In 
the current thesis the e(ects of this compound are described in Chapters 3 and 4. 
Chapter ; describes a clinical trial in which an oral formulation of *+-,-. is investigated 
in a four-week, placebo-controlled, proof-of-concept trial in a population of patients 
with progressive (primary or secondary) multiple sclerosis, su(ering from spasticity in at 
least one of the lower limbs. Both objective and subjective endpoints for spasticity and 
pain, as well as objective and subjective endpoints for sedation and postural instability 
were included as endpoints to determine the eNcacy of the therapy in relation to its 
undesirable e(ects. The mode of action of *+-,-. in the treatment of pain is further 
characterised in healthy volunteers, as reported in Chapter 4. Here, the PainCart was 
utilised to determine the pharmacodynamic e(ects of an oral formulation of *+-,-. and 
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oral paracetamol, compared with placebo and the negative control promethazine. In 
conjunction with the pain tasks, subjective e(ects were measured using the NeuroCart. 
At .-!D, a considerable number of both nonselective and subtype-selective 
%898A modulators have been examined in healthy subjects, using the NeuroCart, 
several of which were described in the thesis by Xia Chen (:?=O). (Chen, :?=O). These 
studies consistently present a similar pattern in the pharmacodynamic e(ect pro'les 
of ɲ:/ɲ; subtype selective %898A receptor modulators. In these studies, the subtype 
selectivity was demonstrated by the presence of signi'cant treatment e(ects on 
tasks representative for speci'c %898A receptor subtypes compared with the 
pharmacodynamic e(ect pro'le of nonselective positive allosteric modulators of the 
%898A receptor. For example, a reduction in saccadic peak velocity (the primary endpoint 
in the task measuring saccadic eye movements) has been associated with modulation 
of the ɲ:/ɲ; subunits of the %898A receptor (Atack, :?=?), whereas performance on 
adaptive tracking, subjective alertness and postural instability (body sway) has been 
related to ɲ= modulation (de Haas et al., :?=?). Cognition and memory impairment 
as measured with the HHQ, have been shown to be associated with ɲ< modulation 
(Collinson et al., :??:a; Crestani et al., :??:). When the 'ndings of subtype selective 
%898A receptor modulators were compared with the non-selective benzodiazepine 
lorazepam, a distinct 'ngerprint was observed. Building on this knowledge, Chapter 5 
presents a First-in-Human study in which the e(ects of /0-12345627, a novel ɲ:/ɲ;/ɲ< 
subtype-select partial %898A positive allosteric modulator were characterised using the 
NeuroCart. Using an intricate study design, a wide dose range was explored as well as 
a head-to-head comparison of /0-12345627 alone and in combination with a positive 
control, lorazepam. 
Even though the %898A receptor system has been recognised for its role in the 
perception of pain, the clinical use of %898ergic therapies for the treatment of pain 
is very limited due to the sedative e(ects associated with their use. However, after 
establishing the clinical pharmacodynamic e(ect pro'le of /0-12345627, the analgesic 
potential also warrants further investigation. Due to its con'rmed selectivity for the 
ɲ:/ɲ;/ɲ< %898A receptor subtypes, /0-12345627 is a potential novel therapy in the 
treatment of (chronic) neuropathic pain, with a lower risk of sedation. This analgesic 
potential is investigated in Chapter 6 of this thesis. In this study, the PainCart was used 
to investigate the analgesic e(ect pro'le of two pharmacologically active dose levels of 
/0-12345627, in a crossover study in healthy subjects.
In this thesis, both biomarker test batteries, the NeuroCart and PainCart are used 
to characterise the pharmacodynamic e(ects in relation to pharmacokinetics and 
safety measurements of novel and well-known potential analgesic and psychoactive 
compounds. This approach allows to investigate and characterise potentially desirable 
and undesirable e(ects of a pharmacological agent in relation to its pharmacokinetic 
pro'le, in phase I or Phase IIa studies. This, in turn, may result in identifying an optimal 
dose at which undesirable e(ects, e.g. sedation, reduced memory performance, or 
subjective drug e(ects do not occur, but analgesia is present.
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%(8/ Human evoked pain models can be used to determine eNcacy of new and 
existing analgesics and to aid in the identi'cation of new targets. Aspects of neuropathic 
pain can be simulated by inducing hyperalgesia resulting from provoked sensitisation. 
This literature review aims to provide insight into the sensitivity of di(erent hyperalgesia 
and allodynia models to pharmacological treatment. 
8,.9)*/  A literature search was performed to identify randomised, double-
blind, placebo-controlled studies that included human hyperalgesia pain models and 
investigated the pharmacodynamic e(ect of di(erent classes of drugs.
+,/:2./ Three hyperalgesia models (PH9, capsaicin and burn) have been used 
most extensively. Assessment of hyperalgesia/allodynia and pharmacological e(ect 
is measured using challenge tests, which generally comprise of thermal (heat/cold) or 
mechanical stimulation (pin prick, stroking or impact). The PH9 model was sensitive to 
the antihyperalgesic e(ects of &#8$!# and opioids. The capsaicin model was somewhat 
sensitive to opioids. The burn model did not detect any antihyperalgesic e(ects when 
&#8$!# or local anaesthetics were administered, but responded to the e(ects of &C!8 
receptor antagonists by moderately reducing mechanical hyperalgesia.
$)&$2:/()&/ Based on pharmacological sensitivity, the PH9 model adequately 
reBects inBammatory pain and was sensitive to &#8$!# and opioids. Findings from the 
capsaicin and burn models raised questions about the translatability of these models 
to the treatment of neuropathic pain. There is a need for a reproducible and predictive 
model of neuropathic pain, either in healthy subjects or in patients.
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Chronic pain is highly prevalent, it is estimated to range between :?-;?% in Europe and the 
United States of America.I,K The nature of pain is complex as many di(erent physiological 
and psychological mechanisms are at play. Commonly, pain is classi'ed according 
to its supposed pathophysiology: nociceptive pain, neuropathic pain, psychogenic 
pain and mixed or unspeci'ed pain.L These di(er in terms of onset and expression: in 
general, nociceptive pain is associated with acute pain, whereas neuropathic pain is 
more frequently chronic in nature. Underlying mechanisms di(er greatly: nociceptive 
pain results from activation by a noxious stimulus of the nociceptive a(erents distributed 
throughout the body. Neuropathic pain has been de'ned as “Pain arising as a direct 
consequence of a lesion or disease a(ecting the somatosensory system”,R which results 
in sensitisation of the somatosensory system. Central sensitisation on the one hand 
results from an increased responsiveness of the neurons in the dorsal horn and thalamus 
(including nociceptive responses to the A-ɴ mechanoreceptors). Peripheral sensitisation 
on the other hand is the consequence of increased sensitivity of nociceptors, resulting 
from lower activation thresholds and increased responsiveness, often associated with 
inBammation.M-S Central or peripheral sensitisation gives rise to the clinical presentation 
of neuropathic pain: allodynia (pain in response to a normally non-nociceptive stimulus) 
and/or hyperalgesia (more intense pain in response to a normally noxious stimulus). The 
treatment of neuropathic pain currently has a largely unmet medical need: analgesics 
are often ine(ective or limited by side e(ects. In the development of new (analgesic) 
drugs, biomarkers can be a useful tool in early phase research.T Evoked pain models 
using biomarkers cannot describe the complexity of pain in a single parameter, yet 
using pain models rather than patients to test the eNcacy of analgesic drugs can be 
advantageous in terms of standardization, proof-of-concept and to provide insight in 
pharmacological background. Furthermore, using pain models excludes confounding 
due to co-existing fever, general malaise and psychological cognitive and social aspects 
of illness. Various human evoked hyperalgesia models have been developed that induce 
central and/or peripheral sensitisation in healthy volunteers in a well-controlled manner. 
This level of sensitisation is subsequently measured and quanti'ed using a normally non-
painful thermal or mechanical challenge. Use of this challenge enables the assessment 
of analgesic eNcacy of novel drugs. 
To be able to benchmark the e(ects of novel pharmacological compounds and 
provide guidance in the selection of an appropriate biomarker, the present study’s 
objective is to evaluate the capacity of each selected model to detect antihyperalgesic 
e(ects of di(erent pharmacological subclasses of drugs. This review also aims to 
map the abundance of methods and degree of heterogeneity among the individual 
hyperalgesia models.
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Literature evaluation
A literature study was performed using C"!Q$&", Web of Science and "C98#" up to 
the :=st of March :?=A. C"#- and free terms were used for the following search terms: 
‘hyperalgesia FD allodynia FD sensitisation’. Searches were limited to healthy human 
adults and manuscripts written in English. There was no limit to year of publication. To 
ensure clinical homogeneity, cutaneous hyperalgesia models were selected based on 
uniformity of methods, and thus comparability. Hyperalgesia models that were used 
in fewer than =? individual clinical trials or hyperalgesia models that had been used to 
investigate fewer than three di(erent classes of analgesics were excluded. This resulted 
in the selection of three cutaneous hyperalgesia models: the PH9 model, the (thermode) 
burn model and the capsaicin model. 
The PH9 (or ‘sunburn’) model is regarded as a model for inBammatory pain and 
hyperalgesia is evoked by exposing an area of skin to an individualised dose of PH9 on 
the leg, arm or back. Prior to the start of the study, the Minimal Erythemic Dose (C"!) 
for each subject is determined, and subsequently a one-, two- or threefold of this dose 
is applied to the skin. Over the course of :-)A hours a clearly discernible dose-related 
area of erythema becomes apparent, where lowered activation threshold for painful and 
non-painful stimuli (primary hyperalgesia) is observed.IU
The thermode burn model is generally considered as a model for heat injury and 
pertaining inBammatory pain. Hyperalgesia evoked by inducing a 'rst degree burn by 
exposing the subject to a speci'c heat paradigm, ranging from =?? seconds to O minutes, 
using a contact thermode at the skin. This procedure induces primary hyperalgesia on 
the site of exposure, but also secondary hyperalgesia in adjacent tissue, resulting from 
central sensitisation. 
The capsaicin model is the most widely used model to mimic symptoms of neurogenic 
hyperalgesia as observed in neuropathic pain. Capsaicin exerts its hyperalgesic e(ects 
via Transient Receptor Potential cation channel subfamily V member = (,D/HG) receptor 
activation. Capsaicin is applied either topically, or as an intradermal or intramuscular 
injection. Since ,D/HG receptors are also activated by heat ( >@;ºC), the method is 
also used in combination with heat exposure in order to potentiate the hyperalgesic 
e(ects of capsaicin. Topical absorption of capsaicin can be variable, therefore the 
extent of hyperalgesia can vary. When capsaicin is applied intradermally, acute severe 
stinging or burning pain occurs, followed by primary and secondary hyperalgesia up 
to :@ hours.IU,II
A thermal or mechanical challenge was the predominant method used to determine 
the magnitude of hyperalgesia. Seldom, an electrical challenge was also used to quantify 
hyperalgesia or allodynia but 'ndings from using this challenge were not included in this 
review due to the lack of standardization and the resulting diNculty in comparability. 
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ENcacy of the investigated pharmacological compound was quanti'ed according to its 
e(ect on pain induced by a mechanical or thermal challenge. Studies lacking adequate 
blinding or randomisation were excluded from this review, as well as studies including 
fewer than A subjects. To address the temporal nature related to evoked hyperalgesia, 
either as a result of the body’s adaptation to (mild) tissue damage, or resulting from 
pharmacokinetics of a chemical hyperalgesic agent, only studies using adequate 
(active or inactive placebo) control were included in this review. Studies solely reporting 
baseline controlled results were excluded. Finally, drugs that are still in the experimental 
phase of drug development were excluded, as the pharmacology of such drugs is not 
yet completely established.
This review categorised the selected randomised, double-blind, controlled trials 
investigating the eNcacy of pharmacological compounds according to hyperalgesia 
model, corresponding challenge and class of pharmacological compound.
Other human evoked hyperalgesia models that were identi'ed, but did not meet the 
entrance criterion regarding frequency of use for inclusion in this review, are, e.g freeze 
lesion,IK-IR mustard oil,IM-IS mentholIT-KI or substances including centrally acting opioids or 
local glutamate.KK-KV
Individual studies
All studies included in this review yielded the following outcomes, according to 
challenge: the e(ect of a pharmacological compound on thermal and mechanical 
Pain Detection Threshold (/!,), Pain Tolerance Threshold (/,,) and pain ratings 
(Visual Analogue Scales (H8#), Numeric Rating Scales (&D#)) in the hyperalgesic area 
and magnitude of area of hyperalgesia and allodynia. Besides provoked hyperalgesia, 
stimulus-independent hyperalgesia was also considered a relevant outcome, with 
outcomes including size and intensity of visual Bare and spontaneous or ongoing pain. 
For this review it was decided to use the term hyperalgesia in accordance with 
commonly used terminology in the reviewed literature referring to hyperalgesia as 
well as allodynia, even if the term allodynia would have been more appropriate based 
on de'nition. Pain responses to mild mechanical (punctate, brush) and thermal (heat/
cold) challenge indicate a pain response to a normally non-noxious stimulus, and thus 
represent allodynia, rather than hyperalgesia.
Due to an anticipated variation in e(ect sizes, the individual results were ranked as 
“positive” (antihyperalgesic e(ect / (statistically) signi'cant improvement compared with 
placebo), or “no e(ect” (no signi'cant di(erence compared with placebo), per separate 
outcome, rather than quantifying the magnitude of e(ect of the pharmacological 
compound. Outcomes for di(erent administration forms were regarded as separate 
outcomes. Di(erential dose or time e(ects were indicated with a note, and scored as a 
positive e(ect, as this model was apparently able to detect an antihyperalgesic e(ect, 
given the appropriate execution of the test.
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Grouping of test results
The outcomes per challenge method were grouped according to type of outcome: 
thermal, mechanical and stimulus-independent. The category “thermal” was sub- 
divided in the speci'c outcomes measured in the individual studies, e.g. heat / cold 
/!, or /,,. The category “mechanical” consisted of static (pin prick), dynamic (stroking 
with a brush, cotton gauze, etc), and impact (using an algometer) stimuli, providing 
the aforementioned outcomes. Stimulus-independent outcomes were related to 
spontaneous pain resulting from hyperalgesia and to intensity and size of Bare. Results 
from the individual studies were subsequently grouped according to drug class 
to provide insight into the pharmacological e(ect of each class of drug on a speci'c 
hyperalgesia-challenge combination. Responsiveness of each model to each particular 
class of drugs was de'ned in this review as the pharmacological sensitivity.
&$)-3#)
Study designs
The literature study yielded )@ individual studies on the three selected hyperalgesia 
models: =A used the PH9 model to induce hyperalgesia, @> studies explored the e(ects of 
various pharmacological compounds on capsaicin-induced hyperalgesia and ;? studies 
investigated thermode burn-induced hyperalgesia. Seven studies examined more than 
one hyperalgesia model. General study characteristics are presented in Table !. The 
participants were aged between =O and A< years.
Even though the PH9, capsaicin and thermode burn models were selected based on 
high degree of standardization, there was considerable variation in the execution of the 
models as shown in Table 1. All studies utilizing PH9 to induce hyperalgesia administered 
a dose of =, : or ; times the Minimal Erythemic Dose (C"!). The administration of = C"! 
was shown to be inconsistent at producing hyperalgesiaKS in one study. Larger variation 
was found among the methods of inducing hyperalgesia with capsaicin. Capsaicin was 
either injected intradermally or applied topically. Of the =A capsaicin studies that used 
heat to further exacerbate/prolong the hyperalgesia, : studies kept the skin at a constant 
temperature, while the remainder used the method of rekindling: 've minutes at a set 
temperature (@?°C or @<°C at 'xed time points) with a thermode placed directly on the skin 
or using a radiant heat lamp. The largest variation was seen in the thermode burn model: 
ten di(erent heat administration regimens were identi'ed, ranging from =?? seconds at 
<?°C (n==) to O minutes at @O°C (n==@), causing blistering in one or more subjects in :?% of 
the studies. The thermode burn and PH9 models were most often administered on one 
or both legs (A>.>% and >;.;% respectively), whereas for administration of capsaicin to 
induce hyperalgesia, one or both arms were selected most often (>).@%). The frequency 
of use of challenge methods among the di(erent hyperalgesia models is shown in Table 2. 
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Sensitivity of the !"# model
The use of the PH9 model as a model for inBammation was relatively uncommon: =A 
studies using this method were identi'ed. Eight classes of drugs were investigated. 
Studies that investigated the e(ects of a combination of drugs are listed in a separate 
category. Table 3 shows an overview of the pharmacological sensitivity of the PH9 model 
per separate challenge method (mechanical, thermal or stimulus-independent) and 
grouped according to drug class.
A total of four studies investigating nonsteroidal anti-inBammatory drugs (&#8$!#), 
including ibuprofenKS-LU and Rofecoxib,LI showed a signi'cant e(ect by reducing hyper-
algesia to thermal and mechanical stimuli. Two studies investigating the e(ects of 
ketorolac alone and in combination with paracetamol found mixed results.LK,LL Mixed 
results were also observed for the benzodiazepines clobazam and clonazepam.LR 
Systemically administered opioids reduced hyperalgesia to thermal and mechanical 
stimuli.LM-LS Transdermal administration of either buprenorphine or fentanyl did not atten-
uate hyperalgesia to heat or static mechanical stimuli, but buprenorphine did have a 
signi'cant e(ect on the /,, to impact stimuli.LS Furthermore, remifentanil in combination 
with gabapentin showed no greater reduction in hyperalgesia than remifentanil alone. LJ
Lidocaine, a local anaesthetic, showed mixed results. One study found an attenuating 
e(ect on hyperalgesia to impact stimuli when lidocaine was injected intravenously.LT 
Another study applied lidocaine topically and found a reduction of hyperalgesia to 
static and dynamic mechanical stimuli, but no attenuating e(ects on hyperalgesia 
to heat stimuli.RU Studies investigating the voltage-gated Calcium channel ɲ:–ɷ 
modulating anticonvulsant, gabapentin,LJ the neurotoxin botulinum toxin ARI and 
paracetamolLL,LV found no signi'cant e(ects on hyperalgesia. Tetrahydrocannabinol 
(*+-,-.), a cannabinoid receptor agonist, also did not show signi'cant positive e(ects 
on hyperalgesia to mechanical and thermal stimuli.RK Noteworthy, *+-,-. even showed 
signi'cantly increased hyperalgesia at speci'c electrical stimuli intensities at speci'c 
time points.RK
Sensitivity of the capsaicin model
The capsaicin model has been used extensively to test the eNcacy of new and existing 
pharmacological compounds. This literature study yielded @> articles eligible for 
inclusion in the current review. A total of =@ classes of pharmacological compounds 
were identi'ed. For both analgesics and corticosteroids, there was only one study 
investigating a drug belonging to these classes. Table 4 provides an overview of the 
'ndings of the individual studies using the capsaicin model grouped by class of drug and 
type of challenge/hyperalgesia. 
Opioids, anaesthetics, N-methyl D-aspartate (&C!8) receptor antagonists, and to 
a lesser degree, the calcium channel ɲK-ɷ ligands, appear to have an attenuating e(ect 
on capsaicin-induced hyperalgesia to mechanical stimuli,RL-RJ although there are also 
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a number of studies for each of these drug classes where no e(ect could be found 
(e.g., @O-@)). The ɲ-: adrenoreceptor agonist clonidine,MU,MI appeared to be e(ective in 
reducing hyperalgesia, particularly in response to mechanical stimuli in two studies.
Although &C!8 receptor antagonists appear to be e(ective in reducing hyperalgesia, 
a number of the studies demonstrate a positive e(ect only at speci'c time points, mostly 
during infusion or measured immediately after infusion or bolus injection, particularly on 
mechanical hyperalgesia (e.g., <:-<@ for ketamine, << for dextromethorphan and <A for 
neramexane) (see the corresponding footnotes in Table 4). The remaining drug classes 
investigated showed no or very limited eNcacy in attenuating capsaicin-induced 
hyperalgesia: &#8$!#),LK,MV analgesics,MJ cannabinoids,RK,MS,MT tricyclic antidepressantsJU,JI 
and antiarrhythmics.JK-JR
Sensitivity of the thermode burn model
This review included ;? studies investigating the eNcacy of pharmacological 
compounds to attenuate hyperalgesia induced by the thermode burn model. Ten 
classes of pharmacological compounds to reduce hyperalgesia were found. Of these 
classes, 've comprised a single compound. In addition, three studies investigating a 
combination of drugs are included. An overview of the results is shown in Table $.
No class of drug showed clear eNcacy when administered to completely reverse 
thermode burn-induced hyperalgesia. However, &C!8 receptor antagonists were 
found to attenuate mechanical, but not thermal hyperalgesia to a moderate extent,MM,JM-VI 
although there was also a number of studies that did not demonstrate this e(ect.VK,VL 
A similar reduction in mechanical hyperalgesia but not on thermal hyperalgesia was 
observed when ketamine was combined with the opioid receptor antagonist, naloxone,JV 
indicating that co-administration of naloxone does not reduce the e(ects of ketamine.
Two studies were performed to investigate the presence of a synergistic e(ect of 
combined treatment of an opioid (morphine) and an &C!8 receptor antagonist, but 
these showed inconclusive results.JT,VK 
Opioids,JT,VU,VR,VM intracellular sodium channel blockers,VJ,VV &#8$!s,VS-SK corticoste-
roids,SL,SR the calcium channel ɲK-ɷ ligand, gabapentin,SM the glutamate antagonist 
riluzole,SJ the opioid receptor antagonist naloxoneSV and P=-receptor activator adenos-
ineSS were inconsistent at attenuating heat, mechanical and non-provoked hyperalgesia. 
(!).-))!+"
This literature review aimed to provide insight in the pharmacological sensitivity of 
three cutaneous hyperalgesia models: the PH9, capsaicin and thermode burn model, 
with the goal to determine the applicability of individual hyperalgesia models in early 
phase pharmacological pain research. The review of the identi'ed randomised, double-
blind, placebo-controlled trials investigating the eNcacy of numerous pharmacological 
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compounds generated an overview of the classes of drugs that are investigated in pain 
paradigms and their eNcacy at reducing speci'c hyperalgesia-challenge combinations.
The summarised 'ndings of the included trials reBect the pharmacological sensitivity 
of three hyperalgesia models in combination with speci'c challenges, which were 
selected based on their standardised methodology and frequency of use. 
The PH9 model was only responsive to the pharmacological e(ects of &#8$!# and, 
to a lesser extent, opioids. The pharmacological sensitivity of the thermode burn model, 
used as a translational model for inBammatory pain as well as neuropathic pain, shows a 
di(erent pro'le compared with the PH9 model. First, &#8$!# and opioids do not seem to 
show antihyperalgesic e(ects when administered to reduce burn-induced hyperalgesia. 
Moderately e(ective at attenuating mechanical hyperalgesia were the &C!8 receptor 
antagonists, whereas thermal hyperalgesia was largely una(ected. Some authors refer 
to the central mechanism involved in secondary mechanical hyperalgesia, in contrast 
with the peripheral sensitisation in primary (thermal) hyperalgesia as an explanation 
for the di(erential e(ect of &C!8 receptor antagonists between heat and mechanical 
hyperalgesia.VU,VI Despite the general regard of capsaicin as a model for neuropathic pain, 
the model appeared insensitive to the classes of pharmacological compounds clinically 
prescribed in 'rst-line treatment for neuropathic pain.ST Calcium channel ɲK-ɷ ligands 
(gabapentin and pregabalin), tricyclic antidepressants or topical lidocaine provided 
limited to no attenuation of hyperalgesia in the majority of the studies investigating 
this model. Most of the studies investigating the e(ects of opioids on mechanical 
hyperalgesia yielded positive results, however only a sparse number of studies 
investigated the e(ects of opioids on thermal hyperalgesia and therefore providing no 
evidence for responsiveness of thermal hyperalgesia induced by capsaicin, or the lack 
thereof, to opioids. A few positive studies investigating clonidine suggest that it exerts its 
e(ects by reducing spinal hypersensitivity through ɲ:-adrenergic agonism in the dorsal 
horn. &C!8 receptor antagonists exert their antihyperalgesic e(ects through inhibition 
of the glutamatergic signalling pathways. A limited number of studies demonstrated that 
the capsaicin model is sensitive to &C!8 receptor antagonists. The results demonstrate 
a di(erential antihyperalgesic e(ect: mechanical hyperalgesia is attenuated in a small 
number of studies, but not thermal hyperalgesia. The capsaicin model appeared to be 
insensitive to the remainder of the pharmacological compounds that were investigated, 
including botulinum toxin A and cannabinoids.
For a number of classes of drugs investigated, this literature review included only 
one study and one compound per drug class. Therefore, for these drug classes, no 
strong recommendations can be made with respect to the suitability of the cutaneous 
hyperalgesia models, other than those based on face validity.
Limitations to this approach
In this review the pharmacological sensitivity of the selected hyperalgesia models is 
based on the capacity of the model to detect an antihyperalgesic e(ect for each class of 
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drug. Inherent to this approach is the assumption that the clinical trials are appropriately 
executed. The included clinical trials had to meet the following criteria: randomised, 
double-blind and placebo or active controlled. Only A.O% to =>.<% of the studies used 
an active control (alone or in combination with true placebo). This may have introduced 
bias when investigating psychoactive pharmacological compounds compared to true 
placebo, as analgesia is known to be prone to placebo response.TU This could be avoided 
by using an active placebo with known lack of analgesia but comparable psychoactive 
e(ects. Dosing regimens and administration forms are included in the tables to provide 
insight in potential di(erences, but for the studies that were included, clinically relevant 
dosing regimens were generally used. 
Variability in reporting of the results was observed on di(erent levels. Due to the 
bilateral nature of evoked hyperalgesia models, both induction and assessment 
of hyperalgesia potentially introduce variability. For example, some authors report 
absolute pain thresholds, whereas others report calculated hyperalgesia (compared to 
healthy control skin). Furthermore, to assess pharmacodynamic response, some groups 
compare a single post-dose measurement with a baseline in a paired t-test analysis, 
whereas other groups include multiple measurements in 8&FH8 . Consequently, a 
statistical meta-analysis of the results of the included clinical trials was not deemed 
feasible, nor does it fall within the scope of the present review.
Hyperalgesia models that were not included in this review, including the freeze lesion 
model, may eventually also prove to be useful tools to detect antihyperalgesic e(ects 
of novel compounds, given the reproducible and non-invasive methodology, but due 
to their limited use thus far no conclusion on pharmacological sensitivity can be made. 
For ethical reasons, evoked hyperalgesia models are characterised by their temporal 
nature: either bodily adaptations to (mild) tissue damage or pharmacokinetics of a 
chemical hyperalgesic agent result in time-dependent hyperalgesia, which attenuates 
over time without intervention. To overcome this, a protocol needs be designed with an 
appropriate control. Nonetheless, this potentially interferes with interpretation of the 
results of analgesics or antihyperalgesics with a prolonged pharmacological e(ect.
Implications for pain research
In early phase drug development, research in healthy subjects can form the bridge 
between animal models and clinical application and provide the basis for proof-of-
concept of new compounds or techniques. Furthermore, experiments can be used to 
investigate the basic mechanisms to characterise sensory dysfunction in patients.TI 
The main concern of human pain research is to appraise the value of a model in terms 
of translation to clinical practice. In this respect the PH9 model is a highly satisfactory 
model for inBammation, as it is highly reproducible and responds well to &#8$!#. The 
thermode burn model responds well to &C!8 receptor antagonists in the attenuation of 
mechanical hyperalgesia. This might reBect a speci'c component of neuropathic pain, 
so-called ‘wind-up’ pain, which is also reduced by &C!8 receptor antagonists in clinical 
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practice.TK However, as the model does not respond well to the other medications 
that are eNcacious in the treatment of neuropathic pain; this model appears to be 
solely capable of mimicking this speci'c element of neuropathic pain. As a model for 
inBammatory pain, the thermode burn model is unsuitable, as it is insensitive to anti-
inBammatory drugs. The capsaicin model shows most sensitivity to the antihyperalgesic 
e(ects of opioids compared with other drug classes. The established drugs for the 
treatment of neuropathic pain, such as the calcium channel ɲK-ɷ ligands only show 
antihyperalgesic e(ects on speci'c endpoints, indicating that 'netuning of the model in 
combination with the correct challenge could potentially provide a pharmacologically 
sensitive model for these classes of compounds. Although sensitisation is present in 
the capsaicin-challenge model, it is due to di(erent mechanisms than those involved 
in clinical presentation of neuropathic pain. Nonetheless, 'netuning of this model may 
render it a useful tool for early phase drug research, as no single model can completely 
replicate the clinical presentation of neuropathic pain. Alternatively, the capsaicin 
model may only mimic the features of clinical (neuropathic) pain in certain healthy 
subjects.TL and just like for the PH9 model where subjects are generally pre-screened 
for ‘responders’ and the model is individualised per subject, this may be necessary for 
the capsaicin model. Pre-screening for ‘responders’, as is occasionally done,TR,TM ensures 
homogeneity and thereby reduces variability. In early phase research for a compound 
with a novel mechanism of action for the indication of neuropathic pain, one needs to 
keep these limitations in mind. As such the capsaicin model is not suitable for go/no-go 
decision-making, but can be a useful tool to aid clinical development of novel analgesic 
treatments. 
.+".3-)!+") 
This literature review demonstrates the importance of carefully considering the 
appropriate design in early phase pharmacological research. Due to the abundance 
of possible working mechanisms, no single human evoked pain model is capable 
to detect antihyperalgesic or analgesic e(ects of each class of drugs. Therefore, the 
appropriateness and translatability of the model has to be taken into account when 
designing an early phase proof-of-concept study. In this respect, the PH9 model can 
be considered a predictive model for inBammatory pain based on its capacity to detect 
antihyperalgesic e(ects from &#8$!#. The thermode burn model is considered to reBect 
a speci'c aspect of neuropathic pain; still, as a whole, the model lacks sensitivity to serve 
as a complete model for neuropathic pain. The capsaicin model in its current form also 
lacks pharmacological sensitivity to be used as a model for neuropathic pain. It may, 
however, provide important insight in mechanisms involved in hyperalgesia, including 
signal transduction and pain perception. In our opinion, further standardization and 
validation is needed before the capsaicin model can be used as a model to screen drugs 
for their e(ect on symptoms of neuropathic pain.
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While investigating the pharmacological sensitivity of hyperalgesia pain models, we 
revealed the lack of robust models for neuropathic pain. Current hyperalgesia models 
evidently do not reBect the clinical presentation of neuropathic pain. Asserting that 
a certain model is representative of neuropathic is overstating the con'dence of the 
models. Neuropathic pain is a heterogeneous entity and further research is needed 
to investigate the link between the evoked pain models and the di(erent types of 
neuropathic pain. Carefully selecting appropriate biomarkers and understanding their 
merits and limitations for early phase drug research is essential for e(ective and eNcient 
drug development. 
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.%'2, ! Characteristics of randomised, double-blind, (active) placebo controlled studies 
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.%'2, " Frequency of use (%) of general methods for the induction of hyperalgesia speci.ed 
according to hyperalgesia model 
Hyperalgesia model Speci;c methods Frequency of use (%)
PH9 
(n = 16)








































Applying heat No heat applied 70.8
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Burn 
(n = 30)
Application 1:40 minute at 50°C 3.3
2 minutes at 48°C 3.3
3 minutes at 45°C 6.7
3-5minutes at 45°C 3.3
4 minutes at 49°C 3.3
5 minutes at 47°C 10
5 minutes at 49°C 13.3
6 minutes at 47°C 3.3
7 minutes at 46°C 6.7
7 minutes at 47°C 46.7













* All studies that used rekindling also pre-heated before capsaicin application for 4 minutes at 34°C.
.%'2, # Frequency of use (%) of main challenge methods speci.ed according to 
hyperalgesia model 







Thermal – Heat Thermode 68.8 50.0 76.7
Halogen bulb 12.5 2.1 3.3
Thermal – Cold Thermode 25.0 8.3 3.3
Mechanical (static)  
– Pin prick
Von Frey 56.3 77.1 80.0




Brush 12.5 43.8 13.3
Cotton 18.8 35.4 6.7
Fingertip 0 0 6.7
Von Frey 0 0 3.3
Mechanical  
– impact stimulus
Algometer (static) 6.3 0 0
Algometer (dynamic) 18.8 2.1 3.3
* Frequencies of use exceed !..% because most studies make use of more than one method.
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.%'2, = Schematic summary of results of randomised controlled trials investigating 













# Morphine ( IV / @ mg) [35]
Remifentanil (IV / ?.> ʅg/
kg/min) [36]AY
Fentanyl (Transdermal / 
μοʅŐ/h, O:h) [38]A
Buprenorphine 
(Transdermal / μκʅŐ/h, 
=@@h) [38]B
Tramadol (IV / ?.; mg/kg, 
?.A mg/kg, = mg/kg) [37]Z
Remifentanil (IV 
infusion/?.>ʅŐ/kg/min) & 







M Pin prick/Area [36]A,[36]B [38]A,[38]
B,[37] 











# Lidocaine (Topical patch 
/ <% medicated plaster) 
[40], (IV-bolus / : mg/kg in 
=? minutes, then : mg/kg/h 
for ;? minutes) [39];
Benzocaine (topical / =? 
% ointment) [96]




M Impact/Pain score [39]
Pin prick/Area [40] 







# Ibuprofen (Oral / @?? mg 
– >?? mg) [:>-;?]
Rofecoxib (Oral / <? mg, 
:<? mg, <?? mg) [31]
Ketorolac (Oral / :? mg) 
[33]A; (Intrathecal / : mg) 
[32]
Ketorolac (Oral / :? mg) 
& Paracetamol (Oral / = 
mg) [33]B




Heat //,, [31],[30] 
M Impact stimulus/Pain 
score
[28]
Pin prick/Area [31], [32] [33]A,[33]B
Pin prick//!, [29],[33]B [33]A 
Stroking/Area [32]
S-I Flare/ intensity [31],[28]


















! Gabapentin (Oral / A?? 
mg) [36]CY
T Heat/PDT [36]C 
Heat/PTT [36]C
M Pin Prick/ Pain score






















"# Clobazam (Oral / :? mg) 
[34]_A
Clonazepam (Oral / = mg) 
[34]_B
T Heat/PDT [34]A [34]B
Heat/PTT [34]B [34]A
Cold/PDT [34]A
M Pin prick/Area [34]A,[34]B







# Botulinum Toxin A 
(Intracutaneous / =?? 
Mouse Units (MU)) [41]
T Heat/PDT [41]
Cold/PDT [41]
M Stroking/ Pain score [41]
Pin prick/Area [41] 






# Paracetamol (Oral / = g) 
[33]C; (IV / ;;? mg) [37]
M Pin prick/PDT [33]C 
Pin prick/Area [33]C,[37] 
Pin prick/Pain score [37] 
T Heat/PDT [33]C,[37] 
Cold/PDT [37] 
(=Thermal, 5=Mechanical, --/=Stimulus-Independent / ! E%ect compared with active placebo: 
diazepam (1 mg). / 1 Signi6cant e%ect found only at ! mg/kg dose of tramadol, not at ..2 mg/kg or ..$ 
mg/kg doses. / 2 Signi6cant e%ect found at 3# and 71 hours post dosing, but not at 13 or !33 hours post 
dosing: neither short nor long term e%ect. / 3 Also electrical stimuli administered, results not shown here. /  
4 Compared with active placebo: diazepam (4 mg) / $ Compared with active placebo: tolterodine (!.27 mg)
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-:+-)/, Cannabinoids have been shown to improve symptoms of Multiple Sclerosis 
(C#) including muscle spasticity and pain through modulation of neuronal excitability 
via presynaptic cannabinoid receptors. Previous formulations of *+-,-. are notorious 
for variable pharmacokinetic pro'les, thereby demanding cumbersome uptitration. The 
current formulation was developed to overcome this and improve clinical application of 
*+-,-. in the treatment of spasticity and pain in C#. The aim of the present study was 
to evaluate the eNcacy of a novel oral formulation of *+-,-. ("./1158) in patients with 
progressive C#.
8,.9)*/ This accelerated proof-of-concept study consisted of two phases: a 
crossover challenge (‘dose-'nding’) phase and a @-week parallel randomized, placebo-
controlled treatment phase. Twenty-four patients with progressive C# and moderate 
spasticity were enrolled. During the treatment phase biomarkers for eNcacy and 
secondary pharmacodynamic e(ects were measured at baseline, and after two and 
four weeks of treatment. Serum samples were collected to determine pharmacokinetic 
parameters and perform population modelling. Safety and tolerability was assessed 
based on Adverse Events and safety measurements.
7(&*(&0/ Pain was signi'cantly reduced when measured directly after administration 
of "./1158 in the clinic, but not when measured in a daily diary. A similar pattern was 
observed in subjective muscle spasticity. Other clinical outcomes were not signi'cantly 
di(erent between active treatment and placebo. Cognitive testing indicated there was 
no decline in cognition after : or @ weeks of treatment due to "./1158 compared to 
placebo.
(8-2($%.()&/ This study speci'cally underlines the added value of thorough 
investigation of /p//! relationships in the target population. Despite the complex 
interplay of psychoactive e(ects and analgesia, the current oral formulation of *+-,-. 
may play a role in the treatment of spasticity and pain associated with C#, as it was well-
tolerated and showed a stable pharmacokinetic pro'le.  
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Multiple sclerosis (C#) is an inBammatory disease of the nervous system characterized 
by highly variable clinical aspects and an unpredictable courseI. Of the many symptoms 
encountered in C#, muscle spasticity and spasms occur in up to O<% of patientsK. These 
symptoms often lead to considerable distress from reduced mobility, and interference 
with activities of daily living. Other disabling features include sensory symptoms (e.g. 
pain), present in up to >A% of the patientsL. Spasticity refers to feelings of sti(ness and 
a wide range of involuntary muscle spasms (sustained muscle contractions or sudden 
movements). Spasticity may be as mild as the feeling of tightness of muscles or may be 
so severe as to produce painful, uncontrollable spasms of extremities. Spasticity may 
also produce feelings of pain or tightness in and around joints and can cause lower back 
pain. Although spasticity can occur in any limb, it is much more common in the legs.
The endogenous cannabinoid system appears to be tonically active in the control 
of spasticityR,M and cannabinoids have been proposed in C# because of their ability to 
reduce the subjective feeling of spasticityJ. Cannabinoids have been shown to modulate 
motor cortical excitability probably through presynaptic cannabinoid receptors 
.9G that control the release of neurotransmitters from axonal terminalsV,S. Delta-)-
tetrahydrocannabinol (*+-,-.) is one of the cannabinoids in the Cannabis sativa plant 
and a direct partial agonist of the cannabinoid receptor .9G.
Several studies have examined the e(ect of (synthetic forms of) *+-,-. in the treatment 
of multiple sclerosis. No signi'cant e(ects of doses between =? mg to :< mg (total daily 
dose, twice daily dosing) of oral *+-,-. were observed on spasticity as measured on 
the Ashworth scale in a large population. However, a small, but clinically relevant bene't 
of treatment with cannabis extract or *+-,-. capsules of dosages up to :< mg/day was 
found in secondary outcome measures of perception of spasticity and mobilityT. Several 
other studies have also found an e(ect of *+-,-. on subjective measures of spasticityIU,II 
and pain in patients with C#T,IK at di(erent dosing regimens. Another study comparing the 
e(ects of an oral formulation of *+-,-. to a cannabis plant extract and to placebo did not 
demonstrate eNcacy in the treatment of spasticity of either product.IL 
Oral bioavailability of *+-,-. is variable due to signi'cant 'rst pass e(ect and the 
current formulation of *+-,-., "./1158 (Namisol®), was shown in a phase I study to 
have superior pharmacokinetic properties to previous formulations, leading to more 
stable *+-,-. plasma levels without high peaks and thus expected early onset of 
treatment e(ects.IR It has a novel tablet formulation of pure *+-,-. that was produced 
using Alitra™ (Echo Pharmaceuticals b.v., Nijmegen, the Netherlands), an emulsifying 
drug delivery technology. This technology was designed to improve the uptake of poorly 
soluble lipophilic compounds, using less surfactant (less than =?% w/w). The current 
study was designed to investigate the pharmacokinetics (/p) and safety and the e(ects 
on spasticity and pain of this novel formulation in a cohort of :@ patients su(ering from 
primary and secondary progressive C#, using a crossover challenge (‘dose-'nding’) 
phase and a :>-day parallel treatment period. 
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This study was designed as a hybrid between a typical multiple dose study to investigate 
/p, /! and safety, and a 'rst-in-patient study to establish proof-of-concept, and hence 
considered to be an accelerated proof-of-concept study that consisted of two phases. 
The challenge phase was designed as a randomized, double-blind, placebo-controlled, 
two-way crossover design to determine the optimal e(ective dose of "./1158 to treat 
spasticity of each individual and limit the risk of Adverse Events, using pharmacokinetic/
pharmacodynamic (/p//!) modelling. Each of the two visits in the challenge phase 
consisted of uptitration of three consecutive drug administrations with a =??-minute time 
interval in ascending order. If well-tolerated, the three dose levels were predetermined 
to be ; mg, < mg and > mg, leading to a total daily dose of =A mg, which was based on 
the /p and /! 'ndings in the previous study.IR In between the administrations of *+-,-. 
or placebo, di(erent measurements for safety, tolerability and biomarkers for were 
performed. In between the two visits was a wash-out period of O-=@ days. 
The four week treatment phase was performed in a randomized, double-blind, 
placebo-controlled parallel fashion to determine safety, tolerability and eNcacy of 
"./1158 in patients with multiple sclerosis su(ering from spasticity and pain. Based 
on the 'ndings of the challenge phase, patients start with a predetermined daily dose 
divided over three intakes. After two weeks of treatment the dose for each subject was 
evaluated, and increased when considered appropriate. The study was approved by 
the Medical Ethics Committee of the HP University Medical Center (Amsterdam, The 
Netherlands). 
The study was conducted according to the Dutch Act on Medical Research Involving 
Human Subjects (ECF) and in compliance with Good Clinical Practice ($.--%./) and 
the Declaration of Helsinki. The study is registered in the EU Clinical Trials Register 
("P!D8.,) under protocol number :?=?-?::?;;-:> and in the Dutch clinical trial 
registry (www.toetsingonline.nl) under dossier number NL;@@@;.?:).=?. The study 
was performed by the Centre for Human Drug Research (Leiden, the Netherlands) and 
HP University Medical Center (Amsterdam, The Netherlands) and was funded by Echo 
Pharmaceuticals.
Twenty-four patients aged => years or older with a diagnosis of progressive (primary 
or secondary) Multiple Sclerosis according to the revised McDonald criteria IM, who had a 
disease duration of >= year and were clinically stable for at least ;? days prior to the start 
of the challenge phase were to be enrolled. In addition, patients had to have moderate 
spasticity as de'ned by an Ashworth score of : or higher (range ?-@) and a Kurtzke 
Expanded Disability Status Scale ("!##) score between @.< and O.< at baseline (range 
?-=?). Spasmolytic therapy was allowed, given that dosage and treatment regimen was 
stable for at least ;? days prior to study participation and remained stable throughout 
study participation. Current use of *+-,-. was exclusionary, as con'rmed per urine 
drug screen. All patients provided written informed consent prior to participation. 
"./1158 and matching placebo tablets were manufactured and provided under the 
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responsibility of Echo Pharmaceuticals B.V. Tablets were available in the strengths 
=.< mg and < mg *+-,-. and contained no other active ingredients. Based on the 
observed pharmacokinetic pro'le in the First-in-Human study, the dosing regimen for 
the treatment phase was 'xed on intake thrice daily of the starting dose as determined 
during the challenge phase. 
Both the challenge- and treatment phase included biomarkers for eNcacy and 
secondary pharmacodynamic e(ects. Both types consisted of objective and subjective 
measurements. The endpoints for the challenge phase were a set of biomarkers for 
eNcacy (objective spasticity: the ratio of the maximum amplitude of the Ho(mann reBex 
to the maximum C response, recorded over the soleus muscle after electrophysiological 
stimulation of the popliteal nerve (-/C ratio)IJ,IV; subjective spasticity and pain expressed 
using a Numerical Rating Scale (&D#)); and biomarkers for secondary pharmacodynamic 
e(ects (changes in internal / external perception (‘feeling high’) as measured with the 
H8# BowdleIS, changes in alertness, mood and calmness as measured with the H8# Bond 
& LaderIT and postural instability), as well as /p endpoints. The primary endpoint for the 
treatment phase was the -/C ratioIJ,IV. Secondary endpoints were biomarkers for eNcacy 
that were either measured in the clinic: AshworthKU, subjective spasticity (&D#), number 
of spasmsKI and pain using an &D# KK and the McGill Pain QuestionnaireKL-KM ); or measured 
at home using a daily diary: subjective spasticity (&D#), number of spasms and pain (&D#). 
Furthermore, a set of functional outcome measures was selected to assess treatment 
e(ects: "!##.KJ the patient’s global impression of change (/%$.),KK quality of sleep as 
determined by the Pittsburgh sleep quality index (/#q$)KV, walking distance recorded 
the Timed :< Foot Walk test (,570E),K, the Fatigue Severity Scale (0##).KT Finally, the 
same biomarkers for secondary pharmacodynamic e(ects were included, namely H8# 
Bowdle, H8# Bond & Lader and postural instability, in addition to a test to assess visual 
perception, attention and working-memory, the Symbol Digit Substitution Test (#!#,)LU 
and Heart Rate.LI
Statistics
A sample size of :@ patients (including active and placebo treatment) was determined 
to have )?% power to detect a di(erence in mean -/C ratio (change from baseline) 
between placebo and "./1158 of :?%, assuming a standard deviation of di(erences of 
:=%, using a paired t-test with a ?.?<? two-sided signi'cance level. 
For both the challenge and the treatment phase, a randomization schedule was 
prepared under the responsibility of an independent statistician within .-!D, but not 
involved in the execution of the study. All sta( involved in the clinical execution of the 
study was blinded until all data was collected and the database was locked. For the 
treatment phase block randomization was applied. The schedule was sent to the hospital 
pharmacy and sealed envelopes for code breaking were available for the investigator. 
Treatment allocation was performed on basis of the date of eligibility of the subject as 
the subject identi'cation numbers are assigned at that moment. 
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The results of the pharmacodynamic endpoints were compared between the "./1158 
and placebo treated group with an analysis of (co)variance with treatment, time and 
treatment by time as 'xed factor and subject as random factor and, if available the 
(average) baseline measurement as covariate. Within the model contrasts are calculated 
over all measurements, only the measurements of week : and only the measurements of 
week @. The Kenward-Roger approximation was used to estimate denominator degrees 
of freedom and model parameters were estimated using the restricted maximum 
likelihood method. The general treatment e(ect and speci'c contrasts were reported 
with the estimated di(erence and the )<% con'dence interval, the Least Square Mean 
(Q#C) estimates and the p-value. Graphs of the Q#C estimates over time by treatment 
were presented with )<% con'dence intervals as error bars.
As body sway and ,570E data were not normally distributed, the data were log-
transformed before analysis and back-transformed after analysis. H8# Bowdle subscale 
scores were log transformed (=?log) after a value of : was added to each score, to avoid 
log transformation from zero. Combined internal, external and feeling high scores were 
calculated on log transformed data.
All calculations of the pharmacodynamic parameters were performed using #8# for 
Windows version ).=.; (#8# Institute Inc., Cary, &., P#8). No adjustments for multiple 
comparisons were employed.
Post-hoc analysis 
Upon review of the data the authors noted that there were patients that indicated to 
experience no subjective spasticity or pain at the start of the treatment phase, due to the 
erratic nature of these symptoms of C#. Therefore a subgroup analysis was performed 
which only included patients indicating to experience subjective spasticity (N==O) or pain 
(N==O) at the start of treatment. Additionally, in order to di(erentiate acute from chronic 
treatment e(ects, an additional analysis was performed in which the measurements 
immediately after the 'rst dosing at the start of the treatment phase were excluded from 
the model and only measurements of week : and @ were used to estimate contrasts.
Pharmacokinetic modelling
The population /p analysis focused on identifying = and : compartmental structural 
models with 'rst-order absorption and elimination to describe the data. The random 
e(ects structure that was applied included a proportional residual error distribution, and 
log-normal distributions for the inter-individual variability ($$H) of the /p parameters. The 
latter was established using an exponential transformation of a normal random e(ects 
distribution. Various types of variance-covariance matrices were tested for the inter-
individual variability. The estimated population values (both 'xed and random e(ects), 
were used to determine individual empirical Bayes’ estimates (post hoc estimates) of the 
pharmacokinetic parameters, and related values such as after single dose: area under 
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the plasma curve from zero to in'nity (8P.U-r), maximal plasma concentration (.max) 
and terminal half-life (,/). Calculations were performed using D v:.=:.? (R Foundation for 
Statistical Computing, Vienna, Austria). The analyses closely followed the guidelines of 
the United States Food and Drug Administration (0!8) and European Medicines Agency 
("C8) for performing and reporting population pharmacokinetic analyses.
&$)-3#)
During the clinical execution a total of :=; potential patients were identi'ed (Figure !). 
Seventy-three patients were found eligible for screening after telephone prescreening, 
of which AA were screened. Between August :?== and January :?=; a total of :@ patients 
were enrolled. Baseline characteristics are described in Table !. There were no relevant 
di(erences between the treatment groups. All randomized patients completed the 
challenge phase and were subsequently enrolled in the treatment phase. One subject 
(randomized to placebo) dropped out during treatment phase due to intolerable Adverse 
Events.
Challenge phase
None of the measurements included to assess acute e(ects on spasticity or pain 
improved signi'cantly after three consecutive dose administrations of "./1158 
during the challenge phase (Table 1). -/C ratio, &D# for pain and spasticity, were not 
signi'cantly di(erent between "./1158 and placebo treatment. 
Several biomarkers for pharmacodynamic e(ects were measured during the 
challenge phase. On a group level, postural instability, heart rate and internal/external 
perception were signi'cantly a(ected by "./1158 administration compared to placebo. 
H8# scores for alertness, calmness and mood were not signi'cantly a(ected di(erently 
by "./1158 than by placebo. 
01/02 modelling
To overcome individual di(erences in tolerability, this study protocol was designed with 
/p//! modelling implemented as an aid to determine individual dose per patient. Results 
from the crossover challenge phase were modelled to assess the individual dose at which 
desired e(ects would occur, in the absence of Adverse Events. However, due to a lack of 
a robust pharmacodynamic response during the challenge phase (spasticity in -/C ratio 
or &D#) or other secondary pharmacodynamic e(ects (e.g. H8# for feeling high), a /p//! 
model could not be established on an individual level as intended. Due to large variability 
in acute pharmacodynamic response, a prediction of plasma concentrations needed to 
exert a desired pharmacodynamic e(ect could not be made. The pragmatic approach 
that we chose instead was uptitration to the level of tolerability to Adverse Events. 
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During the challenge phase, the highest consecutive dose of > mg was not reached in 
two patients due to Adverse Events. Twelve patients did not experience any Adverse 
Events during the challenge phase and were dosed at the maximum allowed starting 
dose per protocol of :@ mg/day (intake > mg thrice daily). Seven of these patients were 
randomized to active treatment. The remaining 've patients randomized to active 
treatment started at a dose of =< mg/day (intake < mg thrice daily), as they experienced 
intolerable Adverse Events after administration of > mg during the challenge phase. Daily 
doses prescribed in the treatment phase are presented in Figure 1. After two weeks of 
treatment the daily dose was increased with @.< mg in all patients, except one. For two 
patients the dose was subsequently decreased to the starting dose (=< mg/day and :@ 
mg/day, respectively), due to Adverse Events, indicating that the maximum tolerated 
dose was reached for these patients.
Treatment phase
Treatment e(ects were measured using di(erent types of outcome measures, 
which we categorized as objective or subjective measures of eNcacy or secondary 
pharmacodynamic response results. The results of the measures of eNcacy are 
summarized in Table 2. No signi'cant treatment e(ect was observed on the objective 
endpoints for spasticity: -/C ratio and Ashworth score. Measures of subjective 
spasticity did demonstrate a chronic treatment e(ect in a post-hoc analysis that 
included patients who reported spasticity at the start of the treatment phase (N==>): 
a non-signi'cant reduction of ?.)@ point (+7s.$: -:.?< – ?.=O, p=?.?)=?). Additionally, in 
a post-hoc analyses of chronic treatment e(ects in patients who reported pain at the 
start of treatment (N==O), pain rating was signi'cantly reduced overall during four weeks 
of treatment with "./1158 (Q#C :.O@ for active treatment versus @.:< for placebo, Q#C 
estimated di(erence -=.<= (+7s.$: -:.O< – -?.:>, p=?.?=)>) (Figure 2). When spasticity 
and pain were measured with a daily diary at home, no signi'cant treatment e(ect was 
observed for either pain (-?.@O (+7s.$: -:.AA – =.O=, p=?.A<>=) or spasticity (-?.?) (+7s.$ 
-=.)) – =.>=, p=?.)=)<). Fatigue, measured using the 0## was signi'cantly reduced after : 
weeks of "./1158 treatment, compared with placebo, Q#C estimated di(erence -?.O@ 
(+7s.$: -=.@; – -?.?@, p=?.?;>:). This di(erence was not signi'cant overall: -?.@: (+7s.$: 
-=.?; –?.:?, p=?.=OA)). Other functional outcome measures for eNcacy including 
"!##, ,570E, /%$., /#q$ did not signi'cantly improve during four weeks of treatment 
(Table 2). 
Other secondary pharmacodynamic e(ects were assessed using two objective 
biomarkers and two subjective questionnaires. The results are described in Table 3. 
None of the tests evidenced a clinically relevant or statistically signi'cant decline of 
postural stability, cognitive functioning, mood or psychotomimetic e(ects. During each 
treatment visit, the patients were asked which treatment they assumed to be receiving 
in order to assess possible bias amongst patients. At the end of the treatment, < (@=.O%) 
patients in the placebo arm guessed correctly that they had received placebo treatment 
!"#$%&' / – &00&!%1 +* 1$#1%)!)%2 #*, *&-'+$#%")! $#)* )* $#%)&*%1 3)%" $'+4'&11)5& 6-7%)$7& 1!7&'+1)1 61
and < (@=.O%) patients were not sure, whereas > (AA.O%) patients on active treatment 
guessed correctly that they had been receiving active treatment. Presumed treatment 
allocation was included in the statistical analyses, but was not a signi'cant factor in 
treatment response. 
A responder analysis was performed, in which responders for spasticity and pain 
(&D#) and were identi'ed and compared in terms of baseline characteristics. This 
analysis did not yield signi'cant di(erences in baseline characteristics between 
responders and non-responders. 
Pharmacokinetics 
Pharmacokinetic parameters were derived from the data collected during the challenge 
phase and during the treatment phase. An overview of the population parameter 
estimates of the 'nal one compartment /p model for *+-,-. is shown in Table 4. 
The model includes inter-individual variability on the elimination rate constant (pKU) 
(ʘ: Estimate ?.?;>, Standard Error (#") ?.?=>) and inter-occasion variability on the 
absorption rate constant (pa) (ʘ: Estimate ?.@O, #" ?.?>O). The parameter estimate for 
pa is ?.??;; min-= (+7s.$= ?.??:< – ?.??@:). The parameter estimate for pKU: ?.?;A min-= 
(+7s.$ = ?.?:: – ?.?<>). The apparent volume of distribution (Happ) is estimated at :>< L. 
(+7s.$ = =O?-@O)). 
Safety
In total, :?? Adverse Events were recorded, the vast majority of which were classi'ed 
as mild. Nine (@.<%) Treatment Emergent Adverse Events (,"8"s) were considered 
moderate and one (?.<%) diagnosis of euphoric mood was judged as severe, as it lead 
to inability to work or perform daily activity. A summary table of all Adverse Events that 
were observed more than once is provided in Table $. The most commonly reported 
Adverse Events were dizziness and euphoric mood, followed by headache, somnolence 
and fatigue. Whenever a subject reported to be ‘feeling high’ this was recorded as 
‘Euphoric mood’ in accordance with C"!!D8 coding, regardless of whether or not the 
subject reported euphoria. ‘Feeling abnormal’ was used to describe changes in internal 
or external perception, without a patient speci'cally mentioning the word ‘high’. Adverse 
Events related to disease state and commonly present in this population, including 
muscular weakness, muscle spasticity, tremor or paraesthesia were recorded only if 
there was an increase compared to prior to the start of the study, as experienced by 
the patient. During the treatment phase, 've Adverse Events lead to a dose adjustment 
or omission of dose increase after two weeks of treatment. No Serious Adverse Events 
(#8"s) occurred during this study. Individual patients reported psychiatric symptoms 
including confusion, disorientation, irritability or apathy, but this was not endemic for 
treatment with "./1158 . One subject reported Adverse Events that ultimately led to 
termination of the participation of this subject after six days of placebo treatment. Four 
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out of twelve patients on active treatment (;;.;%) reported an increase in muscular 
weakness, of which one was considered moderate. The safety pro'le observed during 
active treatment in this study corresponds with the expected Adverse Event pro'le for 
this class of drugs.
(!).-))!+"
This was a phase II accelerated proof-of-concept study to investigate the adverse 
e(ect pro'le and tolerability, pharmacodynamics and pharmacokinetics of a novel oral 
formulation of *+-,-. in patients su(ering from progressive C# and spasticity. The 
current study was performed immediately following the First-in-Human study in healthy 
volunteers. This study was designed as a hybrid between a typical multiple dose study to 
investigate /p, /! and safety, and a 'rst-in-patient study to establish proof-of-concept. 
In this small-sized study (N=:@), we were able to meet these objectives. The challenge 
phase in the study design proved to be an elegant way to investigate /p, /! and safety 
and decide on an appropriate starting dose per individual patient, to avoid cumbrous 
and ineNcient uptitration during the treatment phase. Moreover, the placebo-controlled 
crossover setting reduced the risk of bias. Even though dose selection for the treatment 
phase on an individual level was less re'ned than initially intended due to variability 
in acute /! response which impeded determination of a starting dose using /p//! 
modelling, the challenge phase still lead to an e(ective treatment phase of @ weeks 
in which a pharmacodynamic treatment e(ect could be demonstrated in the target 
population. The e(ect sizes in terms of treatment e(ect of the novel oral formulation of 
*+-,-. on the clinical endpoints of subjective spasticity, pain and various other clinical 
endpoints are consistent with the 'ndings of earlier studies on this topic.II,LK 
Overall, treatment with "./1158 was well-tolerated. The most frequently observed 
events, dizziness, somnolence and changes in mood, including euphoric mood, were 
related to the primary pharmacological mechanism of action. As such these events were 
in line with what was expected. One-third (N=@) of the patients treated with "./1158 
reported muscular weakness during the treatment phase. This muscular weakness 
may be a part of the causal pathway of reduced muscle tension leading to the intended 
treatment of spasticity. 
Subjective spasticity measured with an &D# repeatedly during the treatment visits 
on week ?, : and @ showed an improvement after two and four weeks of treatment, 
which was signi'cant at two weeks of treatment. The same pattern was observed in a 
more pronounced way for the &D# for pain measured as an &D# repeatedly during each 
treatment visit demonstrated an overall improvement in favour of treatment compared 
to placebo. For both spasticity and pain post-hoc analyses were performed, which only 
included patients with any subjective spasticity and pain at the start of treatment, as 
patients with an &D# spasticity or pain of ? at baseline would not have been susceptible 
to improvement, thus leading to a statistical Boor e(ect. For &D# spasticity this analysis 
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in => patients emphasized the pattern that was already seen in the Intention-To-Treat 
($,,) analysis: a reduction in subjective spasticity, which was signi'cant after two weeks 
of treatment, but not after four weeks of treatment and no overall signi'cant treatment 
e(ect. The &D# for pain (N==O) showed a signi'cant overall treatment e(ect and an 
overall reduction in pain of =.:O point. To di(erentiate between acute and (sub)chronic 
treatment e(ects, an additional analysis was performed that included the results of the 
baseline and week : and @, and omitted those measurements taken immediately after 
the 'rst dosing administration of the treatment phase. These analyses accentuated 
the pattern that was observed in the $,, analysis. No signi'cant treatment e(ect was 
observed for the objective measurements of spasticity: -/C ratio and Ashworth. In 
addition, subjective spasticity and pain measured with an &D# using a daily diary during 
the treatment phase showed a limited decrease in level of subjective spasticity and 
pain in patients treated with active treatment compared to placebo, which was not 
statistically signi'cant.
The data-intensive study design allowed for a thorough investigation of the 
relationship between acute and chronic pharmacodynamics and pharmacokinetics in 
the target population. The observed di(erence between acute and daily treatment e(ects 
brought to light the importance of timing of measuring subjective treatment e(ects. 
         The discrepancy between the objective and subjective measures of spasticity seen in 
this study has previously also been observed in phase II and III trials of cannabinoids and 
even occasionally for currently 'rst-line spasmolytics in patients with C#LL. According to 
the reviews by Rog et al. and Lahkan et al.IU,II, only one studyLR reported an improvement 
in Ashworth score, whereas multiple studies reported only subjective improvement of 
spasticity. In the aforementioned reviews and clinical studies the validity of the Ashworth 
scale as an outcome measure for clinically relevant improvement has been questioned, 
partially due to its limited sensitivity for detecting small changes, as is the case for any 
objective measure of spasticityLM. With the goal to further elucidate the pharmacological 
mechanism of action of *+-,-. on spasticity in patients su(ering from C# in this data-
intensive clinical study, this endpoint was included in the protocol nonetheless. Even 
though the study was performed in a double-blind fashion, cannabinoids are known 
to induce subjective psychoactive e(ects, which are potentially undermining blinding 
of study treatment allocation. This could introduce bias, especially when measuring 
subjective outcome measures. However, it is impossible to disentangle desired 
spasmolytic treatment e(ects from psychoactive “unblinding” e(ects, as they both result 
from modulation of the cannabinoid system, and even possibly share the same pathway.
In two out of the three other studies where the e(ects of *+-,-. on -/C ratio were 
investigated, no signi'cant treatment e(ects were seen after @-A weeks treatment 
with oromucosal cannabis-based therapyLJ-LS. In the current study, the baseline -/C 
ratio values observed in the in the m. soleus, were relatively low compared to what is 
generally considered hyperreBexia or muscle spasticityLT. This can possibly be explained 
by the extent of muscle tone observed in these patients: if muscle tone is increased for 
a prolonged period of time, reBexes are often diminished due to reduced excitability of 
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the muscle. This phenomenon was distributed unevenly among the treatment groups, 
as it was observed at the start of treatment and during the challenge phase preceding 
the treatment phase and is thus considered a group di(erence resulting from chance.
During the challenge phase objective (postural stability) and subjective (alterations 
in internal/external perception or mood) pharmacodynamic e(ects were a(ected by 
"./1158 compared to placebo. However, these pharmacodynamic e(ects were not 
observed during the four week treatment phase: patients receiving active treatment did 
not demonstrate an increase in postural instability after two or four weeks of treatment 
compared to placebo. In addition, the minor psychoactive e(ects observed after acute 
administration of "./1158 during the challenge phase were not observed during 
the treatment phase. A comparable pattern was observed in the #!#,, a measure of 
attention, short-term memory and psychomotor speed, which demonstrated a slight 
deterioration after two weeks of treatment with "./1158 compared to placebo. 
This di(erence however, was reversed after @ weeks of treatment, suggesting an 
improvement in reaction time. This slim statistical di(erence was skewed due to a 
ceiling e(ect, and is considered not clinically relevant. It does indicate, however, that no 
clinically relevant deterioration in attention and cognitive functioning had taken place 
during @ weeks of treatment with "./1158.These 'ndings appear to imply habituation 
to the (undesirable) psychoactive e(ects, which was also observed in previous studies 
investigating the potential for cannabinoids in therapeutic applicationsRU. 
To our knowledge the 'rst /p model for *+-,-. in this patient population was created 
based on the data that was collected during the challenge and treatment phase. The 
current /p model exhibits the Bip-Bop kinetics phenomenon, where the pa < pKU and 
therefore the terminal phase is determined by p8. Although resulting in the best model 
't, it is known from previously published /p models RI that this is not true for *+-,-.. 
The reason for this discrepancy is that the mathematical description of the data with 
a one-compartment oral absorption model can be identical when the value for pa and 
pKU are interchanged, and the value for Happ is then scaled. Such a more physiologically 
plausible 't with pa > pKU could not be accomplished with the current data, and therefore 
this should be taken into consideration when interpreting the values for pa, pKU and Happ. 
In line with the variability in pharmacodynamic outcomes observed in this trial, moderate 
variability in pharmacokinetics was observed during both the challenge and treatment 
phase, compared to the phase = trial investigating the /p and /! of "./1158 IR. Thus, this 
increased variability is most likely attributable to an increase in variability observed in a 
heterogeneous patient population, compared to healthy volunteers. Pharmacokinetic 
modelling demonstrates a relatively high typical apparent clearance (=?.:O L/min) and 
typical apparent (central) distribution volume compared to previous 'ndings, which is 
most likely related to a lower bioavailability (previously estimated between @%-=:% RK. In 
addition, a slower absorption rate was observed compared to what was observed in a 
previous study investigating "./1158 in healthy subjectsIR. This was most likely caused 
by a reduced gastro-intestinal motility, which has previously been reported in patients 
with C#.RL
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In this four week study, the subjective measures of the severity of experienced spasticity 
and pain demonstrated a treatment e(ect compared to placebo. These 'ndings are in 
line with what has been previously reported on the e(ects of cannabinoids in patients 
with C#, when measured in the clinic. However, assessment of subjective e(ects 
using a daily diary yielded discrepant results, underlining the importance of selecting 
the appropriate method for determining treatment e(ects, when patients are treated 
at home. The mild Adverse Event pro'le indicates overall good tolerability for this 
formulation of *+-,-.. Pharmacokinetic modelling provided insight in the relatively 
large variability in absorption between and within patients, thereby underlining the 
rationale for this combined crossover and parallel study design. 
According to recent reviewsRR,RM there currently is moderate evidence supporting 
the use of cannabinoids (*+-,-. alone or in combination with cannabidiol), for the 
treatment of spasticity and pain in patients su(ering from C#. Even though research thus 
far has focused on di(erent formulations of cannabinoids (e.g. nabiximols), the 'ndings 
of the present study demonstrate that the current formulation has the potential to play 
a role in the treatment of symptoms including spasticity and pain associated with C#.
In conclusion, this study demonstrates that the current formulation of "./1158 
exerts a similar e(ect on spasticity and pain as other *+-,-. formulations that was 
detectable after two weeks of treatment and was safe and well-tolerated in the target 
population. In line with previous reports, spasticity and pain appear to be inBuenced 
by *+-,-. through higher-level .&# modulation of perception of spasticity rather than 
electrophysiological muscle spasticity itself. Accordingly, "./1158 may have a role in 
symptomatic treatment of spasticity and pain in C#. 
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.%'2, ! Baseline characteristics
Total (N=14) ȴC-.9$ (N=D1) Placebo (N=D1)
Age  
(years)u
Mean (#!) 54.3 (8.9) 57.3 (9.0) 51.4 (8.0)
Range 38-73 41 – 73 38 – 64
Sex  
(n)u
Male 8 (33.3%) 4 (33.3%) 4 (33.3%)
Female 16 (66.7%) 8 (66.7%) 8 (66.7%)
Disease Duration  
(years)u
Mean (#!) 11.5 (5.8) 10.3 (6.5) 12.6 (4.9)
Range 3 - 27 3 – 27 6 – 21
Spasticity  
(n)u
Modi'ed Ashworth  
score of 2
16 (66.7%) 8 (66.7%) 8 (66.7%)
Modi'ed Ashworth  
score of 3
8 (33.3%) 4 (33.3% 4 (33.3%
"!## (total)
u
Mean (#!) 6.2 (0.9) 6.2 (1.2) 6.3 (0.5)
Range 4.5-7.5 4.5 – 7.5 5.5 – 7.5
-' = standard deviation / <'-- = Kurtzke Expanded Disability Status Scale
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.%'2, " Summary of analysis of measures of pharmacological e3ects during the challenge 
phase
2/ Means Contrasts 2/ Means change 
from baseline
Parameter Placebo Active Estimate of di>erence 
(C5%CI)
Placebo Active
F9t".,$H" 8&! #P9t".,$H" C"8#PD"# 0FD "00$.8.o
-/C Ratio 0.333 0.326 -.007 (-.070, 0.057)  
p=0.8238
-0.002 -0.008
&D#: spasticity 3.35 3.64 0.28 (-0.01, 0.58)   
p=0.0595
-0.73 -0.45
&D#: neuropathic pain 2.75 2.71 -0.03 (-0.41, 0.34)   
p=0.8470
-0.23 -0.27
F9t".,$H" C"8#PD"C"&,# 0FD #".F&!8Do /-8DC8.F!o&8C$. "00".,#
Body sway (mm) 775.3 919.4  18.6% (5.9%, 32.8%) 
p=0.0067
-2.0% 16.3%
Heart rate (supine) (bpm) 71.1 74.6  3.5 (1.4, 5.7)   
p=0.0025
-1.0 2.5
#P9t".,$H" C"8#PD"C"&,# 0FD #".F&!8Do /-8DC8.F!o&8C$. "00".,#
H8# External log (mm) 0.323 0.384 0.061 (0.028, 0.094)  
p=0.0009
-0.022 0.040
H8# Internal log (mm) 0.321 0.352 0.030 (0.003, 0.057)  
p=0.0295
-0.030 0.000
H8# feeling high log (mm) 0.322 0.542 0.220 (0.067, 0.373)  
p=0.0070
0.019 0.239
H8# Alertness (mm) 54.5 52.7  -1.7 (-4.1, 0.6)   
p=0.1342
1.3 -0.4
H8# Calmness (mm) 53.8 54.7  0.9 ( -1.5, 3.3)   
p=0.4289
1.8 2.7
H8# Mood (mm) 55.2 56.0  0.8 ( -0.4, 2.0)   
p=0.1699
0.5 1.4
;/5 ratio = ratio of the maximum amplitude of the Ho%mann re8ex to the maximum M response /  
0=-: Numerical Rating Scale / mm = millimeter / bpm = Beats Per Minute / ,)- = Visual Analogue Scale / 
>- Means = Least Square Means / :?@+/ = "4% Con6dence Interval
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.%'2, # Summary of analyses of measures for e4cacy during treatment phase
2/ Means Contrasts 2/ Means change 
from baseline
















0.385 0.386 0.001  
(-.178, 0.179)  
p=0.9929
-.009  
(-.198, 0.180)  
 p=0.9216
0.031  





1.70 1.60 -0.11  
(-0.41, 0.19)  
 p=0.4615
-0.10  
(-0.52, 0.31)  
 p=0.6142
-0.11  




















4.50 3.81 -0.69  














4.52 3.57 -0.94  
(-2.05, 0.17)  
 p=0.0910
&D#: pain  
(Score 1-10)
2.95 2.15 -0.81  
(-1.66, 0.04)  
p=0.0618
-1.09  
(-1.98, -0.20)  
p=0.0183
-0.85  
(-1.74, 0.04)  
 p=0.0612
-0.21 -1.02








(-2.96, -0.41)  
p=0.0124
-1.38  
(-2.65, -0.10)  
 p=0.0360
-0.27 -1.54






4.25 2.74 -1.51  





3.65 3.56 -0.09  
(-1.99, 1.81)  
p=0.9195
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Diary: pain  
(Score 1-10)
2.57 2.10 -0.47  





6.42 6.39 -0.03  
(-0.22, 0.17)  
 =0.7650
-0.12  
(-0.34, 0.11)  
 =0.2935
 0.06  
(-0.16, 0.28)  
 p=0.5759
-0.05 -0.08
,57 feet walk  
(ft/sec):  
subanalysis
3.70 3.87  4.8% 
( -7.8, 19.1%) 
 =0.4425
 4.0% 
( -9.1, 19.0%) 
 =0.5481
 5.6% 





4.08 3.59 -0.49  
(-1.19, 0.21)  
 p=0.1632
-0.58  
(-1.33, 0.16)  
 p=0.1213
-0.39  





4.15 5.15  1.00  
(-0.83, 2.84)  
 p=0.2688
 0.36  
(-1.62, 2.33)  
 p=0.7147
 1.64  





4.33 3.92 -0.42  






(-1.13, 0.25)  
 p=0.2065
-0.13 -0.55
;/5 ratio = ratio of the maximum amplitude of the Ho%mann re8ex to the maximum M response /  
0=-: Numerical Rating Scale / <'-- = Kurtzke Expanded Disability Status Scale / (A?BC = Timed 14  
foot walk / &D/+ = Patients Global Impression of Change / &-E/ = Pittsburgh Sleep Quality Index /  
B-- = Fatigue Severity Scale / >- Means = Least Square Means / :?@+/ = "4% Con6dence Interval
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.%'2, @ Population parameter estimates of one compartment 01 model for 56-789.
-E Parameter C5% CI $< (%)
Primary parameter
ka (min-1) 0.0033 (0.0025;0.0042) 77.7
Lag time (min) 5.26 (5.11;5.41) -
Vapp (L) 285 (170;479)
k20 (min-1) 0.036 (0.022;0.058) 19.6
CLapp (L*min-1) 10.27 (8.72; 12.1) 19.6
T1/2 (min) 213.6 (165; 275) 77.8
Inter-individual variability C2 Estimate -.<. Shrinkage (%)
k20 0.038 0.018 32.2 
ka ($FH) 0.47 0.087 6.8 - 43.1
Residual error ʍ2 Estimate -.<. Shrinkage (%)
Proportional 0.18 0.018 9.4 
-< = Standard Error / Fa = absorption rate constant / ,app = apparent volume of distribution /  
F1. = elimination rate constant / +>app = apparent clearance / /G, = inter-occasion variability /  
Clearance (+>) = aVd * k1.
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.%'2, B Overview of Adverse Events and incidence of events reported more than once.













Number of subjects with at least one 
Adverse Event
20 (83.3%) 10 (41.7%) 10 (83.3%) 7 (58.3%)
Number of di(erent Adverse Events 15 9 34 15
FH"DH$"E F0  8!H"D#"  "H"&,# ($&.$!"&." >G)
Nervous system 
Dizziness 6 (25.0%) 1 (4.2%) 7 (58.3%) 1 (8.3%)
Headache 3 (12.5%) 2 (8.3%) 6 (50.0%) 3 (25.0%)
Somnolence 6 (25.0%) - 3 (25.0%) 2 (16.7%)
Muscular weakness 1 (4.2%) 1 (4.2%) 4 (33.3%) 1 (8.3%)
Muscle spasticity - - 3 (25.0%) 3 (25.0%)
Paresthesia - 1 (4.2%) 2 (16.7%) -
Tremor 1 (4.2%) - 2 (16.7%) -
Tinnitus - - 2 (16.7%) -
Psychiatric / mood
Euphoric mood 5 (20.8%) 1 (4.2%) 4 (33.3%) 2 (16.7%)
Disturbance in attention 1 (4.2%) 1 (4.2%) - -
Insomnia - - 1 (8.3%) 1 (8.3%)
General disorders and administration site conditionsF
Fatigue 3 (12.5%) 2 (8.3%) 2 (16.7%) 3 (25.0%)
Feeling abnormal 4 (16.7%) - 1 (8.3%) 2 (16.7%)
Feeling hot 1 (4.2%) - 2 (16.7%) 2 (16.7%)
Gastrointestinal 
Dry mouth 1 (4.2%) - 2 (16.7%) -
Nausea 1 (4.2%) - - 1 (8.3%)
Increased appetite 1 (4.2%) - 1 (8.3%) -
)< = Adverse Event 
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7(0:+, ! Disposition of patients
7(0:+, " Total daily dose of 56-789 prescribed per subject in the treatment phase  
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7(0:+, #% %&* ' Post-hoc analyses: <=> change from baseline time pro.le for ?@= for  
(A) spasticity (N=:A) and (B) pain (N=:B).
0=- 
= 
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1 Baseline Week 2 Week 4
Time (hh:mm)
0:00 2:00 4:00 Week 2: 0:00 2:00 4:00 Week 4: 0:00 2:00 4:00
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'6)#&'.#
'%$E0+):&* A battery of evoked pain tasks (PainCart) was developed to investigate 
the pharmacodynamic properties of novel analgesics in early phase clinical research. As 
part of its clinical validation, compounds with di(erent pharmacological mechanisms 
of actions are investigated. The aim was to investigate the analgesic e(ects of classic 
and non-classic analgesics compared to a sedating negative control in a randomized 
placebo-controlled crossover study in :@ healthy volunteers using the PainCart.
8,.9)*/ The PainCart consisted of pain tasks eliciting electrical, pressure, heat, cold 
and inBammatory pain. Subjective scales for cognitive functioning and psychotomimetic 
e(ects were included. Subjects were administered each of the following oral treatments: 
paracetamol (=??? mg), *+-,-. (=? mg), promethazine (<? mg) or matching placebo. 
Pharmacodynamic measurements were performed at baseline and repeated up to 
=? hours post-dose. 
+,/:2./ Paracetamol did not show a signi'cant reduction in pain sensation or 
subjective cognitive functioning compared to placebo. Promethazine induced a 
statistically signi'cant reduction in /,, for cold pressor and pressure stimulation. 
Furthermore, reduced subjective alertness was observed. *+-,-. showed a statistically 
signi'cant decrease in /,, for electrical- and pressure stimulation. *+-,-. also 
demonstrated subjective e(ects, including changes in alertness and calmness, as well 
as feeling high and psychotomimetic e(ects.
$)&$2:/()&/ This study found a decreased pain tolerance due to *+-,-. and 
promethazine, or lack thereof, using an evoked pain task battery. Pain thresholds 
following paracetamol administration remained unchanged, which may be due to 
insuNcient statistical power. We showed that pain thresholds determined using this pain 
test battery are not driven by sedation.
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The complex clinical reality of pain medicine demands novel therapeutics. A multi-modal 
battery of evoked pain tasks could be a useful tool to investigate the analgesic properties 
of novel compounds, but needs to be pharmacologically validated for speci'c classes 
of compounds. In the present study the e(ects of three oral drugs were investigated 
and compared to placebo: delta-)-tetrahydrocannabinol (*+-,-.), paracetamol and 
promethazine.
Di(erent cannabinoids have previously been shown to be e(ective in various pain 
conditions, including neuropathic pain related to oncological disease. (Vadalouca et al. 
:?=:) *+-,-. has been shown to be an e(ective analgesic in preclinical studies and 
clinical trials. However, previous formulations of cannabinoid *+-,-. are also known for 
variable pharmacokinetic pro'les and pharmacodynamic responses. (Huestis :??O) To 
overcome barriers in clinical application, novel formulations and cannabinoids are under 
development. (Klumpers et al. :?=:)
Even though paracetamol is one of the most widely used medications in the world, 
there is still debate regarding its exact mechanism of action. Paracetamol is thought 
to be a weak inhibitor of prostaglandins (/%) synthesis. The subsequent main driving 
mechanism of paracetamol analgesia is not completely understood. It has been 
proposed that it exerts most of its e(ects through .F`-5 inhibition, but also inhibition of 
endocannabinoids has been proposed. In addition, various neurotransmitter systems 
(e.g. serotonergic, opioid and noradrenaline) are thought to be involved. (Bertolini et al. 
:??A; Boychuk et al. :?=<; Graham et al. :?=;; Koppel et al. :?=@)
To investigate the role of sedation rather than analgesic e(ects of psychoactive 
compounds a negative control was included in the current study in the form of the -G 
antihistaminergic promethazine (<? mg). Even though it has been observed in preclinical 
research that -G antihistaminergic drugs may have analgesic potential, this has not been 
replicated in clinical practice for oral formulations administered alone. (Rumore and 
Schlichting =)><; Ra(a :??=) Therefore we considered this sedative compound suitable 
as a comparator drug without analgesic e(ects
The primary aim of this study is to investigate the analgesic e(ects of classic and 
non-classic analgesics compared to a sedating negative control in a randomized 
placebo-controlled crossover study in :@ healthy volunteers using the PainCart. As a 
secondary objective, by comparing the e(ects of the ; compounds within each subject 
in a crossover design, and comparing the analgesic pro'le to the pro'les of other 
analgesic compounds that we recently investigated using the battery of evoked pain 
tasks, we aimed to further elucidate the still unknown pharmacological mechanism of 
action of *+-,-. and paracetamol analgesia.
The battery of evoked pain tasks has been pharmacologically validated by investigating 
a broad range of analgesics from various classes, with diverse but well-known 
mechanisms of action. (Okkerse, van Amerongen, et al. :?=A) This 'rst pharmacological 
validation study demonstrated the necessity of utilising a range of pain tasks in 
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early-phase drug research. Namely, each compound provided a unique 'ngerprint of 
e(ects on the test battery. These 'ndings emphasized the importance of utilising a range 
of pain tasks, rather than a single pain task, when determining the pro'le of analgesic 
e(ects of a compound in early phase drug development. Building on this knowledge, the 
present study investigated the e(ects of two (classes of) analgesics, paracetamol and 
ȴ+-,-., and additionally the e(ects of sedation using promethazine as a negative control. 
*$#1+()
Subjects and study design
The study was a double-blind, double-dummy, single dose, randomized, placebo-
controlled, crossover study in which the e(ects of paracetamol, ȴ+-,-. and the 
negative control promethazine were compared to placebo. The study was conducted 
at the Centre for Human Drug Research in Leiden, The Netherlands. The study was 
approved by the Medical Ethics Committee of Stichting Beoordeling Ethiek Biomedisch 
Onderzoek (Assen, The Netherlands) and was conducted according to the Dutch Act 
on Medical Research Involving Human Subjects (ECF) and in compliance with all 
International Conference on Harmonisation Good Clinical Practice ($.--%./) guidelines 
and the Declaration of Helsinki. This study was registered in the public registry of the 
Centrale Commissie Medisch Onderzoek (..CF) in the Netherlands, under registration 
number: &Q<@A@;.?<A.=<
Each subject provided written informed consent before any screening procedures 
were performed. A total of :@ healthy subjects (=: males and =: females) between => and 
@< years of age with a body mass index of => to ;? kg/mK were enrolled. The subjects 
underwent a full medical screening, including medical history anamnesis, a physical 
examination, blood chemistry and haematology, urinalysis, electrocardiogram (".%) and 
assessment of the minimal erythema dose (C"!) for ultraviolet B (PH9) light to assess 
eligibility. Subjects with a clinically signi'cant known medical condition, in particular any 
existing condition that would a(ect sensitivity to cold or pain were excluded. Subjects 
with Fitzpatrick skin type V or VI, widespread acne, tattoos or scarring on the back were 
excluded due to the inability to accurately assess C"!. Also any subject, who was a 
regular user of any illicit drugs, had a history of drug abuse or a positive drug screen at 
screening was excluded. Smoking and the use of xanthine-containing products were 
not allowed during dosing days. Alcohol was not allowed at least :@ hours before each 
scheduled visit and during the stay in the research unit.
Study drugs
Paracetamol (=??? mg), ȴ+-,-. (=? mg), promethazine (<? mg) or placebo was given as 
a single dose. Paracetamol =??? mg is within the labelled dose range in the European 
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Union ("P) and has been shown to be e(ective in reducing various types of pain. The 
currently used formulation of ȴ+-,-. (Namisol®, Echo Pharmaceuticals) has been 
administered in multiple studies including healthy volunteers (Klumpers et al. :?=:) and 
di(erent patient populations. (Ahmed et al. :?=@; Utomo et al. :?=<; van Amerongen 
et al. :?=O) ȴ+-,-. has potential side e(ects, but is generally considered well-
tolerated, even in high dosages. Promethazine is a classic -G antihistamine with some 
anticholinergic e(ects. Daily doses up to =<? mg are prescribed for the treatment of 
allergic rhinitis and motion sickness. Single doses up to <? mg are prescribed to induce 
mild sedation. 
Due to unequal formulations (ȴ+-,-. was formulated as an oral tablet, whereas 
paracetamol and promethazine were formulated as capsules), matched placebo tablets 
for each treatment were administered in a double-dummy fashion to maintain blinding 
of treatment for participants and researchers. 
Pharmacodynamic assessments
Pain detection and tolerance thresholds were measured using a battery of evoked 
pain tasks, as described previously. (Hay et al. :?=A; Okkerse, Alvarez-Jimenez, et al. 
:?=A; Okkerse, Hay, Sitsen, et al. :?=A; Okkerse, Hay, Versage, et al. :?=A; Okkerse, van 
Amerongen, et al. :?=A) The test battery consists of an integrated range of pain tasks for 
measuring di(erent modalities of pain. Assessments were conducted twice pre-dose 
(double baseline) and ?.<, =, :, ;, @, A, > and =? hours post-dose by trained personnel. 
Each measurement round was performed in a 'xed order and took approximately 
;? minutes to complete. To eliminate the risk of tissue damage, all pain tasks had 
a maximum safety cut-o(. The aim of the test battery is to assess as objectively as 
possible the levels of pain induced by di(erent noxious mechanisms in human subjects. 
A training session was included as part of the screening examination to reduce learning 
e(ects during the study and exclude non-responders (i.e. subjects who reach /!, at 
>>?% of the maximum at any of the nociceptive tasks, excluding the heat pain task) 
or extreme responders (subjects indicating to be intolerable to any of the nociceptive 
tasks). All measurements were performed in a quiet room with ambient illumination. 
Per session, there was only one subject present in the same room. To reduce variability 
from a(ects associated with fear of pain, the subjects themselves were responsible for 
starting and ending each pain task. 
The battery of evoked pain tasks consists of the following tasks for nociception: the 
electrical stimulation task, pressure stimulation task, thermal (heat) pain and the cold 
pressor tasks. Furthermore, the test battery includes a model for inBammatory pain, the 
PH9 model and a paradigm to quantify Conditioned Pain Modulation (./C), formerly 
known as Di(use Noxious Inhibitory Control (!&$.). 
For the electrical stimulation task, the pressure stimulation task and the cold 
pressor task, pain intensity was measured continuously (beginning from when the 'rst 
stimulus was applied until the end of the test) using an electronic visual analogue scale 
!"#$%&'#$( '))$))*$"# +, "$-&+.+%"!#!/$, "$-&+012)!+3+%!.'3 '"( 0'!" 0&+.$))!"% !" $'&32 .3!"!.'3 (&-% ($/$3+0*$"# 82
(H8#) scale ranging from ? (no pain) to =?? (most intense pain tolerable). Equipment 
was programmed to cease giving stimuli if the recorded pain intensity reaches the 
maximum pain score (=??) or when the maximum safety level was reached. For the 
abovementioned pain tasks, the pain detection threshold (/!,) (de'ned as H8# score 
> ?), pain tolerance threshold (/,,) (de'ned as H8# score of =??) and Area Under the 
Curve (8P.) or Area Above the Curve (88.) (Cold Pressor only) were determined. 
Additionally, a post-test Visual Analogue Scale (H8#) score (anchored with no pain (?) 
and worst pain imaginable (=??)) was performed to retrospectively assess the worst 
pain experienced during the pain task. For the thermal pain task (normal skin and PH9 
exposed skin) only the (average of triplicate) /!, was determined, since assessment 
of heat /,, is prone to inducing tissue damage. For all nociceptive tasks were a /,, is 
determined (all except thermal pain) the primary endpoint is the /,,. For the thermal 
pain tasks (normal skin and PH9 exposed skin), the /!, is the primary endpoint of 
the measurement. However, since each parameter (/!,, /,,, 8P./88.) provides 
information on di(erent aspects of the nociceptive system and pain perception, all 
variables are taken into account. 
In addition to the evoked pain tasks, subjective assessment of sedation and 
psychotomimetic e(ects were included as /! outcome measures. Visual analogue scales 
(H8#) as originally described by Norris (Norris =)O=) have often been used previously to 
quantify subjective e(ects of a variety of sedative agents. (de Visser et al. :??=; Norris 
=)O=) A set of H8# scales assessing alertness, mood, and calmness (Bond and Lader 
=)O@) were used for subjective assessment of sedation. The H8# allows the subjects to 
evaluate their current subjective states. Each H8# scale consists of : words representing 
opposite feelings placed to the left and right of a horizontal line. The subject is asked to 
mark his/her current feelings. Subjective psychotomimetic (psychedelic) e(ects were 
evaluated using H8# Bowdle. This scale has been used extensively to quantify subjective 
psychotomimetic e(ects of psychoactive compounds, including ketamine. (Bowdle et al. 
=))>) Bowdle Psychotomimetic E(ects Scores consist of thirteen visual analogue lines 
ranging from ? (‘not at all) to =?? (‘extremely’) (van Steveninck =));), addressing various 
(abnormal) states of mind. 
Sample size and randomisation
Based on literature, /!, for the cold pressor assessment was used for the sample size 
calculation as this assessment has been shown sensitive to the e(ects of ȴ+-,-. in 
previous research. (Cooper, Comer, and Haney :?=;a) For the cold /!,, a sample size of 
:@ subjects has >?% power to detect a di(erence in means of ;<%, assuming a standard 
deviation of di(erences of ?.<, using a paired t-test with a ?.?< two-sided signi'cance 
level. For the sample size calculation, placebo data from a previous study with the battery 
of pain tasks were used to determine variability. (Okkerse, van Amerongen, et al. :?=A) 
The balanced Williams design randomization code was generated using #8# version 
).=.; by a study-independent statistician.
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Statistical analysis
To establish whether signi'cant treatment e(ects could be detected on the /! 
outcome variables, variables were analysed with a mixed model analysis of variance 
with treatment, time, sex, treatment by time and treatment by sex as 'xed factors and 
subject, subject by treatment and subject by time as random factors and the average 
baseline measurement as covariate. The Kenward-Roger approximation was used to 
estimate denominator degrees of freedom and model parameters were estimated using 
the restricted maximum likelihood method. The general treatment e(ect and speci'c 
contrasts were reported with the estimated di(erence and the )<% con'dence interval, 
the least square mean estimates and the p-value. Graphs of the Least Squares Means 
estimates over time by treatment were presented with )<% con'dence intervals as error 
bars. All calculations of the pharmacodynamic parameters were performed using #8# 
for Windows version ).=.; (#8# Institute Inc., Cary, &., P#8). The main #8# procedure that 
was used in the analysis was “/DF. C$`"!”. No adjustments for multiple comparisons 
were employed. The contrasts for the relevant time periods based on the expected /p 
pro'les of the compounds of ?-@h are presented. 
&$)-3#)
A total of :< subjects were randomized, of which :; subjects completed study 
participation. Two (:) subjects withdrew consent to participate for personal reasons, one 
of which was replaced. A summary of the baseline demographics is provided in Table !. 
Pharmacodynamics
Time pro'les of the pharmacodynamic responses on /,, for each pain task, except heat 
pain (Normal skin and PH9 skin) for which /!, is displayed, are presented in Figure !. This 
'gure also includes a graphical presentation of ./C (Delta /,, for electrical pain). /,, 
and /!, measurements were log (ln) transformed before analysis, due to the log normal 
distribution of the data. The results are presented as % change from baseline over a 
=?-hour period. A detailed description of the results of the Least Square Means (Q#C) 
analyses for each treatment as well as contrasts compared to placebo (?-@ hours) can 
be found in Table 1. The results of the Q#C analyses for the primary endpoints (/,,) are 
summarized in Figure 1. Each spoke represents one of the pain tasks, resulting in an e(ect 
pro'le compared to placebo per treatment. Here, the dashed placebo line represents the 
value to which other treatment e(ects are normalized. A contrast distal from placebo 
indicates that the Q#C /,, for that treatment is greater than placebo, proximal indicates 
a Q#C /,, lower than placebo.
Furthermore, the results for the subjective scales for cognitive functioning and 
psychotomimetic symptoms are presented in Table 2. Paracetamol did not show a 
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signi'cant reduction in pain sensation compared to placebo. A small increase in 8P. 
(p=?.?;=@) was observed for the pressure pain task, indicating a slight increase in 
perceived pain sensation. Treatment with paracetamol did not lead to any observable 
changes in subjective cognitive functioning or mood. Promethazine demonstrated a 
statistically signi'cant reduction in /,, for the cold pressor pain task (p=?.?=>)) and 
for the pressure stimulation task (p=?.?=@)), as well as an increase in 8P. (p=?.??;:), 
indicating an increase in pain sensation. In addition to the pharmacodynamic e(ects of 
promethazine on the pain task battery, a reduction in subjective alertness (p=?.???:) 
was observed. ȴ+-,-. did not show a statistically signi'cant analgesic e(ect on any of 
the pain tasks. For the electrical stimulation task, the /,, was signi'cantly decreased 
by -=:.O%, (p=?.?=;@), also indicating an increase in pain sensation. Furthermore, a 
signi'cant reduction was observed for the pressure stimulation task /,, (p=?.?=:A) 
and 8P. (p=?.???=). In addition to the e(ects observed on the pain task battery, ȴ+-,-. 
also demonstrated other pharmacodynamic e(ects, including a reduction on the 
composite scale for alertness (-p=<.???=) and an increase on the composite scale for 
calmness (p=<.???=) compared to placebo. Moreover, signi'cant psychotomimetic 
e(ects were observed expressed in changes in internal perception (p=<.???=) and 
external perception (p=<.???=), measured using the H8# Bowdle, as well as H8# Feeling 
high (p=<.???=). Of note, psychotomimetic e(ects were virtually absent after placebo 
treatment, thereby leading to high signi'cance levels even at small e(ect sizes. 
Safety 
During the execution of this study, a total of O) Treatment Emergent Adverse Events 
(,"8"s) were registered. The majority (N=@;, <@%) of these were recorded after 
treatment with ȴ+-,-., after which :? out of :< subjects reported any event. Out of all 
,"8"s, seven (>.>%) were considered moderate, all others were deemed mild. For ȴ+-,-. 
treatment, A?% of subjects reported an adverse event in the System Organ Class (SOC) 
Nervous system disorders, most of which were dizziness (@?%) and headache (:?%). 
Furthermore, ; subjects (=:%) reported euphoric mood and ; subjects (=:%) mild auditory 
hallucinations. A total of four subjects experienced ,"8"s of moderate intensity after 
treatment with ȴ+-,-., leading to one or more missing measurement. For treatment 
with promethazine, most prominently somnolence (N=O, ;?.@%) and fatigue (N=A, :A.=%) 
were observed. For paracetamol treatment, a total of six events were recorded, which is 
comparable to placebo treatment.
To investigate whether adverse events may have impacted the outcome of the pain 
tasks, a subgroup analysis was performed in which the @ subjects that experienced 
at least one adverse event of moderate intensity were omitted from the analyses, as a 
moderate adverse event may have impacted pain tasks adjacent to its occurrence. This 
analysis had no signi'cant impact on the interpretation of the results, therefore it was 
decided to report the results on the intention-to-treat ($,,) population. 
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The main objective of the present study was to investigate the e(ects of a classical 
(paracetamol) and a non-classical (ȴ+-,-.) analgesic on a battery of pain tasks 
(PainCart®), compared to placebo and a negative control (promethazine). The 
e(ects of the di(erent treatment e(ects on each pain task are summarized in Figure 1, 
demonstrating the di(erential e(ect pro'le of each compound for the di(erent pain tasks. 
Contrary to our expectation we found that paracetamol was not e(ective at reducing any 
of the pain modalities measured using the battery of evoked pain tasks. Furthermore, 
ȴ+-,-. did not show any acute analgesic e(ect, and even showed a hyperalgesic e(ect 
on two of 've pain tasks, namely electrical and pressure pain. Finally, the negative control 
promethazine showed an increase in pain sensation for cold, pressure and inBammatory 
pain. In addition to the pain tasks, cognitive tests were performed to assess subjective 
alertness, mood, and psychotomimetic symptoms, which were moderately a(ected 
by treatment with ȴ+-,-. (alertness, calmness, internal and external perception) or 
promethazine (alertness). 
This study did not demonstrate and acute analgesic e(ect of ȴ+-,-., even though 
the subjective psychoactive e(ects were clearly present. As such we can conclude 
that the subjective psychoactive e(ects are not responsible for producing nociceptive 
analgesia. Moreover, the present study helped to further elucidate the mechanism of 
action of paracetamol as our results enable comparison to other analgesics with known 
mechanisms of action. Finally, when combining the 'ndings of the current study with 
the existing body of evidence from this battery of evoked pain tasks, we have shown 
this battery to be a robust tool to determine analgesic e(ects that are speci'c, and thus 
not merely expressing sedation, otherwise the observed subjective sedation would 
have resulted in analgesia. This is an important 'nding for future studies in order to 
benchmark the e(ects of novel analgesics that may demonstrate a degree of sedation, 
including subtype selective %898A agonists or novel mixed CF//&F/ receptor agonists. 
At 'rst glance it may have been surprising that the battery of evoked pain tasks 
was not sensitive to detect analgesic e(ects of paracetamol over a period of @ hours 
post-dose, as it is among the most widely used analgesics worldwide. It has been 
shown to be e(ective in the treatment of di(erent types of clinical pain, although not 
all. While it is e(ective at reducing postoperative pain (McNicol et al. :?=A; Weil et 
al. :??O), episodic tension headache (Stephens, Derry, and Moore :?=A) and acute 
migraine (Derry, Moore, and McQuay :?=?), there is no evidence for its e(ectiveness 
in treating lower back pain (Williams et al. :?=@; Saragiotto et al. :?=A) or pain related to 
osteoarthritis. (Machado et al. :?=<) However, when looking at available literature on 
human evoked pain tasks in healthy volunteers, the image becomes more di(use. For 
each of the pain tasks that were investigated in more than one clinical trial, positive as 
well as negative results have been reported: mixed results were obtained using the Cold 
pressor (Miner :??); Munsterhjelm et al. :??<; Tiippana et al. :?=;; Yuan et al. =))>), 
there was a single negative study for contact heat (Tiippana et al. :?=;), and again mixed 
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results for electrical pain (Bandschapp et al. :?==; Filitz et al. :??>; Olesen et al. :??O; 
Tiippana et al. :?=;), mixed results for pressure pain (Olesen et al. :??O; Pickering et al. 
:??>; Romundstad et al. :??A) and only a single study showing analgesic e(ects on 
inBammatory pain using the PH9 model. (Ortner et al. :?=:) Interestingly, the published 
studies measuring pain experience (post-test &D# or post-test H8#) tend to be more 
likely to show analgesia by paracetamol than studies measuring the more objective pain 
thresholds. This may indicate that paracetamol exerts its analgesic e(ect on the aspect 
of subjective pain experience by means of pain modulation rather than exerting changes 
in nociceptive pain perception thresholds. This di(erential e(ect was not observed in 
the present study. Additionally, the analgesic e(ects of paracetamol in human evoked 
pain models tend to be more subtle than the e(ect sizes that were used for the power 
calculation, therefore the study may have been underpowered. This applies speci'cally 
to for the Cold pressor task, where a non-signi'cant increase in pain thresholds was 
observed. Summarising, based on the 'ndings in literature and the aforementioned 
hypothesis, the outcome might have been di(erent if a two-way crossover compared 
to placebo design was used in which di(erent endpoints, i.e. Laser Evoked Potentials 
(Arendt-Nielsen, Nielsen, and Bjerring =))=; Nielsen, Bjerring, and Arendt-Nielsen =))=; 
Nielsen et al. =)):), were investigated. 
Medicinal use of cannabis dates back tens of thousands of years. (Abel =)>?) In 
the last decade the role for (plant-derived or synthetic) cannabinoids has shifted from 
complementary medicine to regular care for pain related to oncology (Abrams :?=A) 
and neuropathic pain resulting to spinal cord injury (Wilsey et al. :?=A) or Multiple 
Sclerosis (C#). (Turcotte et al. :?=<; Russo et al. :?=A) The oral formulation of ȴ+-,-. 
(Namisol®) that was used in the current study has been shown to be e(ective in 
reducing neuropathic pain in a recently performed study in :@ patients su(ering from 
progressive C# after @ weeks of chronic treatment. (van Amerongen et al. :?=O) However, 
given its interaction with the endocannabinoid system it cannot be considered an 
“antinociceptive” analgesic, even if it may have analgesic e(ects in some conditions. 
This is reBected in the results of clinical studies using human evoked pain models to 
investigate pharmacology and mechanism of action. Only two studies investigating 
the e(ects of either inhaled cannabis or oral ȴ+-,-. showed a statistically signi'cant 
reduction in pain sensation on the cold pressor task (Cooper, Comer, and Haney :?=;b) 
or the heat pain task. (Greenwald and Stitzer :???) Two other studies investigating 
the e(ects on heat pain alone, did not demonstrate this improvement. (Redmond et al. 
:??>; Roberts, Gennings, and Shih :??A) The results of the present study are in line 
with the results of Naef et al. (Naef et al. :??;) and Kraft et al. (Kraft et al. :??>), who 
showed lack of analgesia on a set of pain tasks and even a signi'cant or non-signi'cant 
increase in pain sensation for electrical pain and cold pressor. The 'nding of ȴ+-,-. 
induced hyperalgesia has also been observed in the clinic. (Beaulieu :??A) A possible 
explanation is that this e(ect is dose-related, due to a bell-shaped e(ect curve. As 
proposed by Walter et al. (Walter, Oertel, and Lotsch :?=<), this narrow therapeutic 
window may be the result of co-activation of ,D/8G and ,D/HG channels along with .9G 
receptors by ȴ+-,-. at higher concentrations. The dose of =? mg of the oral formulation 
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of ȴ+-,-. was the highest single dose that is administered to healthy volunteers of 
this formulation to date. (Klumpers et al. :?=:) Due to inter-subject variability this dose 
may have been too high for some, as in four subjects pharmacodynamic assessments 
were delayed or omitted as a result of adverse events associated with subjective 
e(ects and nausea. However, on a group level only a reasonable reduction in subjective 
alertness was reported. Furthermore, a post-hoc analysis excluding the measurements 
that may have been a(ected by 8"s of moderate intensity did not lead to a di(erent 
interpretation of the results compared to the Intention-To-Treat ($,,) analysis. Therefore 
the $,, analysis was maintained and reported here. On the other hand, it is known that 
chronic and even acute exposure to ȴ+-,-. can induce a “transient amotivational state” 
(Lawn et al. :?=A), which may be misinterpreted as an apparent hyperalgesic state. This 
hyperalgesic state is in fact the result of the psychotropic e(ect pro'le of ȴ+-,-., as 
subjects become less motivated to complete the pain tasks. Despite our e(orts, human 
evoked pain tasks remain also sensitive to the a(ective components of pain sensation, 
and thus susceptible to detect changes in motivation as well as pure analgesia. 
Over the recent years some evidence has gathered for the e(ectiveness of 
antihistaminergic drugs as adjuvant in the treatment of various pain states. (Behrbalk et al. 
:?=@; Friedman et al. :?=A; Friedman et al. :?=;) However, there is no evidence for any acute 
analgesic e(ect in humans. As such, promethazine (<? mg) was selected as a negative 
control for ȴ+-,-. and to investigate the e(ects of sedation on the battery of evoked pain 
tasks. In addition to an increased sensitivity for electrical and pressure pain, a decreased 
pain detection threshold for inBammatory pain was observed. Even though histamine is 
involved in the initial phase of erythema development, this role is not prominent in the 
delayed erythemic response (Woodward and Owen =)>:) and as such administration 
:@ hours after PH9 exposure is not likely to have inBuenced the pathophysiology 
of the PH9 induced erythema. Thus, the results of promethazine treatment may 
indicate a reduction of pain endurance, which could result from reduced motivation 
associated with sedative e(ects (expressed as a reduction in subjective alertness), 
rather than suppositious analgesia resulting from delayed or impaired responsiveness. 
     The present study adds to a body of research studies in which this exact battery of 
evoked pain tasks was used to investigate various analgesic compounds alone (Okkerse, 
Hay, Sitsen, et al. :?=A; Okkerse, Hay, Versage, et al. :?=A; Okkerse, van Amerongen, et 
al. :?=A) or combined (Okkerse, Alvarez-Jimenez, et al. :?=A). As such, the battery of 
evoked pain tasks is pharmacologically validated for the e(ects of cannabinoids and 
sedatives. The battery of evoked pain tasks was not sensitive to detect analgesic e(ects 
of paracetamol, but that 'nding by itself provides information on the much debated and 
yet unrevealed pharmacological mechanism of action, as we are able to compare the 
results to other compounds with known mechanism of action. As recognized before (van 
Amerongen et al. :?=A; Lotsch et al. :?=A; Lotsch, Oertel, and Ultsch :?=@), translatability 
of 'ndings from human evoked pain models to clinical pain remains elusive. Nonetheless, 
if used prudently, this battery of pain tasks can provide invaluable information on 
pharmacodynamic and pharmacokinetic relationships in the early phases of drug 
development, especially when combined with other neurocognitive assessments. 
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.%'2, ! Summary demographic and baseline characteristics for all subjects (N=;C)
Age (years) u
Mean (#!) 24.0 (5.6) 
Median 23
Min, Max 18, 45 
'8( (kg/m1) u
Mean (#!) 23.5 (2.9) 
Median 23.7
Min, Max 18.2, 29 
Sex (n) u
Female (%) 12 (48%) 
Male (%) 13 (52%) 
Race u
Other 1 (4%) 
White 24 (96%) 
Fitzpatrick Skin Type u
$$: Always burns & tans minimally 6 (24%) 
$$$: Burns moderate & tan gradually 11 (44%) 
$H: Burns minimally & tans well 8 (32%) 
8,* (mJ/cm) u
Mean (#!) 777 (249)
Median 702
Min, Max 351, 1321
H5/ = Body Mass Index / 5<' = Minimal Erythema Dose.
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.%'2, " Summary of <=> analyses for battery of evoked pain tasks
Endpoint Placebo (n=14) Paracetamol  (n=13) Promethazine  (n=13) ȴC-.9$  (n=14)
LSMean  
(95%CI)






.FQ! /D"##FD  (#)
/,, 13.4 (12.5-14.3) 5.2% (-4.6%, 16.0%) 
p=0.3090
-11.1% (-12.3%, -1.2%) 
p=4.4152
2.5% (-7.0%, 12.9%) 
p=0.6183
/!, 3.2 (2.5-4) 3.5% (-15.0%, 26.0%) 
p=0.7292
-17.0% (-31.8%, 1.2%) 
p=0.0648
-0.8% (-18.5%, 20.7%) 
p=0.9335
88. 860 (803-922) 7.8% (-3.8%, 20.9%) 
p=0.1938
-10.6% (-20.2%, 0.2%) 
p=0.0548
4.1% (-7.0%, 16.6%) 
p=0.4806
H8# 56.9  
(52.8-61)
2.59 (-0.45, 5.63) 
p=0.0940
1.48 (-1.56, 4.52) 
p=0.3366
0.11 (-2.93, 3.15) 
p=0.9444
"Q".,D$.8Q #,$CPQ8,$F& (m8)
/,, 22.1 (20.3-24.1) -8.7% (-18.2%, 1.9%) 
p=0.1023
-7.7% (-17.2%, 3.0%) 
p=0.1495
-16.7% (-61.8%, -6.5%) 
p=4.4139
/!, 9.43 (8.44-10.53) -9.9% (-22.8%, 5.3%) 
p=0.1896
0.8% (-13.7%, 17.8%) 
p=0.9211
-2.7% (-16.6%, 13.4%) 
p=0.7222
8P. 3244 (3112-3376) 171.37 (-21.12, 363.87) 
p=0.0805
76.86 (-115.81, 269.53) 
p=0.4311
12:.85 (:.25, 35:.12) 
p=4.4963
H8# 54.6 (51.8-57.4) 1.71 (-1.18, 4.61) 
p=0.2414
-1.38 (-4.28, 1.52) 
p=0.3467
-0.68 (-3.53, 2.17) 
p=0.6372
./C :  "Q".,D$.8Q #,$CPQ8,$F& (m8)
/,, 1.07 (0.64-1.51) 0.101 (-0.772, 0.973) 
p=0.8206
-0.186 (-1.050, 0.678) 
p=0.6716
0.099 (-0.785, 0.983) 
p=0.8254
/!, 1.24 (0.62-1.87) 0.678 (-0.566, 1.921) 
p=0.2841
0.052 (-1.186, 1.290) 
p=0.9339
-0.144 (-1.398, 1.109) 
p=0.8206
8P. -147 (-192- -102) -24.74 (-107.64, 58.17) 
p=0.5574
13.44 (-69.10, 95.98) 
p=0.7488
9.63 (-73.60, 92.87) 
p=0.8200
H8# 2.60 (1.95-3.47) 9.7% (-24.5%, 59.4%) 
p=0.6238
16.5% (-18.8%, 67.1%) 
p=0.4044
-1.7% (-32.8%, 44.0%) 
p=0.9311
/D"##PD"  #,$CPQ8,$F& (kPa)
/,, 39.9 (36.3-43.9) -5.1% (-11.9%, 2.2%) 
p=0.1653
-5.2% (-18.9%, -1.5%) 
p=4.4192
-2.4% (-18.:%, -6.4%) 
p=4.416:
/!, 16.7 (14.2-19.6) -8.5% (-19.1%, 3.5%) 
p=0.1552
-7.1% (-17.8%, 5.1%) 
p=0.2392




695.41 (66.33, 973.:2) 
p=4.4319
391.23 (118.2:, 8:7.52) 
p=4.4436




1.12 (-1.60, 3.85) 
p=0.4176
-0.20 (-2.92, 2.52) 
p=0.8841
0.35 (-2.35, 3.06) 
p=0.7964
&FDC8Q -"8,  (°.)
/!, 45.1
(44.7-45.6)
0.5% (-0.9%, 2.0%) 
p=0.4434
-0.6% (-2.0%, 0.8%) 
p=0.3830
0.3% (-1.1%, 1.7%) 
p=0.7229
PH9 -"8,  (°.)
/!, 39.7
(39.1-40.2)
0.2% (-1.1%, 1.4%) 
p=0.8033
-6.5% (-9.1%, -1.:%) 
p=<.4441
-1.0% (-2.3%, 0.3%) 
p=0.1220
&(( = Pain Tolerance Threshold / &'( = Pain Detection Threshold / ))+ = Area Above the Curve / 
 )*+ = Area Under the Curve / ,)- = Visual Analogue Scale / +&5 = Conditioned Pain Modulation /  
* Contrasts over .-3 hours post dose. 
!"#$%&' 8 – #*#74&1)! &00&!% $'+0)7& +0 $#'#!&%#6+7 , 9:-%"! #*, $'+6&%"#;)*& )* "&#7%"2 1-<=&!%1  93



























































































































































,)- = Visual Analogue Scale / * Contrasts over .-3 hours post dose.
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7(0:+, ! Overview of Change from Baseline time pro.les for battery of evoked pain tasks 
Panel A = Pressure pain task in kPa (&(() / Panel B = Cold pressor in s (&(() / Panel C = Electrical pain  
task in mA (&(() / Panel D = Conditioned Pain Modulation (+&5) in delta mA (&(() Panel E = Thermal  
pain normal skin in °C (&'() / Panel F = Thermal pain *,H skin in °C (&'() / Lines with Circles (O) = placebo 
/ lines with squares (Q) = paracetamol / lines with triangles (V) = promethazine / lines with diamonds  
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7(0:+, " Spider plot overview of Pharmacodynamic response pro.le for battery of evoked 
pain tasks normalized to placebo (D-E hours)
Dashed placebo line represents the value to which other treatment e%ects are normalized. Distal from 
placebo indicates Least Square Mean &(( greater than placebo, proximal indicates Least Square mean 
&(( lower than placebo. Actual values are described in Table 1. A circle indicates a statistically signi6cant 
(P<...4) di%erence compared to placebo for treatment on pain task.
Heat Normal skin !"# (°C)
Heat $%& skin !"# (°C)
Electrical Stair !##(mA)Pressure Stimulation !## (kPa)
Cold pressor !##(s)
Prometazine '(#)* Paracetamol Placebo
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%(8/  This study investigated the pharmacodynamic (neurocognitive and 
neurophysiological) pro'le of a novel ɲ:/ɲ;/ɲ< %898A subtype selective partial positive 
allosteric modulator (/8C), /0-12345627 with single dose levels ranging from ?.?@ to 
=?? mg.
8,.9)*/ This was a two-part study in @< healthy subjects (&.,1G+7GGww). Part 
A was a double-blind, randomised, placebo-controlled, ascending single oral dose, 
crossover study. Part B was performed after completion of Part A to further explore the 
pharmacodynamics of /0-12345627 alone and in combination with lorazepam (: mg). 
Both parts used the NeuroCart®, a neurocognitive and neurophysiological test battery, 
which assessed pharmacodynamic measurements (saccadic peak velocity (#/H), 
smooth pursuit eye movements, body sway, adaptive tracking, Visual Verbal Learning 
Test (HHQ,), Visual Analogue Scale (H8#) Bond & Lader and pharmaco-""%) that were 
performed at baseline and up to A hours post-dose.
+,/:2./ The majority of the pharmacodynamic assessments were dose-dependently 
a(ected by /0-12345627, and plateaued at di(erent dose levels between approximately 
=? and A< mg. In Part B, the combination of lorazepam (: mg) with /0-12345627 A< mg 
demonstrated infra-additive e(ects or the lack thereof, depending on the functional 
domain, in line with the predicted functional selectivity for ɲ:/ɲ;/ɲ< %898A receptor 
subtypes. In both parts, treatment with /0-12345627 alone or in combination with 
lorazepam is considered safe and well-tolerated.
$)&$2:/()& Pharmacodynamic neurocognitive and neurophysiological pro'ling, 
alone and in combination with lorazepam revealed the unique pharmacological 
characteristics of /0-12345627 that are suggestive of anxiolysis with fewer signs of 
sedation, compared to classic non-selective benzodiazepines.
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ɶ-Aminobutyric acid (%898) is the main inhibitory neurotransmitter in the mammalian 
central nervous system (.&#) and is involved in a vast number of functions and 
behaviours (Curtis and Johnston, =)O@). %898A receptors are heteropentameric 
ligand-gated chloride ion channels that mainly contain two ɲ, two ɴ, and one ɶsubunit 
(McKernan and Whiting, =))A). %898A receptors are involved in the fast inhibitory 
function of %898 by providing rapid hyperpolarization of postsynaptic neurons. 
Conventional, non-selective benzodiazepines are positive allosteric modulators (/8C#) 
of the %898A receptors (Curtis and Johnston, =)O@).
Since the serendipitous discovery of chlordiazepoxide in =)A? (Frommele et al., 
=)A?), benzodiazepines are among the most widely prescribed drugs for the treatment 
of a wide range of diseases, including generalised anxiety disorder (%8!) (Reinhold 
and Rickels, :?=<), panic disorder (Starcevic, :?=@), insomnia (Neubauer, :?=@) and 
(neuropathic) pain (Chou and Hu(man, :??O). Although conventional non-selective 
benzodiazepines are considered safe and well-tolerated, clinical use is dose-limited by 
adverse e(ects (8"s) including sedation, postural instability and memory disturbance 
(Mets et al., :?=?; Davidson et al., :?=?). Animal studies have shown that %898A ɲ= activity 
is related to the sedative side e(ects (Rudolph et al., =)))), and studies in healthy human 
subjects with ɲ=-sparing, ɲ:/ɲ; /8C# have con'rmed these 'ndings (Atack, :??<; Atack, 
:?=?). In addition, %898A ɲ: and ɲ; subunits have been related to anxiolytic (Smith et 
al., :?=:), analgesic (Knabl et al., :??>), and recently unexpectedly also suggested to be 
associated with a mild form of sedation in rhesus monkeys (Duke et al., :?=>). Finally, the 
ɲ< subunits are believed to be involved in cognitive functioning and memory (Atack et 
al., :??A; Atack, :?==).
/0-12345627 is a novel %898A subtype selective modulator which exhibits functional 
selectivity for receptors containing ɲ:, ɲ; or ɲ< over those containing ɲ= subunits, a 
pro'le which was con'rmed in vivo by assessing ɲ:/ɲ; and ɲ= pharmacology through 
quantitative beta frequency and zolpidem drug discrimination in rats respectively 
(Nickolls et al., :?=>). /0-12345627 is under development for the treatment of epilepsy.
The objective of this First-in-Human trial was to explore safety, tolerability, 
pharmacodynamics (/!) and pharmacokinetics (/p) of /0-12345627 after a single dose 
across a wide exposure range. It is possible that /0-12345627 will be administered 
as adjuvant therapy to a non-selective benzodiazepine, e.g. lorazepam. As such, an 
additional objective of the present study was to investigate the e(ects of /0-12345627 
when co-administered with lorazepam (: mg), compared to placebo and lorazepam 
alone. This also allows to benchmark the observed e(ects /0-12345627 to a non-
selective benzodiazepine, as lorazepam has been shown to demonstrate no speci'city 
for the %898A receptor subtypes (Dämgen and Lüddens, =)))).
Pharmacodynamics were assessed using a validated .&# test battery, the 
NeuroCart®, which has been extensively used to investigate the e(ects of various .&# 
active compounds where it has been shown sensitive to detect the e(ects of subunit 
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selective positive allosteric %898A receptor modulators (Zuiker et al., :?=<; Chen et al., 
:?=<; Chen et al., :?=@) at the Centre for Human Drug Research (.-!D). 
Previously, parts of the study results were presented in relation to preclinical 
'ndings for /0-12345627 (Nickolls et al., :?=>). The current article focuses on the 
results of the neurocognitive test battery as a whole, and fully characterises the clinical 
pharmacodynamic e(ects in this First-in-Human study. 
*$#1+()
This study was registered in ClinicalTrials.gov under registration number: NCT?=)<==@@. 
The 'nal protocol, amendments and informed consent documentation were reviewed 
and approved by the Independent Ethics Committee ($".) Stichting Beoordeling 
Ethiek Biomedisch Onderzoek (Stichting 9"9F) in Assen, the Netherlands. This study 
was conducted at the Centre for Human Drug Research (Leiden, the Netherlands) in 
compliance with the ethical principles originating in or derived from the Declaration of 
Helsinki and in compliance with all International Conference on Harmonization Good 
Clinical Practice ($.-- %./) Guidelines. 
This was a two-part study. Part A was a double-blind, randomised, placebo-
controlled, ascending single oral dose, placebo-substitution, ;-cohort crossover 
study. Part B (Cohort @) was performed after completion of the 'rst three cohorts to 
further explore the pharmacodynamics of /0-12345627 alone and in combination with 
lorazepam (: mg). A total of @< subjects were included: Cohorts =, : and ; each comprised 
=? subjects and =< subjects were included in Cohort @. Cohorts = and : received 've dose 
levels each in an alternating fashion, thus allowing to explore =? ascending dose levels 
in a two-cohort crossover design. In cohort ;, another 've ascending dose levels were 
investigated. For each cohort there was a washout period of at least seven days. The 
'ndings of Cohorts =, : and ; (Part A) were incorporated to decide on appropriate doses 
for Cohort @ (Part B), in which the e(ects of two dose levels of /0-12345627 alone and 
one dose level in combination with lorazepam (: mg) were compared to placebo and 
lorazepam (: mg) as active control in a complete <-period crossover design using a single 
Latin square. The investigator assigned subject numbers sequentially to the subjects as 
they were screened for the study. The sponsor provided a randomization schedule to the 
investigator and, in accordance with the randomization numbers, the subject received 
the study treatment regimen assigned to the corresponding randomization number. 
Cohort @ included a block size of < to ensure all sequences were evenly allocated.
Sample size 
A sample size of =? subjects in each of Cohorts =, : and ; (with > active, : placebo in 
each period), was based on the need to minimise 'rst exposure to humans of a new 
chemical entity and the requirement to provide adequate safety and pharmacodynamic 
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information at each dose level. A sample size of =< subjects in Cohort @ was selected 
to ensure a balanced design and to provide suNcient power to demonstrate a 
pharmacodynamic e(ect. This was based on assumed within subject standard 
deviations of ;O deg/second (sec) for #/H and ?.;) ln (mm) for body sway as observed in 
Cohorts =, : and ; of the study.
Subjects
Forty-'ve healthy subjects were recruited from .-!D’s database. Subjects were male or 
postmenopausal female, aged =>-<< years, with a 9C$ of =O.< to ;?.< kg/mK. Subjects were 
to refrain from smoking, ca(eine and alcohol from :@ hours prior to each investigational 
period. Subjects were instructed to use a highly e(ective method of contraception. The 
use of medication other than study drug was not allowed during study participation.
Treatments
In Part A subjects were randomised to receive < ascending single doses of /0-12345627 
or placebo. The starting dose was determined based on preclinical modelling at ?.?@ mg, 
which was expected to yield a .max of ?.;=ng/mL, corresponding to an unbound .max of 
?.?@ng/mL, which in turn corresponds to a predicted total DF of =>%, and an ɲ: subunit 
DF of ~;%. 
The 'ndings of Part A were used to determine the dose levels of /0-12345627 for Part 
B. In this randomised <-period placebo and active control crossover design, =< subjects 
received /0-12345627 (=< mg), /0-12345627 (A< mg), lorazepam (: mg), /0-12345627 
(A< mg) + lorazepam (: mg) and placebo. 
Following an overnight fast of least =? hours, subjects received study treatment in 
the morning. /0-12345627 was administered as an oral suspension and one dose level 
(:< mg) was administered as oral tablets as well. Lorazepam (: mg) was administered 
as an oral tablet. To ensure blinding of treatment allocation, matching placebo was 
administered in a double-dummy fashion (Part B only).
Safety
Adverse events, clinical laboratory, electrocardiogram (".%), blood pressure and heart 
rate measurements were collected throughout the study. 
Pharmacokinetics
Plasma samples were analysed for /0-12345627 concentrations at York Bioanalytical 
Solutions (York, Pp) using a validated, sensitive and speci'c high-performance liquid 
chromatography tandem mass spectrometric method (-/Q.-C#/C#). /p samples were 
collected prior to dosing and at ?.:<, ?.<, =, =.<, :, @, A, >, =:, =A :@, ;A, @> and O: hours post-dose. 
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Pharmacodynamics
Pharmacodynamic assessments were performed using an integrated test battery, the 
NeuroCart®. Measurements were conducted by a trained operator in accordance with 
the Standard Operating Procedures of .-!D. The assessments to be performed as part 
of the NeuroCart® battery were: Saccadic Eye Movement, Smooth Pursuit, Adaptive 
Tracking, Body Sway, Bond and Lader Visual Analogue Scales (H8#) and Pharmaco-
electroencephalography (p-""%). An overview of the di(erent tasks and associated 
functional domains can be found in Table !. Pharmacodynamic measurements were 
performed prior to dosing (twice in order to record double baseline values, thus reducing 
variability) and at ?.<, =, =.<, :, @, A, =: hours post-dose. In addition, the Visual Verbal 
Learning Test (HHQ,) was performed at = hour and A hours (Part A) or :.< hours (Part B) 
post-dose. Subjects were tested individually in a quiet room with ambient illumination.
Saccadic Eye Movements
Measurements of saccadic eye movements were recorded as previously described (de 
Haas et al., :??O; de Haas et al., :??)). Average values of Saccadic Peak Velocity (#/H) 
were calculated for all artefact free saccades. #/H is closely related to the anxiolytic 
properties of benzodiazepines (Chen et al., :?=:) and this parameter has been validated 
as the most sensitive biomarker for their e(ects (de Visser et al., :??;; van Steveninck et 
al., =))@; van Steveninck et al., =))A; van Steveninck et al., =)))).
Smooth pursuit 
For smooth pursuit eye movements, the target moved at a frequency ranging from ?.; 
to =.= Hz, by steps of ?.= Hz. The amplitude of target displacement corresponded to ::.< 
degrees eyeball rotation to both sides. Four cycles were recorded for each stimulus 
frequency. The method is validated at .-!D (van Steveninck et al., =)))) based on the 
work of Bittencourt et al (Bittencourt et al., =)>;) and the original description of Baloh 
et al (Baloh et al., =)OA). The time in which the eyes were in smooth pursuit of the target 
was calculated for each frequency and expressed as a percentage of stimulus duration. 
The average percentage of smooth pursuit for all stimulus frequencies was the target 
parameter.
Adaptive Tracking
The adaptive tracking test was performed as originally described by Borland and 
Nicholson (Borland and Nicholson, =)O<; van Steveninck et al., =)))) using customised 
equipment and software. The average performance over a ;.<-min period were used 
for analysis. Adaptive tracking is a pursuit-tracking task, where a circle moves randomly 
on a screen. The subject must try to keep a dot inside the moving circle by operating a 
joystick. The test is adaptive in nature, namely if this e(ort is successful, the speed of the 
moving circle increases. Conversely, the velocity is reduced if the test subject cannot 
maintain the dot inside the circle.
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Body Sway
Body sway was measured with an apparatus similar to the Wright ataxiameter (Wright, 
=)O=), which integrates the amplitude of unidirectional body movements transferred 
through a string attached to the subject’s waist. Two-minute measurements were made 
in the anteroposterior direction with eyes closed, with subjects standing comfortably on a 
'rm surface with their feet slightly apart. Body sway is a measure of postural stability that 
has previously been shown to be sensitive to sleep deprivation (van Steveninck et al., =)))), 
ethanol (van Steveninck et al., =));) and benzodiazepines (van Steveninck et al., =));). 
Bond and Lader Visual Analogue Scales (<%/)
Visual analogue scales as originally described by Norris (Norris, =)O=) were previously 
used to quantify subjective e(ects of benzodiazepines (van Steveninck et al., =))=). From 
the set of =A scales, three composite factors were derived as described by Bond and 
Lader (Bond and Lader, =)O@), corresponding to alertness, mood, and calmness. These 
factors were used to quantify subjective drug e(ects.
Pharmaco-electroencephalography 
""% recordings were made using gold chloride electrodes with the same common 
ground electrode as for the eye movement registration (international =?/:? system). The 
electrode resistances were kept below < kOhm. ""% signals were obtained from leads 
Fz-Cz and Pz-Oz and a separate channel to record eye movements (for artefacts). For 
each lead, fast Fourier transform analysis was performed to obtain the sum of amplitudes 
in the very low (?.<-: Hz), delta (:-@ Hz), theta (@-O.< Hz), alpha (O.<-=;.< Hz), beta (=;.<-;< 
Hz) and gamma (;<-@>.) Hz) frequency ranges. The duration of ""% measurements was 
A@ s per session. Change in amplitudes in the beta frequency band of the ""% was found 
to be a relevant measure of the pharmacological e(ect intensity of benzodiazepines 
(Mandema et al., =)):).
Visual Verbal Learning Test (<<2.)
Measurement of memory comprises di(erent components of learning behaviour, 
i.e., acquisition, consolidation, storage, and retrieval. The HHQ, (Schmitt et al., :???) 
contained ; di(erent subtests that covered a wide scope of learning behaviour. The test 
started with sequential presentation of ;? common monosyllabic nouns. Each word was 
shown for : seconds. When the series ended, the subject was required to verbally recall 
as many words as possible. The same list was presented in the same way in ; successive 
trials. The highest individual trial score was the Immediate Recall score. After a delay, 
subjects were asked again to recall as many words as possible without prompting. The 
number correctly recalled was the Delayed Recall score. Finally, old/new recognition 
was measured by showing the subjects a series of ;? words on the computer display 
that included words from the original set and =< new words. Subjects responded to each 
presentation by indicating as quickly as possible whether the given word was one of the 
original set (Delayed recognition). 
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Statistical analysis
Data from cohorts =, : and ; (Part A) were analysed separately to data from cohort @ (Part 
B). Body Sway was loge-transformed prior to analyses. A mixed e(ects model was 'tted 
for each endpoint separately, using data collected during the 'rst A hours post-dose 
(except HHQ, endpoints which only had a single associated post-dose measurement). 
The randomisation code was generated by an independent team. Randomisation 
numbers were sequentially allocated by the study physician, and blinded study 
treatments were prepared and dispensed by an independent operating pharmacy. 
For Cohorts =, : and ; (Part A), the 'xed e(ects included in the model were baseline, 
time, treatment and treatment by time interaction. Time was included as a repeated 
e(ect within each subject*period. Baseline was included as : separate variables, the 
average baseline for the subject, and the deviation of each treatment period baseline 
from the average baseline for each subject. The interaction of the latter baseline and 
time was also included as a 'xed e(ect. For HHQ,, the 'xed e(ect in the model was 
treatment, with subject 'tted as a random e(ect. For Cohort @ (Part B), the models were 
the same as above, except an additional 'xed e(ect term for period was included (all 
endpoints, including HHQ,). 
For all cohorts, the Least Square Means (Q#C) together with )<%CIs were obtained for 
each treatment averaged across all post-dose time points, and also for each treatment at 
each separate time point (if applicable). Di(erences in Q#C between treatments (all PF 
doses, lorazepam K mg and the combination of PF and lorazepam) and placebo, together 
with +7s.$# were obtained. For the analysis of Cohort @ (Part B), the di(erences in 
Q#C between treatments (both PF doses and the combination) and lorazepam (: mg), 
together with +7s.$#, were also obtained.
Pharmacodynamic interaction was investigated post-hoc for the neurocognitive 
and neurophysiological outcome measures by calculating the contrasts of the sum 
of the e(ects of individual treatments (/0-12345627 (A< mg) and lorazepam (: mg)) 
versus the e(ects of co-administration of /0-12345627 (A< mg) + lorazepam (: mg). 
Supra- or infra-additive pharmacodynamic interactions are signi'ed by a statistically 
signi'cant di(erence (p < ?.=). No di(erence indicates that the co-administration of both 
treatments results in the addition of both individual treatments. /0-12345627 (A< mg) 
co-administered with lorazepam (: mg) vs. /0-12345627 (A< mg) + lorazepam (: mg)
&$)-3#)
Subjects
Each subject provided written informed consent before any screening procedures 
were performed. A total @< healthy subjects were enrolled in this study. .F&#FD, Bow 
chart is available as supplemental. There were no discontinuations or withdrawals, 
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so all randomised subjects completed the study per protocol. All ;? subjects in part A 
(cohorts =, : and ;) were healthy male subjects. The majority of subjects (:A out of ;?) 
were caucasian. In part B (cohort @, n = =<) all subjects except one were male. There were 
no notable di(erences between mean weight, height or 9C$ across all cohorts (Table 1).
Safety
A detailed overview of the observed adverse events in Part A is described by Nickolls et 
al. (Nickolls et al., :?=>). No serious adverse events were observed during the study. No 
clinically signi'cant changes in vital signs, ".%s or other safety parameters were observed. 
The most frequently reported 8"s were dizziness, somnolence, bradyphrenia, elevated 
mood, fatigue, headache and orthostatic hypotension, all of which were mild in severity. 
       In Part B lorazepam (: mg) treatment alone resulted in similar type of 8"s compared 
to /0-12345627 =< mg treatment, but with a lower incidence of total 8"s compared with 
A< mg of /0-12345627 treatment group. Reported adverse events are summarised 
according to system organ class (#F.) in Table 2, where the most commonly observed 
8"s (dizziness and somnolence) are presented individually as well. All observed 
treatment emergent 8"s were mild in severity. Co-administration of /0-12345627 A< 
mg and lorazepam : mg did not result in an additive e(ect in terms of number or intensity 
of adverse events. There was no clear di(erentiation or pattern observed in terms of 
distribution of 8"s, in terms of #F. or intensity. 
Pharmacokinetics
The plasma /p parameter estimates for =@ ascending doses of /0-12345627 (Part A) 
are described by Nickolls (:?=>). Summarising, /0-12345627 was well absorbed with 
median ,max of = to @ hours. Average half-life ranged from A.? to >.) hours. In general, 
plasma /0-12345627 8P. inf and .max increased apparently linear across the dose 
range. However, no formal test was performed to con'rm this. In cohort ; (Part A) a 
comparison between the oral suspension formulation and an oral tablet formulation was 
performed for a dose of :< mg. The observed median ,max for the tablet formulation was 
:.? hours, compared to a median ,max of @.? hours when administered as suspension at 
the same dose level. TI/K was similar with the mean value of >.: hours for both treatments. 
Inter-subject variability for /0-12345627 exposure based on geometric .Hs was low to 
moderate, ranging between =;% and ;)% for .max. In cohort @ (Part B), analogous to the 
observations in Part A, /0-12345627 was absorbed rapidly and demonstrated a similar 
half-life compared with the observations of the 'rst part of study. When /0-12345627 
A< mg was administered in combination with lorazepam : mg, a slight increase was 
seen for /0-12345627 8P. inf and .max by approximately =:% and =;% respectively, 
compared with /0-12345627 A< mg administered alone. Median ,max (:.? hours) and 
mean half-life (approximately > hours) values were similar for /0-12345627 alone and 
co-administration with lorazepam : mg.
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Pharmacodynamics – Part A
An overview of the results of the pharmacodynamic di(erences in overall Least Square 
Means (presented with )<% Con'dence Interval) for the complete dose range (?.?@ mg 
to =?? mg) compared with placebo is shown in Figures =-; and Supplement =. 
From a dose of @ mg /0-12345627 onwards up to the highest dose (=?? mg), Saccadic 
Peak Velocity (degrees/second) was statistically signi'cantly decreased compared 
to placebo, in a dose-response manner. Smooth pursuit eye movements were only 
statistically signi'cantly di(erent from placebo at =?, =< and =?? mg. Percentage correct in 
adaptive tracking was statistically signi'cantly reduced compared to placebo for all dose 
levels above =? mg /0-12345627, except for the :< mg /0-12345627 tablet formulation. 
Between the dose levels of =? and :< mg a dose-related response was observed, from 
:< mg onwards the e(ect demonstrated a plateau. Postural instability, measured 
using body sway, increased in a dose-related fashion for each cohort with statistically 
signi'cantly increases in the higher dose levels. The maximum e(ect was observed at 
a dose level of =? mg, indicating a plateau. H8# alertness showed a seemingly dose-
related reduction from @ mg of /0-12345627 onwards, except for the dose level of A mg 
of /0-12345627. (Supplement =) Di(erent parameters were measured using the HHQ, 
(Figure 1). Immediate recall was signi'cantly impaired during the 'rst treatment visits 
for Cohort = (?.?@ mg of /0-12345627). Then, from the dose level of @ mg /0-12345627 
onwards, immediate recall was statistically signi'cantly reduced. Delayed recall 
demonstrated a similar pattern. Delayed recognition however, showed a more di(use 
pattern. Pharmaco-""% (Figure 2) demonstrated a dose-dependent power increase in 
the low frequency bands ɷ and ɽ, which appeared to reach a plateau between A and :< 
mg. Beta (ɴ) frequency band activity however demonstrated an apparent dose-response 
over all dose levels. No clear changes were was observed in the ɲ frequency band. 
       Pharmacodynamics – Part #
In cohort @, a placebo-controlled head-to-head comparison between =< mg /0-12345627, 
A< mg /0-12345627 (alone and in combination with : mg lorazepam) and lorazepam 
(: mg) was performed. The results are presented in Table 3 as Q#C with contrasts to 
placebo and contrasts to lorazepam (: mg). The results of the most relevant outcome 
measures are graphically summarised in Figure 3. Pharmacodynamic interaction 
analysis was performed on the primary endpoints and is described in Table 4.
Saccadic eye movements
All treatments statistically signi'cantly reduced #/H compared to placebo. Additionally, 
both doses of /0-12345627 (alone or in combination with lorazepam (: mg)) 
demonstrated a signi'cant greater reduction in #/H than lorazepam (: mg) alone. 
Co-administration of /0-12345627 (A< mg) in combination with lorazepam (: mg) did 
not result in an infra- or supra-additive pharmacodynamic interaction e(ect (p=?.:<).
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Smooth pursuit
None of the treatments were statistically signi'cantly di(erent from placebo. 
Co-administration of /0-12345627 (A< mg) in combination with lorazepam (: mg) did 
not result in an infra- or supra-additive pharmacodynamic interaction e(ect (p=?.;O).
Adaptive tracking 
All treatments statistically signi'cantly reduced performance on adaptive tracking 
compared with placebo. The reduction in performance was greatest when lorazepam (: 
mg) was administered alone. Contrasts to lorazepam (: mg) showed that the di(erence 
in magnitude in adaptive tracking performance reduction was statistically signi'cantly 
lower for both =< and A< mg of /0-12345627 (alone or in combination with lorazepam (: 
mg)), compared to lorazepam (: mg) alone. Co-administration of /0-12345627 (A< mg) 
in combination with lorazepam (: mg) induced a statistically signi'cant (p<?.??=) infra-
additive e(ect.
Body Sway 
All treatments statistically signi'cantly increased postural instability expressed as body 
sway. Treatment with lorazepam (: mg) alone resulted also in a statistically signi'cant 
di(erent compared with /0-12345627 (=< mg). Co-administration of /0-12345627 (A< 
mg) in combination with lorazepam (: mg) induced a statistically signi'cant (p<?.??=) 
infra-additive e(ect.
<%/ Alertness
Subjective alertness was only statistically signi'cantly reduced compared to placebo 
after treatment with a combination of /0-12345627 (A< mg) and lorazepam (: mg). 
In addition, A< mg /0-12345627 statistically signi'cantly a(ected the subscales of 
Bond & Lader for mood and calmness. (Results not presented) Co-administration of 
/0-12345627 (A< mg) in combination with lorazepam (: mg) did not result in an infra- or 
supra-additive pharmacodynamic interaction e(ect (P = ?.)>).
<<2. 
Three outcome measures of the HHQ, are presented here. Immediate recall, delayed 
recall and delayed recognition. For immediate recall, the number of correct words was 
statistically signi'cant reduced for all treatments compared to placebo. Total number of 
correct words in delayed recall was statistically signi'cantly reduced for all treatments 
and there was no di(erence between the treatments compared to lorazepam (: mg). 
Delayed recognition showed a slightly di(erent pro'le: all treatments, except for =< mg 
/0-12345627, statistically signi'cantly the reduced number of correct words compared 
to placebo. Consequently, treatment with lorazepam (: mg) caused a statistically 
signi'cantly larger impairment of delayed recall than =< mg /0-12345627 treatment. 
The other treatments did not di(er signi'cantly from lorazepam (: mg). 
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Co-administration of /0-12345627 (A< mg) in combination with lorazepam (: mg) 
induced a statistically signi'cant (p<?.??=) pharmacodynamic interaction on Immediate 
recall (p=?.??@) and Delayed recall (p=?.??<O), resulting in infra-additive e(ects. 
However, the observations for Delayed recognition showed a reverse pro'le: the largest 
deterioration in performance was induced by treatment of lorazepam (: mg) alone, 
which was statistically signi'cantly lower after co-administration of /0-12345627 (A< 
mg) in combination with lorazepam (: mg). 
p-,,0
All treatments resulted in statistically signi'cantly lower ɲ-power activity compared to 
placebo. ɴ-power band activity was statistically signi'cantly increased for all treatments 
compared with placebo. What is more, the increase observed for A< mg /0-12345627 
alone and in combination with lorazepam (: mg) was statistically signi'cantly higher 
compared to lorazepam (: mg) alone. Treatment with =< mg /0-12345627, A< mg 
/0-12345627 alone or in combination with lorazepam (: mg) statistically signi'cantly 
decreased ɷ-power band activity compared with placebo and with lorazepam (: mg) 
alone. Lorazepam (: mg) alone was not di(erent from placebo. In contrast, ɽ-power band 
activity did not show any di(erentiation between /0-12345627 or lorazepam (: mg). 
(!).-))!+"
This First-in-Human (0$-) study investigated safety and tolerability as well as the 
pharmacodynamic and pharmacokinetic properties of /0-12345627, a novel ɲ:/
ɲ;/ɲ< %898A subtype selective partial positive allosteric modulator. Single doses 
of /0-12345627 were safe and well-tolerated. The observed adverse events were in 
line with what was expected based on its predicted pharmacology. The severity of the 
observed adverse events remained mild, irrespective of dose or co-administration with 
lorazepam.
In this study, a clear, dose-dependent, pharmacodynamic e(ect pro'le for 
/0-12345627 was observed. In Part A, saccadic peak velocity (#/H), adaptive tracking, 
body sway, ""%, and H8# alertness were a(ected in a dose-related fashion, up to 
certain dose levels where the e(ects appeared to plateau. Visual verbal learning (HHQ,) 
demonstrated similar dose related impairments. The dose level where the plateau was 
reached di(ered per individual test. For adaptive tracking the maximum e(ect occurred 
around the dose level of :< mg, whereas the maximum e(ect for #/H was observed 
at A< mg. In contrast with the relatively large e(ects on #/H, the Smooth pursuit eye 
movements only demonstrated a signi'cant reduction in performance at the highest 
dose levels for each cohort. Pharmaco-""% revealed dose-related e(ects on the ɴ-, ɷ-, 
and ɽ power bands.
The lowest dose at which a statistical signi'cant di(erence was observed after 
treatment with /0-12345627 reBected the interplay between the relative aNnity for 
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the di(erent %898A receptor subtypes in combination with the functional activity as 
demonstrated using the QPatch automated electrophysiology assay (Nickolls et al., 
:?=>). For instance, higher relative binding aNnity for ɲ=ɴ;ɶ: receptor, coupled with its 
low functional activity results in earlier onset of the ɲ=-mediated pharmacology and 
a small magnitude of e(ect. Conversely, the lower relative binding aNnity and higher 
intrinsic activity at ɲ:ɴ:ɶ: and ɲ;ɴ;ɶ: results in a clear dose-response response, which 
becomes increasing apparent at higher dose levels. 
When comparing the pharmacodynamic e(ects of two doses /0-12345627 (=< mg 
and A< mg) to lorazepam (: mg) alone, and in combination with lorazepam (: mg) in Part 
B, distinct pharmacodynamic e(ect pro'les were observed between the partial subtype 
selective and the non-selective %898A agonists. This is illustrated in Figure !, in which 
the e(ect pro'les on the di(erent tasks of the di(erent treatments are visualised. It clearly 
illustrates the subtype selective e(ects of ɲ:/ɲ;/ɲ< modulation over ɲ= modulation, 
compared to non-selective %898A modulation. A dose of =< mg or A< mg /0-12345627 
induced a signi'cantly greater reduction in #/H compared to lorazepam (: mg), which 
by itself compared to placebo already signi'cantly reduces #/H. A similar pattern was 
observed for H8# Alertness and Delayed recall (HHQ,). On the other hand, administration 
of lorazepam (: mg) alone showed a greater decline in performance on adaptive tracking 
and body sway compared to administration of /0-12345627. Overall, the observed 
e(ect pro'le of A< mg /0-12345627 combined with lorazepam (: mg) resembled the 
e(ect pro'le of treatment with A< mg /0-12345627 alone more closely than the e(ect 
pro'le observed after treatment with lorazepam (: mg) alone. 
A reduction in #/H has previously been linked to modulation of the ɲ:/ɲ; subunits of 
the %898A receptor (Atack, :?=?), whereas performance on adaptive tracking has been 
related to ɲ= modulation (de Haas et al., :?=?). As such, large e(ects on #/H, and relatively 
small e(ects on adaptive tracking of /0-12345627, compared to lorazepam (: mg) are 
indicative of functional subtype selectivity for the ɲ: and ɲ; subunits (Chen et al., :?=:). 
Cognition and memory impairment as measured with the HHQ, have been shown to be 
associated with ɲ< modulation (Collinson et al., :??:; Crestani et al., :??:). The observed 
increase in activity in the ɴ power band and decrease in activity in the ɽ power bands are 
in line with what is previously reported for the non-selective benzodiazepine, diazepam 
(Jobert and Wilson, :?=<; Yamadera et al., =));). In contrast, the observed decrease 
in activity in the ɷ power band after treatment with lorazepam di(erentiates from the 
expected increase in this power band as previously reported (Chen et al., :?=<), which 
was not seen in the present study. 
Co-administration of /0-12345627 (A< mg) and lorazepam (: mg) further underlines 
the subtype selective e(ect pro'le for /0-12345627. Combination of both treatments 
caused a slight increase in pharmacokinetic exposure of /0-12345627, which is not 
considered to have a signi'cant impact on the observed pharmacodynamics. Post-
hoc statistical testing was performed to assess pharmacodynamic interactions. No 
evidence for interaction of the pharmacodynamic e(ects was observed for #/H, smooth 
pursuit and H8# alertness, which can be explained by non-selective receptor activation 
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by lorazepam (: mg) in addition to selective ɲ:/ɲ; activation by /0-12345627. What is 
more, infra-additive e(ects were observed for adaptive tracking (p=?.???=) and body 
sway (p=?.???:). A reduction in e(ect for these psychomotor functions compared to 
administration of lorazepam (: mg) alone, may indicate that due to competitive activity at 
the %898A receptor, /0-12345627 acts as an antagonist, resulting from partial agonism, 
at ɲ= subunits, which diminishes lorazepam’s high intrinsic activity as a non-selective full 
agonist. This is in line with the earlier observations that partial agonists are expected 
to antagonise the e(ects of full agonists that may require higher fractional receptor 
occupancy to exert their e(ects (Patat et al., =))<). 
An interesting trend in the e(ect pro'le was observed for the HHQ, outcome 
measures. Both Immediate recall (p=?.??@) and Delayed recall (p=?.??<O) demonstrated 
statistically signi'cant antagonistic interaction. Here, the deteriorating e(ects of 
/0-12345627 A< mg appear to be diminished by co-administration of lorazepam : 
mg. Delayed recognition demonstrated the opposite: the magnitude of decline in 
performance by lorazepam : mg was reduced by co-administration of /0-12345627 
(p=?.??:)). These slightly divergent observations on the memory domain indicate that 
recall and recognition are potentially a(ected di(erently and as such can be considered 
pharmacologically distinct subdomains. A similar pattern was observed in the study by 
Patat et al. (=))<). Here however, co-administration of lorazepam (: mg) and a partial 
benzodiazepine agonist, alpidem (<? mg 9$! (Bis In Diem) for eight days), did produce an 
additive e(ect in terms of e(ect size, unlike the antagonistic interaction observed in the 
present study. More importantly, the apparent discrepant observations between (short-
term and delayed) recall and delayed recognition were also observed here. Di(erential 
memory performance in (word) recognition and recall has been described before 
(Tulving, =)O;). In experiments designed to investigate the generation-recognition 
theory, it was shown that under certain conditions subjects consistently failed to 
recognise words that they were in fact able to recall. This was the foundation for the 
“Encoding speci'city principle”, according to which the memory trace of an event and 
the properties of an e(ective retrieval cue are determined by the speci'c encoding 
operations, e.g. physical environment or semantics (Hannon and Craik, :??=), performed 
by the system during the encoding phase of input stimuli. Divergent e(ects of di(erent 
benzodiazepines on these distinct subdomains have been reported subsequently 
(Curran, =)>A). Hypothesising, as treatment with lorazepam alone in the current 
study resulted in the largest reduction in delayed recognition performance, this may 
be associated with lorazepam’s sedative properties, mediated via ɲ= %898A receptor 
subtype activation, rather than ɲ< %898A receptor subtype activation inducing memory 
impairment. Thereby it e(ectively hampers the ability to store and retrieve information 
from the episodic memory (Patat et al., =))<). This hypothesis has not been con'rmed 
by statistical testing, as the study was not powered to detect this e(ect, but remains an 
interesting trend in the observations. 
The present study is a First-in-Human, hypothesis-generating clinical study designed 
to guide decision-making and explore the pharmacodynamics and pharmacokinetics, as 
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well as safety, of /0-12345627 in healthy subjects using a test battery of neurocognitive 
tasks (NeuroCart®). Therefore, the study was powered to detect a potential pharma- 
codynamic e(ect on the primary endpoints. However, given the novelty of the 
pharmacological mechanism of action, secondary parameters for which no formal 
power calculation was performed are taken into account when reviewing the generated 
results. Consequently, interpretation of these 'ndings requires more caution and is 
potentially more prone to type I or type II error, since no correction for multiple testing 
was performed. These statistical limitations are partially o(set however when the 
changes are corroborated by the dose-e(ect relationship described in the Results 
section and shown in Figures = to ;. However, in this two-phase study, two dose levels (=< 
mg and A< mg) from Part A were investigated in more detail in a full crossover study using 
the positive control lorazepam (: mg) in Part B. This approach allowed for an internal 
replication and the congruent 'ndings on the di(erent endpoints con'rm the validity of 
the study 'ndings and indicate the risk of bias due to chance 'ndings is low.
In the current study, a similar reduction in #/H compared with lorazepam (: mg) 
was observed at the dose level of @ mg /0-12345627. This could reBect similar ɲ:/ɲ; 
%898A agonistic activity, which for a number of similar compound has been found to be 
closely associated with #/H-e(ects (Chen et al., :?=:). On the other hand, performance 
on adaptive tracking, smooth pursuit eye movements and body sway was considerably 
less a(ected by /0-12345627 than by lorazepam (: mg) alone, which would suggest 
a lower propensity for adverse events related to .&# depression. The e(ect pro'le 
appears to direct towards a favourable e(ect pro'le in terms of anxiolysis, with fewer 
signs of sedation, compared to classic non-selective benzodiazepines. Based on the 
'ndings in the present study an estimation of a potentially anxiolytic dose 'rst takes 
into consideration that a typical dose of lorazepam for the treatment of anxiety is :-; 
mg one to three times daily. Second, there may be neurophysiological di(erences in 
the sensitivity to ɲ:/ɲ; %898A modulation between healthy subjects included in this 
investigation and the target population. This may be due to changes in the level of 
allosteric endogenous modulators, or changes in the subunit composition of the %898A 
receptor. A single dose of @ mg /0-12345627 resulted in a similar reduction in #/H as 
lorazepam (: mg). Taking the abovementioned factors into consideration, the projected 
dose for a clinically relevant anxiolytic e(ect would be a two- or threefold of this dose. 
The anxiolytic eNcacy of /0-12345627 was investigated in :?=A in a @-week clinical 
trial in %8! patients, who were currently treated with but partial non-responders to 
standard %8! treatment (Simen et al., :?=)). Here, adjuvant therapy of dose levels of 
:.< mg and O.< mg 9$! did not result in a statistically signi'cant improvement in anxiety 
symptoms measured with the Hamilton Anxiety Inventory. Di(erent explanations have 
been proposed for the lack of clinically meaningful anxiolytic e(ect. Apart from the fact 
that the study was underpowered due to early termination (not for safety or eNcacy 
reasons), pharmacokinetic exposure may have been too low. This could be attributable 
to administration of low dose levels in general. The translation of =< mg single dose, as 
administered in the present study, to O.< mg 9$! repeated dose has not been con'rmed 
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in terms of pharmacodynamic e(ect pro'le. As the present study is performed in a highly 
controlled environment in healthy subjects, higher receptor occupancy may need to be 
achieved to exert the desired clinical e(ects in an outpatient setting than the receptor 
occupancy that was achieved in the %8! patient study that has been performed. (Simen 
et al., :?=))
The functional selectivity for ɲ:/ɲ; subunits of the %898A receptor has also been 
identi'ed as a potential target for the treatment of chronic (neuropathic) pain. After a 
clinical pharmacology study in healthy subjects was performed in which doses of =< and 
A< mg /0-12345627 demonstrated an analgesic e(ect on pressure pain and the cold 
pressure task (van Amerongen et al., :?=)) a study in chronic low back pain patients was 
performed. (Gurrell et al., :?=>) In this randomised, placebo and active-controlled clinical 
trial, the parallel treatment group trial consisted of a one-week single-blind placebo 
run-in phase, followed by a four-week double-blind treatment phase. Patients were 
randomised to receive either /0-12345627, naproxen or placebo 9$! for four weeks. 
The primary endpoint was the numerical rating score (&D#) of low back pain intensity 
(Q9/$) after @ weeks of active treatment. The study was stopped prematurely for futility, 
and whilst the reason for the lack of analgesic e(ect is not completely clear, it has been 
suggested to be a result of not achieving suNcient receptor occupancy to drive eNcacy. 
Both patient studies included secondary endpoints to assess pharmacodynamic 
response, for example the Digit Symbol Substitution Test (!##,) and the Hopkins Verbal 
Learning Test Revised (-HQ,-D), measures for general cognitive functioning and memory 
performance. The results on these tasks indicate that pharmacologically active doses 
were administered, which unfortunately did not translate to clinical eNcacy. 
Overall, it can be concluded that /0-12345627 was safe and well-tolerated by the 
healthy subjects participating in this study. The pharmacodynamic pro'le that was 
characterised using a test battery of neurocognitive tests corresponds well with its 
predicted functional selectivity for the ɲ:/ɲ;/ɲ< subunits of the %898A receptor, and was 
in line with preclinical observations (Nickolls et al., :?=>). The head-to-head comparison 
to lorazepam (: mg) alone and in combination with A< mg /0-12345627 demonstrated 
that the combination was safe and well-tolerated. The treatment combination produced 
a distinct pharmacological interaction pro'le. On the endpoints representative for ɲ= 
%898A subtype receptor activation, a competitive interaction diminished the e(ects 
of lorazepam : mg alone, due to /0-12345627’s low intrinsic eNcacy for this receptor 
subtype. On the endpoints representative for ɲ:/ɲ;/ɲ< %898A subtype receptor 
activation an additive e(ect was observed, due to non-competitive binding activity at 
these receptor subtypes. Compared to lorazepam (: mg) less sedation was observed at 
dose levels of /0-12345627 corresponding to a potentially anxiolytic dose.
!"#$%&' > – $"#'6#!+,2*#6)! &00&!% $'+0)7& +0 $0-?@/A.B@> , # 1-<%2$& 1&7&!%)5& 4#<## 6+,-7#%+' 113
+,7,+,&$,/
Atack JR. (:??<) The benzodiazepine binding site of %898(8) 
receptors as a target for the development of novel 
anxiolytics. Expert Opin Investig Drugs =@: A?=-A=>.
Atack JR. (:?=?) %8988 receptor alpha:/alpha; subtype-
selective modulators as potential nonsedating 
anxiolytics. Curr Top. Behav Neurosci :: ;;=-;A?.
Atack JR. (:?==) %8988 receptor subtype-selective modula-
tors. II. alpha<-selective inverse agonists  for cognition 
enhancement. Curr Top. Med Chem  ==: =:?;-=:=@.
Atack JR, Bayley PJ, Seabrook GR, et al. (:??A) L-A<<,O?> 
enhances cognition in rats but is not proconvulsant 
at a dose selective for alpha<-containing %8988 
receptors. Neuropharmacology <=: =?:;-=?:).
Baloh RW, Kumley WE, Sills AW, et al. (=)OA) Quantitative 
measurement of smooth pursuit eye movements.  
Ann Otol. Rhinol. Laryngol ><: ===-==).
Bittencourt PR, Wade P, Smith AT, et al. (=)>;) 
Benzodiazepines impair smooth pursuit eye 
movements. Br J Clin Pharmacol =<: :<)-:A:.
Bond A and Lader M. (=)O@) The use of analogue scales in 
rating subjective feelings. Br J Med Psychol @O: :==-:=>.
Borland RG and Nicholson AN. (=)O<) Comparison of the 
residual e(ects of two benzodiazepines (nitrazepam 
and Burazepam hydrochloride) and pentobarbitone 
sodium on human performance. Br J Clin Pharmacol 
:: )-=O.
Chen X, de HS, de KM, et al. (:?=:) An Overview of the .&#- 
Pharmacodynamic Pro'les of Nonselective and Selec-
tive %898 Agonists. Adv Pharmacol Sci :?=:: =;@<:;.
Chen X, Jacobs G, de Kam ML, et al. (:?=<) AZDA:>?, a 
novel partial gamma-aminobutyric acid A receptor 
modulator, demonstrates a pharmacodynamically 
selective e(ect pro'le in healthy male volunteers.  
J Clin Psychopharmacol ;<: ::-;;.
Chen X, Jacobs G, de KM, et al. (:?=@) The central nervous 
system e(ects of the partial %898-Aalpha:,; 
-selective receptor modulator AZDO;:< in comparison 
with lorazepam in healthy males. Br J Clin Pharmacol 
O>: =:)>-=;=@.
Chou R and Hu(man LH. (:??O) Medications for acute 
and chronic low back pain: a review of the evidence 
for an American Pain Society/American College of 
Physicians clinical practice guideline. Ann Intern Med 
=@O: <?<-<=@.
Collinson N, Kuenzi FM, Jarolimek W, et al. (:??:) Enhanced 
learning and memory and altered %898ergic synaptic 
transmission in mice lacking the alpha < subunit of the 
%8988 receptor. J Neurosci ::: <<O:-<<>?.
Crestani F, Keist R, Fritschy JM, et al. (:??:) Trace fear 
conditioning involves hippocampal alpha< %898(8) 
receptors. Proc Natl Acad Sci *-) )): >)>?->)><.
Curran H. (=)>A) Tranquillising memories: A review of 
the e(ects of benzodiazepines on human memory. 
Biological Psychology :;: =O)-:=;.
Curtis DR and Johnston GA. (=)O@) Amino acid transmitters 
in the mammalian central nervous system. Ergeb. 
Physiol A): )O-=>>.
Dämgen K and Lüddens H. (=)))) Zaleplon displays  
a selectivity to recombinant %8988 receptors  
di(erent from zolipdem, zopiclone and 
benzodiazepines. Neuroscience Research 
Communications :<: =;)-=@>.
Davidson JR, Feltner DE and Dugar A. (:?=?) Management 
of generalized anxiety disorder in primary care: 
identifying the challenges and unmet needs. Prim. 
Care Companion. J Clin Psychiatry =:.
de Haas SL, de Visser SJ, van der Post JP, et al. (:??O) 
Pharmacodynamic and pharmacokinetic e(ects of 
TPA?:;, a %898(8) alpha(:,;) subtype-selective 
agonist, compared to lorazepam and placebo in 
healthy volunteers. J Psychopharmacol :=: ;O@-;>;.
de Haas SL, Franson KL, Schmitt JA, et al. (:??)) The 
pharmacokinetic and pharmacodynamic e(ects of 
SLA<.=@)>, a %898-A alpha:,; selective agonist, in 
comparison with lorazepam in healthy volunteers. 
 J Psychopharmacol :;: A:<-A;:.
de Haas SL, Schoemaker RC, van Gerven JM, et al. (:?=?) 
Pharmacokinetics, pharmacodynamics and the 
pharmacokinetic/ pharmacodynamic relationship  
of zolpidem in healthy subjects. J Psychopharmacol  
:@: =A=)-=A:).
de Visser SJ, van der Post JP, de Waal PP, et al. (:??;) 
Biomarkers for the e(ects of benzodiazepines in 
healthy volunteers. Br J Clin Pharmacol <<: ;)-<?.
Duke AN, Meng Z, Platt DM, et al. (:?=>) Evidence 
That Sedative E(ects of Benzodiazepines Involve 
Unexpected %8988 Receptor Subtypes: Quantitative 
Observation Studies in Rhesus Monkeys. J Pharmacol 
Exp Ther ;AA: =@<-=<O.
Frommele E, Fleury C, Schmidt-Ginskey J, et al. (=)A?) On 
the pharmacodynamic action of new tranquilizing 
agent: methaminodiazepoxide or Librium. 
Experimental study. Therapie =<: =:;;-=:@@.
Gurrell R, Dua P, Feng G, et al. (:?=>) A randomised, 
placebo-controlled clinical trial with the alpha:/;/< 
subunit selective %8988 positive allosteric modulator 
/0-12345627 in patients with chronic low back pain. 
Pain =<): =O@:-=O<=.
!"#$%&'#$( '))$))*$"# +, "$-&+.+%"!#!/$, "$-&+012)!+3+%!.'3 '"( 0'!" 0&+.$))!"% !" $'&32 .3!"!.'3 (&-% ($/$3+0*$"# 114
Hannon B and Craik FIM. (:??=) Encoding speci'city revis-
ited: The role of semantics. Canadian Journal of 
Experimental Psychology/Revue canadienne de psy-
chologie expérimentale <<: :;=-:@;.
Jobert M and Wilson FJ. (:?=<) Advanced Analysis of Phar-
maco-""% Data in Humans. Neuropsychobiology O:: 
=A<-=OO.
Knabl J, Witschi R, Hosl K, et al. (:??>) Reversal of patho-
logical pain through speci'c spinal %8988 receptor 
subtypes. Nature @<=: ;;?-;;@.
Mandema JW, Tuk B, van Steveninck AL, et al. (=)):) Phar-
macokinetic-pharmacodynamic modeling of the 
central nervous system e(ects of midazolam and its 
main metabolite alpha-hydroxymidazolam in healthy 
volunteers. Clin Pharmacol Ther <=: O=<-O:>.
McKernan RM and Whiting PJ. (=))A) Which %8988-recep-
tor subtypes really occur in the brain? Trends Neurosci 
=): =;)-=@;.
Mets MA, Volkerts ER, Olivier B, et al. (:?=?) E(ect of hyp-
notic drugs on body balance and standing steadiness. 
Sleep Med Rev =@: :<)-:AO.
Neubauer DN. (:?=@) New and emerging pharmacothera-
peutic approaches for insomnia. Int Rev Psychiatry :A: 
:=@-::@.
Nickolls SA, Gurrell R, van Amerongen G, et al. (:?=>) Phar-
macology in translation: the preclinical and early 
clinical pro'le of the novel alpha:/; functionally selec-
tive %8988 receptor positive allosteric modulator 
/0-12345627. Br J Pharmacol =O<: O?>-O:<.
Norris H. (=)O=) The action of sedatives on brain stem oculo-
motor systems in man. Neuropharmacology =?: =>=-=)=.
Patat A, Perault MC, Vandel B, et al. (=))<) Assessment 
of the interaction between a partial agonist and a 
full agonist of benzodiazepine receptors, based on 
psychomotor performance and memory, in healthy 
volunteers. Journal of Psychopharmacology ): )=-=?=.
Reinhold JA and Rickels K. (:?=<) Pharmacological treat-
ment for generalized anxiety disorder in adults: an 
update. Expert Opin Pharmacother =A: =AA)-=A>=.
Rudolph U, Crestani F, Benke D, et al. (=)))) Benzodiazepine 
actions mediated by speci'c gamma-aminobutyric 
acid(8) receptor subtypes. Nature @?=: O)A->??.
Schmitt JA, Jorissen BL, Sobczak S, et al. (:???) Tryptophan 
depletion impairs memory consolidation but improves 
focussed attention in healthy young volunteers. J Psy-
chopharmacol =@: :=-:).
Simen A, Whitlock M, Qiu R, et al. (:?=)) An >-Week, 
Randomized, Phase :, Double-Blind, Sequential Par-
allel-Group Comparison Study of Two Dose Levels of 
the %8988 Positive Allosteric Modulator /0-12345627 
Compared With Placebo as an Adjunctive Treatment 
in Outpatients With Inadequate Response to Standard 
of Care for Generalized Anxiety Disorder. J Clin Psy-
chopharmacol ;): :?-:O.
Smith KS, Engin E, Meloni EG, et al. (:?=:) Benzodiaze-
pine-induced anxiolysis and reduction of conditioned 
fear are mediated by distinct %8988 receptor sub-
types in mice. Neuropharmacology A;: :<?-:<>.
Starcevic V. (:?=@) The reappraisal of benzodiazepines in 
the treatment of anxiety and related disorders. Expert 
Rev Neurother =@: =:O<-=:>A.
Tulving ET, M. (=)O;) Encoding speci'city and retrieval pro-
cesses in episodic memory. Psychological reviews >?: 
;<:-;O;.
van Amerongen G, Siebenga PS, Gurrell R, et al. (:?=)) 
Analgesic potential of /0-12345627, an ɲ:/ɲ;/ɲ< sub-
type-selective %8988 partial agonist, in humans. 
British Journal of Anaesthesia.
van Steveninck AL, Gieschke R, Schoemaker HC, et al. 
(=));) Pharmacodynamic interactions of diazepam 
and intravenous alcohol at pseudo steady state. Psy-
chopharmacology (Berl) ==?: @O=-@O>.
van Steveninck AL, Gieschke R, Schoemaker RC, et al. 
(=))A) Pharmacokinetic and pharmacodynamic inter-
actions of bretazenil and diazepam with alcohol. Br J 
Clin Pharmacol @=: <A<-<O;.
van Steveninck AL, Schoemaker HC, den HJ, et al. (=))@) 
E(ects of intravenous temazepam. I. Saccadic eye 
movements and electroencephalogram after fast and 
slow infusion to pseudo steady state. Clin Pharmacol 
Ther <<: <;<-<@<.
van Steveninck AL, Schoemaker HC, Pieters MS, et al. 
(=))=) A comparison of the sensitivities of adaptive 
tracking, eye movement analysis and visual analog 
lines to the e(ects of incremental doses of temazepam 
in healthy volunteers. Clin Pharmacol Ther <?: =O:-=>?.
van Steveninck AL, van Berckel BN, Schoemaker RC, et 
al. (=)))) The sensitivity of pharmacodynamic tests 
for the central nervous system e(ects of drugs on the 
e(ects of sleep deprivation. J Psychopharmacol =;: 
=?-=O.
Wright BM. (=)O=) A simple mechanical ataxia-meter. J 
Physiol :=> Suppl: :OP-:>P.
Yamadera H, Kato M, Ueno T, et al. (=));) Pharma-
co-""% mapping of diazepam e(ects using di(erent 
references and absolute and relative power. Pharma-
copsychiatry :A: :<@-:<>.
Zuiker RG, Chen X, Osterberg O, et al. (:?=<) &#GG65G, 
a partial subtype-selective %8988 agonist, elic-
its selective e(ects on the central nervous system in 
randomized controlled trial with healthy subjects. J 
Psychopharmacol.
!"#$%&' > – $"#'6#!+,2*#6)! &00&!% $'+0)7& +0 $0-?@/A.B@> , # 1-<%2$& 1&7&!%)5& 4#<## 6+,-7#%+' 115
.%'2, ! Overview of neurocognitive tasks included in the NeuroCart® and associated 
functional domains





Saccadic Peak Velocity (deg/sec)




Smooth pursuit Proportion in smooth pursuit (%)
Visuomotor 
coordination
Adaptive tracking  Average performance (%)
#! of average performance (%)*
Balance Body sway Anteroposterior movement (mm)
Subjective Alertness, 
mood, calmness 





Memory Visual Verbal 
Learning Test 
(HHQ,)
Immediate recall: Number correct
Immediate recall: Number incorrect*
Delayed recall: Number correct
Delayed recall: Number incorrect*
Delayed recognition: Number correct
Delayed recognition: Number incorrect*
Average reaction time for Correct words (msec)*
#! of average reaction time for Correct words (msec)*








* Results not presented in manuscript.
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.%'2, " Summary of subject characteristics 
Part % Part ' Total
Number of Subjects N=DG N=DG N=DG N=D5 N=45
Gender: n (%)
Male 10 (100) 10 (100) 10 (100) 14 (93) 44 (98)
Female 0 (0) 0 (0) 0 (0) 1 (7) 1 (2)
Age (years)
Mean (#!) 33.0 (10.3) 28.0 (8.0) 27.6 (7.6) 28.2 (8.8) 29.1 (8.6)
Range 22-48 20-47 18-43 18-53 18-53
Weight (kg)
Mean (#!) 77.6 (11.0) 76.1 (9.7) 77.0 (9.5) 73.1 (9.2) 75.5 (9.3)
Range 59.0-92.6 57.8-93.2 62.7-93.8 62.5-98.1 57.3-98.1 
Height (cm)
Mean (#!) 179.4 (6.9) 183.6 (4.8) 183.7 (5.8) 179.6 (5.6) 181.3 (6.0)
Range 167.2-192.6 176.3-194.0 172.7-192.2 168.8-191.9 167.2-194.0
'8( (kg/m2)
Mean (#!) 24.1 (3.3) 22.6 (2.8) 22.8 (2.3) 22.7 (3.2) 23.0 (2.8)
Range 19.0-28.4 17.5-27.8 17.8-25.6 18.9-29.9 17.5-29.9
H5/ = Body Mass Index / -' = standard deviation / Kg = kilogram
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D5 mg  
(N=D5)
-7-HB#I"JB@






B@ mg + Lorazepam 
1 mg (N=D5)
Cardiac Disorders 0 0 0 1 (0) 0
Ear and Labyrinth 
Disorders
0 1 (1) 0 0 0
Eye Disorders 0 0 2 (2) 2 (2) 2 (2)
Gastrointestinal 
Disorders




2 (1) 5 (5) 6 (4) 5 (4) 7 (6)
Infections and 
Infestations
0 0 1 (0) 0 0
Metabolism and 
Nutrition Disorders
0 0 1 (1) 1 (1) 0
Nervous System 
Disorders
4 (4) 11 (10) 12 (12) 11 (11) 14 (13)
Dizziness 2 (2) 6 (6) 8 (8) 3 (3) 7 (7)
Somnolence 2 (2) 7 (7) 7 (7) 8 (8) 8 (8)
Psychiatric 
Disorders
0 0 5 (5) 2 (2) 0
Renal and Urinary 
Disorders





1 (0) 0 0 0 0
Total preferred 
term events
DG (K) 14 (11) 43 (3K) 14 (11) 34 (3D)
-G+ = System Organ Class / 5<''=) = Medical Dictionary for Regulatory Activities / Numbers shown in 
brackets represent the number of treatment-related adverse events.
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.%'2, @ Pharmacodynamic Interaction pro.le of 0F-GHIJKLHM (OC mg) and lorazepam (; mg) 
presented as overall <=>eans (NC% Con.dence Interval)
Calculated summation 
of (-7-HB#I"JB@  65 
mg) + (Lorazepam 1 mg)
Co-administration of 
-7-HB#I"JB@ 65 mg  
+ Lorazepam 1 mg
Saccadic peak 
velocity (deg/sec)
LSMeans v. Placebo -130.6 -107.9
Estimate of di(erence -22.7 (-61.5, 16.1)
P value 0.25
Smooth pursuit (%)a LSMeans v. Placebo -5.1 -1.7
Estimate of di(erence -3.4 (-10.9, 4.1)
P value 0.37
Adaptive tracking (%)b LSMeans v. Placebo -16.5 -7.2
Estimate of di(erence -9.3 (-13.7, -4.9) 
P value 0.0001
Body Sway (ln mm) LSMeans v. Placebo (%) +226% +76%





LSMeans v. Placebo -8.7 -4.4
Estimate of di(erence -4.2 (-7.1, -1.4)
P value 0.004
HHQ, Delayed  Recall 
(number correct) 
LSMeans v. Placebo -11.6 -6.6
Estimate of di(erence -5.0 (-8.4, -1.5)
P value 0.0057
HHQ, Delayed  
Recognition (number 
correct) 
LSMeans v. Placebo -9.5 -4.0
Estimate of di(erence -5.5 (-9.0, -2.0)
P value 0.0029
H8# Alertness (mm) LSMeans v. Placebo -4.7 -4.8
Estimate of di(erence 0.058 (-5.1, 5.2)
P value 0.98
,)- = Visual Analogue Scale / ,,>( = Visual Verbal Learning Test 
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7(0:+, ! Pharmacodynamic e3ects on Saccadic Peak Velocity (=0"), Smooth Pursuit, 
Adaptive tracking, Visual Analogue Scale ("P=) Alertness and Body sway of 0F-GHIJKLHM  
and lorazepam presented as overall <=> (NC% Con.dence Interval) compared with placebo.
mg = milligram / (T) =tablet formulation / -&, = Saccadic Peak Velocity (deg/sec) / ,)- = Visual Analogue 
Scale / *Di%erences to placebo for body sway are represented as %di%erences, otherwise represent 
absolute di%erences.
7(0:+, " Pharmacodynamic e3ects on ""<7 of 0F-GHIJKLHM and lorazepam presented  
as overall <=> (NC% Con.dence Interval) compared with placebo.
mg = milligram / (() = tablet formulation
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7(0:+, # Pharmacodynamic e3ects on QQR of 0F-GHIJKLHM and lorazepam presented as 
overall <=> (NC% Con.dence Interval) compared with placebo.
mg = milligram / (() = tablet formulation
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7(0:+, = Spiderplot overview of <=> for saccadic eye movements, smooth pursuit eye 
movements, adaptive tracking, body sway, immediate recall memory, subjective alertness
Graph represents contrasts per treatment per functional domain compared with placebo. Distal from 
centre indicates Least Square Mean estimation greater than placebo. An open circle (P ) indicates a 
statistically signi6cant (P<...4) di%erence.
Decrease !"# ($-%&' ms)
Decrease Adaptive tracking 
($-%&%)
Increase Body sway Log 
($-$.( ln (mm))
Decrease ##)*  Immediate recall 
($-( words correct)
Decrease ##)*   Delayed recall 
words correct)
Decrease ##)*    Delayed recognition 
($-( words correct)
Decrease Smooth pursuit ($-&$ms)
Decrease #+! Alertness ($-%$ mm)
",-06372865 (%' mg) ",-06372865 (-' mg) Lorazepam (& mg) ",-06372865 (-' mg) + Lorazepam (& mg)
($-( 
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'6)#&'.#
'%$E0+):&* This study investigated the analgesic e(ects of two dose levels (=< and 
A< mg) of a novel ɲ:/ɲ;/ɲ< %898A subunit selective partial positive allosteric modulator 
(/8C), /0-12345627, compared to placebo and pregabalin (;?? mg) as a positive 
control.
8,.9)*/  We performed a randomised placebo-controlled crossover study 
(&.,?::;>O=O) in :? healthy subjects, utilizing a battery of pain tasks (electrical, 
pressure, heat, cold- and inBammatory pain, including a paradigm of conditioned pain 
modulation). Pharmacodynamic measurements were performed at baseline and up to 
=? hours post-dose.
+,/:2./ A dose of =< mg /0-12345627 increased Pain Tolerance Thresholds (/,,) 
for pressure pain at a ratio of =.== (+1s.$: =.?:, =.::) compared to placebo. A dose of A< mg 
/0-12345627 led to an increase in /,, for the cold pressor at a ratio of =.=O (+1s.$: =.?;, 
=.;:), and pressure pain task: =.== (+1s.$: =.?=, =.:=). Pregabalin showed an increase in /,, 
for pressure pain at a ratio of =.=< (+7s.$: =.?A, =.:A) and cold pressor task: =.;= (+1s.$: =.=A, 
=.@>).
$)&$2:/()& We conclude that /0-12345627 has analgesic potential at dose levels 
that do not induce signi'cant sedation or other intolerable adverse events limiting its 
clinical use. Additionally, the present study further established the potential role for this 
battery of pain tasks as a tool in the development of analgesics with a novel mechanism 
of action, for the treatment of various pain states including neuropathic pain and to 
establish proof-of-concept. 
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ɶ-Aminobutyric acid (%898) is the main inhibitory neurotransmitter in the mammalian 
central nervous system (.&#) and in that capacity it is involved in a myriad of functions 
and behaviours.I %898A receptors are heteropentameric ligand-gated chloride ion 
channels that mainly contain two ɲ, two ɴ, and one ɶsubunit.K Conventional, non-
selective benzodiazepines are positive allosteric modulators (/8C#) of the %898A 
receptors.L Animal studies have shown that %898A ɲ= activity is responsible for the 
sedative e(ectsR and studies in healthy human subjects with ɲ=-sparing, ɲ:/ɲ; /8C# 
have con'rmed these 'ndings in humans.M-V %898A ɲ: and ɲ; subunits have been 
associated with anxiolysisS, whereas the ɲ< subunits are believed to be involved in 
cognitive and memory performance.T-II
Since Melzack and Wall’s Gate control theory in =)A<.IK it is widely accepted that 
a central modulatory mechanism that regulates pain perception is present in the 
mammalian nervous system. However, only recently the putative role for %898A and 
glycine receptors in this modulatory processing of nociceptive input and its role in the 
development of neuropathic pain has been con'rmed.IL-IM This potential pharmacological 
target for the treatment of chronic pain was 'rst established by a preclinical study 
investigating the subtype selective ɲ:/ɲ; %898A receptor ligand, Q-636,wG4. This 
treatment clearly impaired the nociceptive response, both in a reduction in nociceptive 
input to the brain as well as reduced brain activity in associative-emotional components 
of pain, as shown by functional magnetic resonance imaging (fCD$) in rats.IJ Further 
pharmacological evidence was provided in a preclinical investigation where the novel 
subtype-selective %898A receptor-positive modulator &#GG3+w, which possesses a 
functional eNcacy selectivity pro'le of ɲ< > ɲ; > ɲ: > ɲ= at %898A ɲ subunit-containing 
receptors, showed analgesia at doses a :?-to @?-fold lower than the dosages that 
induced sedation or reduced motor function.IV Likewise, the ɲ:/ɲ; %898A receptor 
ligand, -^G22, demonstrated a dose-dependent antihyperalgesic e(ect in mouse 
models of neuropathic and inBammatory pain. These e(ects were observed at dose 
levels that not exhibited reduced motion or sedation.IS The e(ects of both &#GG3+2 
and -^G22 were reversed by the benzodiazepine antagonist Bumazenil, indicating that 
the observed analgesia was indeed mediated via the benzodiazepine binding site of 
the %898A receptors. A preclinical experiment in four lines of point-mutated mice, in 
which only one of the receptor subtypes ɲ=/ɲ:/ɲ;/ɲ< at %898A receptors remained 
benzodiazepine sensitive, has elegantly shown that targeting speci'cally ɲ: %898A 
receptors achieves strong antihyperalgesic e(ects. In these mice, diazepam and 
midazolam produced ɲ:-mediated analgesia, in the absence of sedation, reduced 
locomotion or development of tolerance, after treatment with diazepam and midazolam, 
both non-selective benzodiazepines. Reversal of hyperalgesia was also observed, albeit 
to a lesser extent, in those mice expressing ɲ; or ɲ< %898A receptors.IT
The role for %898ergic pain modulation in humans is supported by two clinical 
studies in healthy subjects using evoked acute and hyperalgesic pain models to 
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investigate the analgesic potential of two non-selective benzodiazepines, clobazam and 
clonazepam.KU,KI Additionally, several clinical studies in speci'c pain populations have 
shown their eNcacy in treating pain, although it can not be excluded that these e(ects 
were due to their myorelaxing properties, rather than genuine analgesia.KK,KL However, 
although conventional non-selective benzodiazepines are considered safe and 
reasonably well-tolerated, clinical use for the treatment of pain is precluded by adverse 
e(ects (8"s) including sedation, postural instability and memory disturbance.KR,KM 
/0-12345627 ($P/8. name: O-ethyl-@-(@’- ethylsulfonyl)-A-Bouro- :’methoxybiphe-
nyl-;- yl)-OH-imidazo@,<-:-pyridazine) is a potent ligand of the allosteric benzodiazepine 
site of the %898A receptor, which exhibits functional selectivity for receptors contai- 
ning ɲ:, ɲ; or ɲ< over those containing ɲ=.KJ Therefore, /0-12345627 has the potential to 
provide analgesia but with less sedation than non-selective benzodiazepines. 
The present study aims to explore the analgesic e(ect pro'le of /0-12345627. This 
was performed by investigating the e(ects of two di(erent dose levels in a comparison 
to placebo and a positive control (pregabalin) using a validated test battery of human 
evoked pain models.KV Since its approval, pregabalin plays a prominent role in the 
treatment of acute- and postoperative pain,KS-LU and neuropathic pain.LI Furthermore, its 
analgesic properties have been quanti'ed before, using this pain test battery, where a 
dose of ;?? mg pregabalin demonstrated a distinct analgesic e(ect pro'le.LK,LL As such, 
the present study was to provide information on the analgesic potential of an ɲ:/ɲ;/ɲ< 
subtype selective %898A partial agonist, at dose levels that were previously shown to 
exert a more favourable neurocognitive pharmacodynamic e(ect pro'le compared to a 
non-selective benzodiazepine.KJ 
*$#1+()
Subjects and study design
The study was a double-blind, double dummy, single dose, randomised, placebo-
controlled, @-period crossover study in which the e(ects of two dose levels of 
/0-12345627 were compared to placebo and pregabalin (;?? mg) was included as a 
positive control. The study was conducted at the Centre for Human Drug Research in 
Leiden, The Netherlands. The study was approved by the Medical Ethics Committee 
of Stichting Beoordeling Ethiek Biomedisch Onderzoek (Assen, The Netherlands) and 
was conducted according to the Dutch Act on Medical Research Involving Human 
Subjects (ECF) and in compliance with all International Conference on Harmonization 
Good Clinical Practice ($.--%./) guidelines and the Declaration of Helsinki. This study 
was registered in the public registry of ClinicalTrials.gov under registration number: 
&.,155364G4.
Each subject provided written informed consent before any screening procedures 
were performed. A total of :? healthy male subjects between => and << years of age 
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with a body mass index of =O.< to ;?.< kg mZ were enrolled. The subjects underwent a 
full medical screening, including medical history taking, a physical examination, blood 
chemistry and haematology, urinalysis, electrocardiogram (".%) and assessment of the 
minimal erythema dose (C"!) for PH9 light to assess eligibility. Subjects with a clinically 
signi'cant known medical condition, in particular any existing condition that would 
a(ect sensitivity to cold or pain were excluded. Subjects with Fitzpatrick skin type V or 
VI, widespread acne, tattoos or scarring on the back were excluded due to the inability to 
accurately assess C"!. Also, any subject who was a regular user of any illicit drugs, had a 
history of drug abuse or a positive drug screen at screening was excluded. Smoking and 
the use of xanthine-containing products was not allowed during dosing days. Alcohol 
was not allowed at least :@ hours before each scheduled visit and during the stay in the 
research unit.
Two dose levels of /0-12345627 (=< mg and A< mg) were selected based on the safety 
and tolerability data from the previous single dose and multiple dose studies as well as 
the anticipated receptor occupancy (DF) predictions based on a previous PET study. KJ 
=< mg dose was predicted to give ~<?% DF at ɲ: and A< mg dose was predicted to give 
~ >?% DF at ɲ:. A dose of ;?? mg pregabalin has been investigated in previous human 
evoked pain model studies LL,LR and was well-tolerated and lies within the labelled dose 
range in the European Union ("P).
Safety
All observed or volunteered Adverse Events (8"s) regardless of treatment group or 
suspected causal relationship to the investigational product are recorded. An 8" is 
considered any untoward medical occurrence in a subject participating in the clinical 
investigation. The following anchors for severity assessment by a quali'ed medical 
doctor were deployed: Mild (Does not interfere with subject’s usual function; Moderate 
(Interferes to some extent with subject’s usual function); and Severe (Interferes 
signi'cantly with subject’s usual function). All directly observed 8"s and all 8"s 
spontaneously reported by the study subject are recorded. In addition, each study 
subject is questioned about 8"s, using non-probing questions, following local Standard 
Operating Procedures. 
Pharmacodynamic assessments
Pain thresholds were measured using a battery of human evoked pain models, as 
described previously.KV,LK,LL The battery consists of an integrated range of pain tasks 
for measuring di(erent modalities of pain, which takes approximately ;? minutes 
to complete. Assessments were conducted twice pre-dose (double baseline) and 
?.<, =, :, ;, @, A, > and =? hours post-dose by trained personnel. A training session was 
included as part of the screening examination to exclude non- or extreme responders. 
To reduce variability from a(ects associated with fear of pain, the subjects themselves 
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were responsible for starting and ending each pain task. To eliminate the risk of tissue 
damage, all pain tasks had a maximum safety cut-o(.
The utilised battery of evoked pain tasks consists of the following tasks for 
nociception: the electrical stimulation task, pressure stimulation task, heat pain and the 
cold pressor task. Furthermore, the test battery includes a model for inBammatory pain, 
the PH9 model and a paradigm to quantify Conditioned Pain Modulation (./C). 
For the electrical stimulation task, the pressure stimulation task and the cold pressor 
task, pain intensity was measured continuously (beginning from when the 'rst stimulus 
was applied until the end of the test) using an electronic Visual Analogue Scale (H8#) scale 
ranging from ? (no pain) to =?? (most intense pain tolerable). For the abovementioned pain 
tasks, the Pain Detection Threshold (/!,), Pain Tolerance Threshold (/,,), Area Under 
the Curve (8P.) and a post-test Visual Analogue Scale (H8#) score were determined. For 
the thermal pain tasks (normal skin and PH9 exposed skin) only the (average of triplicate) 
/!, was determined, since assessment of heat /,, is prone to induce tissue damage. 
Pharmacokinetic assessments 
During all study periods, blood samples (; mL) to provide a minimum of =.< mL plasma for 
pharmacokinetic (/p) analysis /0-12345627 were collected pre-dose and at ?.<, =, :, ;, 
@, <, A, > and =? hours after study drug administration for /p analysis. Pharmacokinetic 
parameters were maximum observed plasma concentration (.max), area under 
the plasma concentration-time pro'le from time ? to the time of last quanti'able 
concentration (8P. last) and time for .max (,max) were calculated for each subject using 
non-compartmental analysis of plasma concentration-time data.
Statistics
The sample size and decision criteria were based on the mean e(ect over the 'rst A hours 
post-dosing for the primary endpoints: /,, for the pain tasks cold pressor, pressure pain 
and electrical pain, and the /!, for the thermal pain tasks (normal skin and PH9 skin). A 
sample size of :? subjects was selected to ensure balance in the design and to provide 
acceptable operating characteristics for decision-making based on conservative 
estimates of within-subject standard deviations (#!) from two previous studies.LK,LM 
Consequently, not each drop-out had to be replaced. The criterion used for each 
primary comparison was having at least )<% con'dence that the e(ect of either dose of 
/0-12345627 was better than that of placebo. This is equivalent to a one-sided test for 
statistical signi'cance using an alpha of ?.?<. No adjustment was made for multiplicity 
as this was an early-phase clinical study designed to explore the pharmacodynamics 
of /0-12345627. The Williams design (balanced for 'rst-order carry-over e(ects) 
randomization code was generated by an independent team. Randomisation numbers 
were sequentially allocated by the study physician, and blinded study treatments were 
prepared and dispensed by an independent operating pharmacy. 
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A mixed e(ect repeated measures model was 'tted for each endpoint, using data col-
lected during the 'rst A hours post treatment. This time window was selected based on 
the pharmacokinetic and pharmacodynamic pro'le as observed in the First-in-Human 
study.KJ The 'xed e(ects included in the model were baseline, period, time, treatment 
and treatment by time interaction, with baseline as a covariate. Subject was 'tted as a 
random e(ect and time point was repeated within each subject by period as a repeated 
e(ect. Baseline was included as : separate variables.LJ The /,, and /!, endpoints for 
the electrical-, pressure-, and cold pressor task were log-transformed prior to analysis. 
The treatment e(ects and comparisons to placebo for the log-transformed outcome 
measures were back transformed and are reported as geometric Least Square Means 
(Q#Cs) and ratios, respectively along with corresponding )?% con'dence intervals. For 
the thermal pain tasks (normal skin and PH9 exposed skin) /!, and secondary param-
eters for each pain task (8P. and H8#), no log-transformation was performed and the 
contrasts are presented as absolute mean di(erences in Q#Cs versus placebo with )?% 
con'dence intervals. Conditioned pain post-H8# was conducted post-hoc utilizing the 
same approach as that from the other analyses.
&$)-3#)
A total of :? subjects were randomised, of which =) subjects completed the study. One 
subject was excluded due to a positive drug screen prior to the second study period. The 
majority of the subjects were white ()?%). A summary of the baseline demographics is 
provided in Table !. 
Pharmacodynamics 
The pharmacodynamic e(ect pro'les for each treatment on the primary endpoints are 
graphically summarised in Figure !. The results of the analyses for the /,, for all pain 
tasks, except for thermal pain (/!, for Normal Heat and PH9 Heat) are presented. Time 
pro'les for each treatment on the primary endpoints are shown in Figure 1.
A detailed overview of the results of the analyses for the pharmacodynamic output 
variables (/,,, /!,, 8P. and H8#) is provided in Table 1. =< mg /0-12345627 signi'cantly 
increased Pressure /,, at a ratio of =.== (+1s.$: =.?:, =.::) compared to placebo. A dose 
of A< mg /0-12345627 signi'cantly increased Cold pressor /,, at a ratio of =.=O (+1s.$: 
=.?;, =.;:), as well as H8# for Electrical stimulation compared to placebo. Over the A-hour 
period, a statistically signi'cant increase at a ratio of =.== (+1s.$: =.?=, =.:=) on Pressure /,, 
was also observed for /0-12345627 A< mg versus placebo. However, Pressure /!, was 
statistically signi'cant decreased, indicating an increased sensitivity in pain detection. 
The positive control, pregabalin (;?? mg) signi'cantly a(ected pain sensation for Cold 
pressor /,, by =.;= (+1s.$: =.=A, =.@>) compared to placebo as well as Cold pressor 8P.. 
Additionally, Pressure /,, was signi'cantly increased at a ratio of =.=< (+7s.$: =.?A, 
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=.:A), as well as Pressure 8P.. No statistically signi'cant e(ects were detected for any 
of the three treatments versus placebo for any of the endpoints related to the thermal 
pain tasks (normal skin and PH9 skin). As a result of the conditioning stimulus, the /,, 
for electrical pain was on average decreased by =.=A mA in the placebo group. None 
of the ./C parameters were statistically signi'cant di(erent between the three active 
treatments and placebo. 
Pharmacokinetics
Median plasma /0-12345627 concentration-time pro'les are presented in Figure 2 and 
pharmacokinetic (/p) parameters are summarised descriptively in Table 2. Following 
administration of single oral doses of /0-12345627 =< mg and A< mg, median ,max was 
observed at : and ; hours, respectively. Both plasma /0-12345627 8P. last and .max 
appeared to increase proportionally with dose from =< mg to A< mg. Summary statistics 
for 8P. inf and ,/ were not reported because <<?% of the subjects had reportable 
parameter values; /p was sampled to =? hours and thus terminal phase was not 
characterised. No active metabolites were identi'ed. 
Safety 
The majority of subjects reported 8"s in the system organ class (#F.) of nervous 
system disorders, general disorders and administration site conditions, almost all of 
which were considered treatment-related. The three most frequently reported adverse 
events after treatment with /0-12345627 =< mg were dizziness (;)%), fatigue (;;%) and 
bradyphrenia (:>%). For treatment with /0-12345627 A< mg the six most frequently 
observed adverse events were dizziness (<;%), somnolence (;:%), bradyphrenia (;:%), 
fatigue (:A%), balance disorder (:A%) and feeling abnormal (:A%). For treatment with 
the positive control pregabalin ;?? mg the three most frequently observed adverse 
events: somnolence (<<%), fatigue (@?%) and dizziness (;<%), which was in line with 
what is previously reported for single dosing of pregabalin (;?? mg).LV In the placebo 
treated arm, nasopharyngitis (=A%), headache (=A%) and bradyphrenia (=A%) were most 
frequently reported. All recorded 8"s were mild in severity.
(!).-))!+"
In this clinical study investigating the e(ects of /0-12345627, the two dose levels (=< mg 
and A< mg) were safe and well-tolerated. The doses were selected to achieve ~<?% and 
~>?% receptor occupancy at ɲ: %898A receptors, respectively. The observed adverse 
events were mild and con'rm previous observations.KJ 
/0-12345627 demonstrated an analgesic e(ect on Pressure pain and the Cold 
pressor task. The magnitude of e(ect was greater for a dose of A< mg compared with a 
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dose of =< mg for the Cold pressor but the e(ects were similar for the Pressure pain task. 
Pregabalin ;?? mg attenuated pain induced using the Cold pressor and the Pressure 
pain task. 
At present, to our knowledge few studies have previously reported the e(ects of 
%898ergic modulating compounds utilising evoked pain models in healthy subjects in 
a comparable setting as the current study. What is more, no studies using this type of 
multimodal methodology to investigate the analgesic potential for ɲ:/ɲ;/ɲ< subtype 
selective %898A agonists in healthy subjects were found. One study investigating 
the e(ects of two non-selective benzodiazepines, clonazepam and clobazamKI was 
identi'ed. In this study, an antihyperalgesic e(ect was demonstrated using the capsaicin 
model in combination with a cu( algometry challenge, in addition to other methods. 
Even though the deployed methodology is di(erent from the present study, some 
parallels can be drawn. For example, /0-12345627 also attenuated pressure /,,, of 
which similar 'ndings suggestive of analgesia were previously reported. Furthermore, 
the earlier observed lack of treatment e(ects on cutaneous electrical pain and ./C, 
were also seen here. 
Absence of analgesia against PH induced inBammatory pain of /0-12345627 is 
perhaps surprising, as spinal %898A ɲ: receptors have been identi'ed as potential targets 
to exert antihyperalgesic e(ects in preclinical research.IL,IJ,IS,LS %898A ɲ: receptors are 
located and act at a spinal level.LT Hyperalgesia resulting from cutaneous (PH9 induced) 
inBammation, is thought (albeit debatable) to be of peripheral originRU, resulting from 
decreased activation thresholds for local nociceptive and non-nociceptive neurons 
alike. This is a response to damaged !&8 as a result of exposure to PH9 radiation, which 
results in the induction of &0ʃ9 that leads to local production of cytokines $Q-G, $Q-2 and 
,&0-ɲ.RI This speci'c type of inBammation and associated inBammatory hyperalgesia 
is distinct from other types of experimentally induced inBammation typically used in 
preclinical research in its origin and underlying pathophysiology.RK,RL PH9-induced 
hyperalgesia is most e(ectively counteracted by inhibition of cyclooxygenase (.F`), thus 
preventing the formation of prostaglandins and thromboxane, which are responsible for 
the lowered activation thresholds.LK,RR,RM /0-12345627 exerts its e(ects via %898ergic 
modulation of the central nociceptive system, which is known to demonstrate mixed 
e(ects on PH9 induced inBammatory pain in human evoked pain studies.RJ The absence 
of antihyperalgesic e(ects is at odds with previously reported antihyperalgesic e(ects 
of clobazam on PH9 induced heat perception thresholds.RV A potential explanation 
could be the less profound %898A receptor subtype selectivity of clobazam compared 
to /0-12345627, as its metabolite N-desmethyl clobazam is proposed to demonstrate 
more selectivity for ɲ: %898A receptors over ɲ= %898A receptors, compared to the 
parent.RS Similar to the 'ndings in the present study, it was shown that ./C was not 
a(ected by treatment with the nonselective benzodiazepine lorazepam.RT The role for 
%898ergic interneurons in descending modulation and their role in chroni'cation of pain 
has been recognised previously.MU-MK The underlying mechanism has been described as 
the %898 disinhibition hypothesis of analgesia.ML This hypothesis describes a particular 
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descending periaqueductal gray - rostroventricular medulla (/8%-DHC) pathway that 
mediates the phenomenon of stress-induced analgesia. This pathway exerts analgesia 
via suppression of inhibitory %898ergic inputs onto output neurons that constitute 
the descending analgesic pathway. However, the ./C paradigm based on electrical 
pain, which was used in the current study, may not be the most suitable paradigm to 
determine the potential e(ects of %898ergic intervention, as it has been shown that 
spinal enkephalins and %898 presynaptically modulate mechanonociception via 
Aɷ 'bres, whereas electrical stimulation is generally thought to activate both Aɷ and 
C 'bres.MR,MM Finally, as also suggested previouslyRT the lack of a modulating e(ect on 
./C by %898A agonism in the present study, may be explained by the fact that in the 
healthy state the role of %898ergic interneurons in ./C is optimised for endogenous 
%898A agonism and thus not susceptible for external inBuence in the absence of 
true stressors. In contrast, patients su(ering from chronic pain, where it is known that 
%898ergic dysregulation may be a large contributing factorIJ, may be susceptible for 
pain alleviation through %898A modulation. This hypothesis is moderately substantiated 
by the overlap observed in e(ect pro'les of pregabalin and /0-12345627. This overlap in 
clinical application may suggest that /0-12345627 has a potential role in the treatment 
of di(erent types of neuropathic pain, similar to pregabalin.MJ Alternatively, variability of 
./C response is higher than the variability of the other pain tasks and perhaps the study 
was underpowered to detect an e(ect on ./C response.
Even though the clinical application of /0-12345627 and pregabalin may 
demonstrate a slight overlap, their mechanism of action is di(erent. Pregabalin is a 
calcium channel antagonist that shows speci'c binding af'nity for the ɲK-ɷ auxiliary 
subunits of voltage-gated calcium channels (H%..). There have been a number of 
studies showing an up-regulation of H%..# in dorsal root ganglion and dorsal horn 
in neuropathic pain.MV Administration of pregabalin is shown to partially reverse the 
up-regulated calcium ɲK-ɷ subunits at the pre-synaptic nerve terminals in the dorsal 
horn.MS Even though there is a structural resemblance with %898 , di(erent studies have 
shown that pregabalin does not appear to mimic %898 or pharmacologically enhance 
its actions.MT As such, pregabalin is not considered a positive control from a mechanistic 
perspective, but rather from a clinical perspective. More importantly its analgesic e(ects 
and the reproducibility thereof on the pain test battery that was used in the current study 
have been demonstrated multiple times before. (Siebenga et al., :?=>).
The population included in the study was considered to be very homogeneous, 
which improves the internal validity but may impact generalisability of the study results 
to other populations. The study included only male subjects, of which )?% was white. 
The existence of sex di(erences in terms of sensitivity to clinical and experimental pain is 
widely known.JU,JI It has been suggested that sex-speci'c di(erences in %898A receptors 
may play a role in this di(erentiation.JK However, it is also known that the menstrual cycle 
inBuences pain perceptionJL,JR, which would interfere signi'cantly with the crossover 
design of the study, therefore it was decided to include only male subjects were in the 
present study. Furthermore, since the PH9 model was a primary endpoint of the study, 
!"#$%&' @ –#*#74&1)! &00&!% $'+0)7& +0 $0-?@/A.B@> , # 1-<%2$& 1&7&!%)5& 4#<## 6+,-7#%+'  135
subjects with Fitzpatrick skin type V or VI were excluded due to the inability to accurately 
assess C"! and to safely induce PH9 induced inBammation, leading to a predominantly 
white study population. Research has identi'ed di(erences in pain sensitivity between 
di(erent ethnic or racial populations in experimental pain research.JM,JJ Whether those 
'ndings can be extrapolated to the Dutch population and what is the exact cause of the 
di(erences in pain perception is unknown. 
The present study is an early-phase hypothesis-generating clinical study designed 
to guide decision-making and explore the pharmacodynamics and pharmacokinetics 
of /0-12345627 in healthy subjects using a multi-modal battery of pain tasks. As such, 
the study was powered to detect a potential analgesic e(ect on the primary endpoints. 
However, given the novelty of the pharmacological mechanism of action, secondary 
parameters for which no formal power calculation was performed are taken into account 
when reviewing the generated results. Consequently, interpretation of these 'ndings 
requires more caution and is potentially more prone to type I or type II error, since no 
correction for multiple testing was performed. 
The 'ndings in the present study are indicative of the analgesic potential for 
/0-12345627 at the doses tested, in addition to the neurocognitive anxiolytic potential 
that has been identi'ed previously.KJ The observed e(ect pro'le does not appear to 
result from sedation alone for various reasons. In both this study and a previous study, 
/0-12345627 was shown to exert only mild sedative e(ects. Second, in a recently 
performed studyJV, we showed that the test battery of evoked pain tasks was not sensitive 
to the e(ects of sedation, by investigating the e(ects of a sedative -G antihistaminergic 
agent, promethazine. 
Translation of the 'ndings of a human evoked pain model utilised in healthy subjects 
to clinical pain remains elusive, but the present study has demonstrated clearly that 
/0-12345627 has analgesic potential, at dose levels that do not induce signi'cant 
sedation or other intolerable adverse events limiting its clinical use. This analgesic 
potential however, was not found in a recent clinical study where the e(ects of :.< 
mg (one week) followed by O.< mg (three week treatment period) /0-12345627 on 
chronic low back pain were investigated.JS These discrepant 'ndings may result from 
several factors, but the di(erence in dosing regimen and consequently lower receptor 
occupancy in the patient study could be the putative cause. 
Finally, the present study further established the potential role for this battery of 
pain tasks as a tool in the development of analgesics with a novel mechanism of action, 
for the treatment of various pain states including neuropathic pain and to determine 
proof-of-concept. 
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.%'2, ! Summary of subject characteristics 
Age (years)






Mean (#!) 78.7 (10.5)
Range 60.1-100.7
'8( (kg/m1)
Mean (#!) 23.3 (2.9)
Range 18.5- 27.2
H5/ = Body Mass Index / -' = standard deviation / Kg = kilogram
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.%'2, # Summary of Pharmacokinetic parameters for single administration of :C and OC mg 
0F-GHIJKLHMS
Treatment -7-HB#I"JB@
Dose level D5 mg
(N=DK)
65 mg  
(N=DC) 
Cmax (ng/mL)a 59.04 (37) 304.8 (33)
Tmax (h)b 2.00 (0.500 - 4.00) 3.00 (0.500 - 5.00)
8P.last QJɒKP/a 342.4 (57) 1837 (41)
a =Geometric mean (%Geometric +,) / b Median (range)K 
7(0:+, ! Spiderplot summary of Pharmacodynamic response pro.le for pain test battery 
normalised to placebo
Dashed placebo line (green) represents a value of ! to which other treatment e%ects are normalised. 
Distal from the centre beyond the placebo line indicates Least Square Mean &((/&'( greater than 
placebo, towards the centre and within the placebo line indicates Least Square mean &((/&'( lower 
than placebo. A closed circle (O) indicates meeting pre-speci6ed decision criteria relative to placebo for 
treatment on pain task.
Heat Normal skin !"# (°C)
Heat $%& skin !"# (°C)
Electrical Stair !## (mA)Pressure Stimulation !## (kPa)
Cold Pressor !## (s)
!'-06372865 (()  mg) !'-06372865 (*) mg) Pregabalin (+,, mg)
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7(0:+, " Graphical overview of Pain Thresholds Time pro.les for pressure pain task 
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7(0:+, # Pharmacokinetic pro.le for single administration of :C and OC mg 0F-GHIJKLHM 
median plasma 0F-GHIJKLHM concentration over time.  
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The present thesis describes the use of broad pharmacodynamic e(ect pro'ling to 
characterise the clinical pharmacology of classic and non-classical analgesia. Analgesic 
drugs that modulate widespread targets in the nervous system can be expected to 
a(ect numerous .&# functions, which requires multimodal characterisation of pain 
processing and neurocognition. This is illustrated on the basis of two case studies of 
pharmacological agents that target cannabinoid .9G and %898ergic %898A receptors: 
two of the most widely distributed systems of receptors and neurotransmitters 
that are involved in a myriad of physiological functions. The distribution of receptors 
throughout the central nervous system render "./1158 , an oral formulation of ѐ+-,-., 
and /0-12345627, a positive allosteric modulator of ɲ:/;/< subunit-containing %898A 
receptors, ideal candidates for extensive neurophysiological and analgesic e(ect 
pro'ling in early phase clinical research. Pro'ling human pharmacology with a strong 
focus on pharmacodynamics may help to better understand the therapeutic potential 
and safety limitations of a compound before selection of doses and patient populations 
for phase II proof-of-concept studies. 
)-**'&2  +,  )#-(!$)
Over the past two decades, two multimodal test batteries for .&# drug pro'ling have 
been developed and validated at .-!D: the NeuroCart® as a compilation of drug 
sensitive neurocognitive assessments, and the PainCart® for the quanti'cation of 
di(erent aspects of pain processing. Originally, the PainCart addressed various major 
types of evoked pain responses, but it did not contain measurements for hyperalgesia, 
which is a hallmark of inBammatory or neuropathic pain. The second chapter describes 
a literature study into the pharmacological sensitivity of hyperalgesia pain models. 
Due to variability in utilised methodology, the report focused on three models: the 
PH9 model, the capsaicin model and the thermode burn model. Although capsaicin 
has generally been regarded as a model for neuropathic pain, the model appeared 
to be insensitive to the classes of pharmacological compounds clinically prescribed 
in the 'rst-line treatment of neuropathic pain (e.g. tricyclic antidepressants, calcium 
channel ɲK-ɷ ligands). The thermode burn model is used as a translational model 
for both neuropathic and inBammatory pain but is only moderately sensitive to the 
attenuating e(ects of &C!8 receptor antagonists. However, the inherent risk of tissue 
damage, in combination with the limited pharmacological sensitivity, result in an 
inappropriate model for either inBammatory or neuropathic pain. The PH9 model for 
inBammatory pain demonstrated high pharmacological sensitivity to &#8$!#, in line 
with their proposed anti-inBammatory mode of action. Based on this literature review, 
the test battery of evoked pain tasks, PainCart, was expanded with the PH9 model as a 
biomarker for inBammatory hyperalgesia, while it was decided to continue the search 
for a reproducible and predictive model of neuropathic pain, either in healthy subjects 
or in patients.
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An oral formulation of *+-,-. was investigated in a four-week clinical trial in patients 
with (primary or secondary) progressive Multiple Sclerosis (C#) and moderate spasticity, 
which was described in Chapter ;. ENcacy and secondary e(ects were expressed in 
both objective (e.g. electrophysiology, postural stability) and subjective Numerical Rating 
Scales (e.g. &D# spasticity / &D# Pain, H8# Bowdle and H8# Bond and Lader) endpoints. 
    To overcome inter-individual variability in pharmacokinetics and pharmacodynamic 
response, a crossover challenge phase was built in the study design, to enable 
individualised dosing. The challenge phase consisted of an up-titration of three 
consecutive doses, ;, < and > mg, accompanied by intensive /p sampling, NeuroCart 
measurements of functional .&# e(ects and monitoring of adverse events (8"s). /p/
/! modelling was included to identify the appropriate dose for each individual at which 
the desired e(ects were observed in the absence of adverse events. However, due to 
the lack of a robust /! response during the challenge phase, a reliable model to predict 
individual doses could not be established. Since there was also no e(ect on pain during 
the challenge phase, dosing for the treatment phase was based on tolerability. 
During the treatment phase, the selected dose levels were generally well-tolerated, 
although some limited dose adjustments were needed. No signi'cant treatment e(ect 
was observed on the objective endpoints for spasticity: -/C ratio and Ashworth score. 
Subjective spasticity measured with an &D# repeatedly during the treatment visits on 
weeks ?, :, and @ improved after : and @ weeks of treatment, which was signi'cant at 
: weeks of treatment. The same pattern was observed in a more pronounced way for 
the &D# for pain. This outcome, measured as an &D# repeatedly during each treatment 
visit, revealed a signi'cant overall improvement in favour of treatment compared with 
placebo. The psychoactive e(ects observed after short-term administration of *+-,-. 
during the challenge phase were not observed during the treatment phase.
Similar to the observed variability in /! outcomes observed in this trial, moderate 
variability in /p properties was observed during both the challenge and treatment 
phases. This is most likely attributable to the more heterogeneous patient population 
compared with healthy volunteers that were investigated before. /p modelling revealed 
a relatively high typical apparent clearance and typical apparent volume of distribution 
compared with previous findings, which is most likely related to slightly lower 
bioavailability of the oral formulation. In addition, a slower absorption rate was observed, 
which we assumed to be resulting from reduced gastrointestinal motility, which has 
previously been reported in patients with C#.
The clinical trial described in Chapter @ was performed to expand earlier pharmacological 
validation studies of the original PainCart and further elucidate the 'ndings described in 
the third chapter of this thesis. The aim was to investigate the analgesic e(ects of classic 
and non-classic analgesics compared to a sedating negative control in a randomized 
placebo-controlled crossover study in :@ healthy volunteers, using the battery of evoked 
pain tasks that was previously validated for other classes of analgesics. The biomarker 
battery consists of pain tasks eliciting electrical, pressure, heat, cold and inBammatory 
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pain. For each pain task, the Pain Detection Threshold (/!,), Pain Tolerance Threshold 
(/,,) and subjective score (H8#) were recorded. Subjective scales for alertness, 
mood and psychotomimetic e(ects were included. Subjects were administered each 
of the following oral treatments: paracetamol (=??? mg), *+-,-. ("./1158) (=? mg), 
promethazine (<? mg) or matching placebo. Contrary to our expectations, we found 
that paracetamol was not e(ective at reducing any of the pain modalities measured 
using the battery of evoked pain tasks. Furthermore, *+-,-. did not show any acute 
analgesic e(ect, and even showed a hyperalgesic e(ect on two of 've pain tasks, namely 
electrical and pressure pain. Finally, the negative control promethazine showed an 
increase in pain sensitivity for cold, pressure and inBammatory pain. In addition to the 
pain tasks, cognitive tests were performed to assess subjective alertness, mood and 
psychotomimetic symptoms, which were moderately impaired by treatment with *+-,-. 
(alertness, calmness, internal and external perception) or promethazine (alertness). 
      Paracetamol has been shown to be e(ective in the treatment of di(erent types of 
clinical pain, although not in all. However, when looking at available literature on human 
evoked pain tasks in healthy volunteers, the image becomes more di(use. For each of 
the pain tasks that were investigated in more than one clinical trial, positive as well as 
negative results have been reported. The e(ects of paracetamol on acute evoked pain 
processing remain elusive, which may reBect its uncertain mechanism of action. 
The lack of acute e(ects of *+-,-. on the PainCart was not entirely unexpected. 
Based on its interaction with the endocannabinoid system, *+-,-. cannot be 
considered an antinociceptive analgesic, even if it may have analgesic e(ects in some 
conditions. This is reBected in the results of clinical studies using human evoked pain 
models to investigate pharmacology and mechanism of action. The 'nding of *+-,-. 
induced hyperalgesia has also been observed in the clinic. This may be the result 
from a narrow therapeutic window in combination with variable pharmacokinetics. 
Alternatively, this could have been a primary pharmacodynamic e(ect by which the 
participants were less motivated to complete the pain tasks, resulting in lower pain 
detection and pain tolerance thresholds. Another possibility is that .&# depression 
can reduce the cognitive control of predictably evoked pain. These last two hypotheses 
are supported by the observed lack of acute analgesia and mild hyperalgesia on some 
pain tasks after administration of promethazine. At any rate, these 'ndings illustrate the 
importance of broad pro'ling to determine the optimal therapeutic window of centrally 
acting (.&# depressant) analgesics.
The results of the studies in Chapters ; and @ support the notion that repeated 
*+-,-. administration exerts a gradual pharmacodynamic e(ect that may treat the 
perception of neuropathic pain or spasticity, rather than exerting pure acute nociceptive 
e(ects or a(ecting electrophysiologically measurable phenomena. 
The chapters < and A describe a series of early human studies, which for the 'rst time 
integrated the NeuroCart and PainCart pro'ling of a centrally acting drug, /0-12345627. 
This is a novel partial %898A ɲ:/ɲ;/ɲ< subtype-selective positive allosteric modulator 
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that is under development for the treatment of di(erent indications, including anxiety 
disorders, neuropathic pain and photosensitive epilepsy. The two-part study design 
allowed for the investigation of di(erent objectives. In Part A, a wide dose range was 
investigated to determine safety, /p and /! response. Based on the results, two dose 
levels (=< and A< mg) were selected for a direct comparison and interaction study with 
lorazepam (: mg) in Part B. 
The comparison with placebo and the combination of lorazepam (: mg) with 
/0-12345627 A< mg demonstrated additive or infra-additive e(ects, depending on the 
functional domain, in line with the predicted functional selectivity for ɲ:/ɲ;/ɲ< %898A 
receptor subtypes, but also revealing for which %898A subtypes there is a competitive 
or non-competitive receptor interaction. No synergy was observed. For Saccadic peak 
velocity (#/H), Smooth pursuit and H8# Alertness no interaction, but addition was 
observed, which can be explained by non-selective receptor activation by lorazepam (: 
mg) in addition to selective ɲ:/ɲ; activation by /0-12345627. For the other functional 
domain tests, Adaptive tracking, Body Sway and HHQ,, infra-additive e(ects were observed 
when lorazepam and /0-12345627 were administered simultaneously. A reduction in 
e(ect size for these psychomotor functions compared to administration of lorazepam (: 
mg) alone, may indicate that due to competitive activity at the %898A receptor subtypes, 
/0-12345627 acts as an antagonist, resulting from partial agonism, at ɲ= subunits, 
which diminishes lorazepam’s high intrinsic activity as a non-selective full agonist. 
       Extensive pharmacodynamic and pharmacokinetic pro'ling as performed in Chapter 
< provided valuable insight in the receptor pharmacology of /0-12345627 speci'cally, 
but also of subtype-speci'c %898A positive allosteric modulators in general. The subtle 
interplay between intrinsic eNcacy and receptor subtype aNnity was unveiled. In terms 
of its clinical development, a clear dose-response e(ect was established. Based on this 
study, two pharmacologically active doses were selected for further pharmacodynamic 
e(ect pro'ling in Chapter A. 
Based on the 'ndings of the preceding chapter and the accumulating evidence 
that %898A receptors may play a modulating role of nociceptive processing in various 
neuropathic pain states, a study was performed focusing on analgesic e(ect pro'ling of 
/0-12345627. This was performed as a double-blind, randomised, placebo-controlled, 
single dose, crossover study in which the e(ects of two doses of /0-12345627 (=< and 
A< mg) were compared with placebo and pregabalin (;?? mg) as a positive control. 
Pharmacodynamic assessments (pain thresholds) were executed using the battery of 
evoked pain tasks and intensive /p sampling was done. /0-12345627 had an analgesic 
e(ect on pressure pain and the cold pressor task. The magnitude of e(ect was greater 
for A< mg compared with =< mg for the cold pressor, but the e(ects were similar for the 
pressure pain task. Pregabalin ;?? mg lowered pain thresholds induced by the cold 
pressor and the pressure pain tasks. From a mechanistic perspective, translation of 
'ndings from a human evoked pain model in healthy subjects to clinical pain remains 
uncertain, but the present study clearly shows that /0-12345627 has analgesic potential 
at doses that do not induce signi'cant sedation or other intolerable 8"s.
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Pain is a complex multifaceted process that involves many peripheral and central 
pharmacological systems. This thesis centred on the early development of two centrally 
acting analgesics that a(ect the endocannabinoid .9G system and subtypes of %898A 
receptors. In both cases, extensive pro'ling of neurocognitive, neurophysiological and 
pain processing was performed to provide further insights into the complicated interplays 
between .&# depression, acute nociception and pain experience. Integration of this 
information can be useful in the determination of the anticipated therapeutic window, the 
expected adverse e(ect pro'le and potential indications for subsequent clinical trials. 
The endocannabinoid system is a highly complex, not fully understood, biological 
system that exerts various subtle and less subtle e(ects when targeted. This context 
makes "./1158 (*+-,-.), which speci'cally targets endocannabinoid receptors in 
the .&#, an ideal candidate for pharmacological characterisation of neurocognitive, 
neurophysiological and pain processing in early phase clinical research. The analgesic 
potential revealed in the study in C# patients was investigated in healthy volunteers 
using the PainCart, after earlier studies had identi'ed pharmacologically active doses 
using the NeuroCart. Here it became clear that the analgesia against neuropathic pain 
observed in C# patients, is distinct from purely nociceptive analgesia. Instead *+-,-. 
alters pain experience at a di(erent level. In line with the e(ects observed on subjective 
pain in C# patients, the e(ects observed on spasticity suggest an analogous mode 
of action: there was a signi'cant di(erence in subjective spasticity after two weeks 
of treatment, albeit not signi'cant over the @ week treatment period, but this was not 
reBected in the objective electrophysiological measurements of spasticity ("C%). Even 
though no clear change in objective endpoints (pain thresholds or "C%) was observed, 
the subjective experience of these unpleasant sensations was altered nonetheless.
It has been suggested that the eNcacy *+-,-. is attributable to the fact that patients 
are too “high” to accurately report the level of experienced pain. This is not con'rmed 
in the study in healthy subjects where feeling high (changes in internal and external 
perception) was recorded, but not associated with analgesia or reports of reduced pain 
perception. 
*+-,-. demonstrates moderately variable /p and /!. In an e(ort to reach suNcient 
plasma concentrations to exert analgesia, the selected dose level of this oral formulation of 
*+-,-. in the study in healthy subject measuring evoked pain thresholds may have been 
too high for some, as evidenced by reported adverse events and increased sensitivity 
to pain (hyperalgesia). This experimental model supports the earlier observations of a 
narrow therapeutic window for *+-,-. and the interactions between neurocognitive 
control and pain processing. Metabolism of *+-,-. is known to be complex, resulting 
in various active and inactive metabolites, with di(erent and largely unknown /p and 
/! characteristics and interactions. Therefore it is diNcult to directly compare acute 
and chronic e(ects, as these may be driven by di(erent pharmacological constituents. 
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Even though the clinical bene'ts and analgesic potential of *+-,-. are widely 
recognised, the complete mechanism of action remains incompletely explained. 
Nonetheless, the two chapters described in this thesis have contributed to the body 
of research by taking two di(erent viewpoints: from the mechanistic approach of 
biomarkers for pain in healthy subjects to clinical endpoints for pain and spasticity in a 
target population of C# patients. 
%898ergic neurons and interneurons are distributed throughout the .&# and are 
involved in a broad spectrum of functions. Targeting %898A receptor subtypes instead 
of non-selective receptor modulation by conventional benzodiazepines has become 
increasingly interesting since the discovery that the various receptor subtypes show 
distinct distribution patterns which are associated with different functional and 
clinical e(ects. Treatment with ɲ= sparing positive allosteric modulators for %898A will 
potentially achieve analgesia or anxiolysis in the absence of dose-limiting sedation, 
which is largely attributed to the ɲ= subunit. The extensive neurophysiological e(ect 
pro'ling of a wide dose range of /0-12345627 and subsequent comparison to lorazepam 
alone and in combination with /0-12345627, provided valuable insight in the receptor 
pharmacology of partial and full, or subtype speci'c and non-selective allosteric 
agonists. The interplay between intrinsic activity and relative aNnity of /0-12345627 
resulted in a comprehensive pharmacodynamic e(ect pro'le in man. Per task, or range 
of tasks, respective for a speci'c %898A receptor subtype and individual dose-e(ect 
relationship was established. The 'ndings in this study con'rmed the predicted ɲ:/ɲ;/
ɲ< %898A receptor subtype selectivity for /0-12345627 and guided dose selection for 
subsequent investigations in evoked pain although a dose of A< mg more convincingly 
demonstrated analgesic e(ects on di(erent pain tasks. 
Even though a dose of A< mg /0-12345627 demonstrated substantial .&# e(ects, 
including a reduction in #/H, reduction in adaptive tracking, increase in postural 
instability and reduced memory performance, it is unlikely that these speci'c e(ects 
drive the observation in the absence of analgesia, as it has been demonstrated that the 
battery of evoked pain tasks is not overly sensitive to the e(ects of mere sedation, which 
may even reduce pain thresholds. 
Before the results of the early human studies of /0-12345627 described in this thesis 
were fully integrated, a study in low back pain patients was performed. Mainly based on 
preclinical predictions and early human adverse e(ects, a loading dose of :.< mg 9$! for 
the 'rst week was followed by O.< mg 9$! for the following three weeks. (Gurrell et al., 
:?=>)*. The study did not show clinically relevant e(ects. Without the results reported in 
this thesis, the negative 'ndings in the latest study could have been interpreted in such 
a way that the 'ndings from preclinical research are not readily translatable to humans. 
However, reviewing the preclinical and clinical reports in their entirety, the results of the 
study described in Chapters < and A, suggest that insuNcient receptor occupancy was 
* Gurrell R, Dua P, Feng G, et al. (:?=>) A randomised, placebo-controlled clinical trial with the alpha:/;/< subunit 
selective %8988 positive allosteric modulator /0-12345627 in patients with chronic low back pain. &)/0 =<): =O@:-=O<=.
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achieved in this clinical trial. The e(ects on the NeuroCart and the PainCart suggested 
that targeting ɲ:/ɲ;/ɲ< %898A receptor subunits has the potential to result in detectable 
analgesic e(ects in humans at doses of around A< mg. Therefore, integration of the 
detailed assessments that are described in this thesis could be used to redesign a study 
in patients su(ering from neuropathic or other types of pain, perhaps also including low 
back pain at higher doses.
At 'rst glance, translation of the results of the PainCart studies appears ambiguous. In 
chapter @ the biomarker test battery did not demonstrate acute analgesia from *+-,-. in 
healthy volunteers, even though this compound had shown analgesic e(ects in a phase 
IIa study in patients, reported in Chapter ;. Similarly (and conversely), /0-12345627 
exerted di(erent degrees of analgesia in Chapter A, but this contrasted with the negative 
'ndings of a clinical study in chronic low-back pain patients /0-12345627. 
However, the apparently incongruent 'ndings essentially illustrate how test batteries 
should be composed and used and how the results need to be interpreted. Foremost, 
this thesis shows that translation of the pharmacodynamic characterisation of centrally 
acting analgesics in healthy volunteers using evoked pain biomarkers is not unequivocal, 
as has been recognised before. The 'ndings of an early phase study using biomarkers 
should be interpreted in the correct context, acknowledging their merits and limitations. 
This includes two important aspects, which are both sensitive to .&# active drugs: 
the complexity of pain processing and the interactions with other neurocognitive and 
neurophysiological functions. 
Pain is a complex phenomenon that is by de'nition a subjective experience. 
Quantifying this subjective experience can be performed using wide range of methods, 
signifying the multifaceted nature of the concept of pain. Rating scales, including a 
Numerical Rating Scale (&D#), Visual Analogue Scale (H8#) or pictorial scales are widely 
used, but their robustness and sensitivity to intervention has been questioned. More 
comprehensive scales measuring speci'c qualitative dimensions including McGill’s Pain 
Questionnaire, the Brief Pain Inventory (9/$), or condition speci'c questionnaires are 
used to provide more insight in both a(ective and sensorial qualities of pain experience. 
To overcome to potential source of variability stemming from cognitive processing 
needed to complete such scales, more “objective” psychophysical methods can be used. 
The primary endpoints for the tasks in the multi-modal test battery are pain thresholds: 
the stimulus intensity increases linearly over time, at a certain stimulus intensity pain is 
'rst detected, the Pain Detection Threshold. The pain score is subsequently recorded 
using a H8# slider, which is moved to the other side until the Pain Tolerance Threshold 
is reached. This automatically ceases the stimulus. Since no visual or other feedback is 
provided to a subject at the point of reaching a threshold, no anchors are created. Apart 
from the experienced sensation of pain, the subject is not guided in a certain direction 
for subsequent tasks. Using this methodology provides a more robust and reliable pain 
recording, by eliminating part of cognitive processing. The test remains subject however 
to task vigilance and compliance.
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Considering that pain is a subjective experience, di(erent elements need to be 
integrated in a clinical study design. For example, using a crossover study design is 
imperative to reduce the impact of inter-individual variability. Additionally, typically 
a highly homogenous study population of Caucasian males in the same age range is 
selected during the early phases of research. These measures greatly improve the 
internal validity of a study, but may impact generalizability of study 'ndings to other 
populations. This applies to other healthy population is general, but especially to patients 
su(ering from pain. Evidently, in early phase clinical pharmacology research there are 
de'nite di(erences in the population under investigation and the patient su(ering from 
neuropathic pain who is treated eventually. For obvious ethical reasons, it is impossible 
to induce chronic neuropathic pain in a controlled clinical setting in healthy volunteers. 
Apart from the ethical reasons, this is not even desirable, because di(erent questions are 
answered at di(erent stages of clinical research. 
The questions that can be answered by using a multi-modal pain biomarker in early 
phase clinical research are abundant. By using standardised pain stimuli – compared 
with the Buctuating pain experienced by a patient – outcome measures are more robust 
and allow reliable comparison of multiple measurements over time. By executing 
assessments in a controlled environment, di(erent measures can be taken to minimise 
bias stemming from a(ect, including anxiety, uncertainty on the duration and cause of 
the experienced pain. Di(erent steps that are taken at .-!D to reduce this potential 
source of variability include the use of a standardised script for the measurement 
assistants, the subjects receive a training session before that actual measurements, 
and most importantly, the subjects themselves are responsible for starting and stopping 
the pain task. These elements are distinctively di(erent from a clinical pain patient, but 
thereby greatly improve its use as a research tool.
Applying a multi-modal pain test battery allows to investigate di(erent elements 
of the nociceptive system. The di(erentiation in underlying mechanisms results in a 
separation in pharmacodynamic response to a pharmacological agent. Comparing 
the pharmacodynamic e(ect pro'le of a novel potential analgesic to the e(ect pro'le 
of a known mechanism of action sheds new light on the (known) mechanism of action. 
Investigating the mechanism of action, or establishing a dose-response relationship 
is not only valuable for novel treatments, but clinical practice may also bene't from 
expanding knowledge on the mode of action of widely used treatments.
When this pain biomarker is combined with pharmacokinetic sampling, the 
relationship between pharmacodynamic e(ects and plasma concentration can be 
determined. A potential lag in onset of e(ect may indicate speci'c target tissue needs to 
be reached, or metabolites are formed that drive pharmacodynamic response. What is 
more, by determining these relationships as early as possible the design of a subsequent 
proof-of-concept study could be greatly improved. 
The development of analgesic drugs is greatly facilitated by incorporation of multimodal 
evoked pain models as /!-measurements in methodologically sound early human 
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drug studies. But it should also be realised that centrally active agents generally a(ect 
other central nervous systems and functions. These functions in turn can impact on 
the results of pain tests and the predictability of therapeutic doses and indications, in 
various ways. First, performance of tasks is directly a(ected by motivation and attention, 
which may be reduced by drugs that cause sedation or interfere with reward processing. 
Pain awareness can be altered –enhanced, modi'ed or reduced– by drug interactions 
with sensory information processing, including subcortical or insular projections and 
prefrontal control areas. Second, adverse .&# e(ects can limit the therapeutic window 
of potentially e(ective analgesics. For drug developers who are not an expert in pain 
pharmacology, adverse e(ects in healthy subjects have a larger ‘face validity’ than 
complicated arti'cially evoked pain models. Consequently, the selection of clinical doses 
for an early ‘proof-of-clinical-eNcacy’ study is based less on analgesia models than on 
the intensity of adverse .&# e(ects, which are either used as recognisable ‘surrogates of 
.&# penetration’ or to optimise clinical tolerability and market competitiveness.
Early development of central analgesics requires a broad assessment and proper 
integration of all relevant pharmacological characteristics of the compounds, and the 
interactions with (and between) neurophysiological processes that are involved in 
pain processing and neurocognition. In a way, this thesis failed to provide empirical 
evidence for these points, since neither the early development program of the .9G-
agonist or the partial subtype selective %898A agonist showed clear predictive value 
of early multimodal characterization in healthy subjects, for clinical eNcacy in a patient 
population. This lack of predictability may have been related to inevitable di(erences 
between healthy subjects and patients, which can only be solved by performing these 
types of multimodal studies in the target population. But before this can be concluded, 
other more feasible improvements in the early development program of central 
analgesics should be considered, particularly the proper integration of all preclinical 
and human data. This will help to carefully predict an (individualised) therapeutic dosing 
regimen that balances bene'cial and potentially detrimental e(ects, and matches 
Buctuations of symptoms or adverse e(ects. The multimodal .&# e(ect pro'le and the 
complete pharmacological characterisation of the drug may also provide support for 
selection of the most eligible patient population, by attuning the drug’s pharmacological 
properties and evoked pain response pro'le to the pathophysiological or symptomatic 
characteristics of the pain condition. In addition, secondary pharmacological properties 
and neurocognitive effects can be matched to comorbid conditions like sleep 
disturbance, mood disorders or spasticity. The predictability of early human studies 
is further increased by the use of well-characterised, pharmacologically comparable 
and therapeutically established analgesics as positive or historic controls. Several of 
these prerequisites were not suNciently ful'lled in the early development programs in 
this thesis, which may well explain their limited clinical predictive value. At the same 
time, this illustrates how essential it is to rational early drug development to integrate all 
information, and how easily practical issues and complexity tend to interfere.
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As with all models, the use of the PainCart or the NeuroCart have their intrinsic limitations. 
However, by understanding and acknowledging their strengths and weaknesses, a 
pharmacological characterisation performed using multi-modal test batteries of evoked 
pain and neurocognition can provide a deeper understanding of:
ɒ A pharmacological agent’s mechanistic mode of action;
ɒ The relationship between pharmacokinetics and pharmacodynamics;
ɒ The relationship between intended and secondary pharmacological actions. 
These very basic attributes of a drug under development should be known as early as 
possible, in order to allow for an eNcient and e(ective developmental path. Omitting 
these questions in the early phases of research may pose diNculties later on, as they will 
need to be answered eventually. 
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The studies reported in this thesis add to a body of research in which this battery of 
evoked pain tasks (PainCart) has been used as a biomarker to characterise the analgesic 
potential of eight currently marketed drugs in the treatment of various types of pain and 
various novel compounds. This extensive experience with the battery of evoked pain 
tasks is bene'cial in two ways: it provides a context that allows for comparison and 
benchmarking of the pharmacological agent under investigation against compounds 
with an established mode of action. The di(erent pain modalities deployed in the 
battery of evoked pain tasks represent di(erent elements of the nociceptive pathway 
and pain experience. Consequently each pain task demonstrates distinct sensitivity 
to pharmacological intervention. By integrating the results of the di(erent pain tasks, 
a pharmacodynamic e(ect pro'le emerges, representative for its mode of action. 
Moreover, from a di(erent perspective: the addition of six more treatments, all from 
di(erent drug classes, thus with various modes of action, enriches the biomarker itself. To 
date, a database of approximately :< pharmacological agents have been characterised. 
This includes both pharmacological agents that are marketed and agents that are still 
under development. As a result, the test battery of evoked pain tasks becomes a more 
comprehensive and informative biomarker. 
Implementing biomarkers for pain and neurophysiological functioning in early phase 
clinical research provides a better understanding of a compound’s characteristics, 
especially when used successively. Characterising a wide dose range of a novel 
compound using the neurophysiological test battery with tasks that have been shown 
to be representative for speci'c receptor pharmacology yields a neurophysiological 
pharmacodynamic e(ect pro'le that provides the insight in the relationship between 
intended and adverse e(ects. Selecting one or more dose levels that were shown to 
be pharmacologically active for further characterisation using the multi-modal pain 
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test battery con'rms the initial 'ndings of pharmacological activity. More importantly, it 
reveals valuable mechanistic information on the relationship between the concepts that 
are measured using the di(erent biomarker test batteries, creating a comprehensive 
pharmacodynamic e(ect pro'le. This knowledge will help to e(ectively design the next 
steps in clinical development.
Obviously, measuring biomarkers for pain in early phase research will not provide 
all the answers. The complete cascade of pain perception is highly complex and 
involves potential pharmacological targets throughout the complete peripheral and 
central nervous system. Chronic pain is highly heterogeneous, which makes clinical 
research complex in itself. However, even though it may be impossible to capture this 
pathology within a single model, or even a set of models, the nociceptive system remains 
a fundamental element of the cascade. Therefore, implementing the multi-modal test 
battery of evoked pain tasks to challenge this particular element from multiple angles 
provides valuable pharmacological information of an intervention.
Some treatments are known not to exert direct nociceptive analgesia but are 
e(ective in the treatment of di(erent neuropathic pain states regardless, for example 
anticonvulsants and tricyclic antidepressants. Previously, compounds of these classes 
(i.e. pregabalin and imipramine) have been investigated using the battery of evoked pain 
tasks as described in this thesis. These experiments have shown that these treatments, 
even though they would not be considered direct analgesics, did induce analgesia on 
di(erent pain tasks, analogous to /0-12345627. As demonstrated in Chapter @ of this 
thesis, the battery of evoked pain tasks in not sensitive to the e(ects of sedation alone, 
which indicates that these observations are not driven by secondary psychoactive 
pharmacodynamic e(ects. Therefore, even though the multi-modal battery of evoked 
pain tasks does not mimic a neuropathic pain patient to the complete extent, providing 
a nociceptive stimulus activates the cascade of pain perception nonetheless. This 
pharmacological sensitivity illustrates the congruence between the pathology under 
investigation and the model.
Notwithstanding the above, the absence of statistically signi'cant acute analgesia 
does not necessarily demonstrate that a pharmacological agent will be ine(ective 
in treating pain perception in a speci'c pain population. Apart from the statistical 
consideration that the lack of a statistically signi'cant di(erence with placebo is not 
evidence that the e(ect of a treatment is equal to placebo, there are other factors that 
require careful consideration when interpreting “negative” results. The most obvious 
reason is an underpowered study: due to the novel nature of an early phase clinical 
investigation, the variability is unknown at the time of initiating a study. This may have 
contributed to the observed lack of analgesic e(ect after administration of paracetamol. 
Furthermore, when benchmarking against clinical e(ects of for example a gold standard 
treatment in a patient population, the magnitude of e(ects in healthy subjects may be 
diminished, leading to more subtle e(ects. These factors increase the risk of a type II 
error, thus failing to reject a false null hypothesis. In addition to the risk of inducing more 
subtle e(ects in healthy subjects compared with patients, there is also the possibility 
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that a speci'c element of the pain cascade that is dysregulated in the pathological 
state is not susceptible for improvement in the healthy state as it is optimised. This is 
where additional pharmacodynamic pro'ling may play a role: by demonstrating that a 
drug is pharmacologically active at a certain dose level, it may still have an analgesic 
potential, even in the absence of statistically signi'cant di(erences with placebo when 
characterised using the test battery of evoked pain tasks. The results of a clinical study in 
which pharmacodynamic e(ect pro'ling is performed using biomarkers in the form of a 
multi-model test battery of pain tasks or neurophysiological tasks, provide a piece of the 
puzzle, thereby connecting the pharmacokinetic, preclinical, safety and further clinical 
pieces of the puzzle.
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Het klinisch onderzoek naar nieuwe therapieën voor de behandeling van (chronische) 
pxn beweegt zich in twee richtingen. Enerzxds worden er volledig nieuwe moleculen 
ontwikkeld,  ofwel door het optimaliseren van reeds bestaande farmaceutische 
concepten dan wel door het ontwikkelen van compleet nieuwe ‘First-in-Class’ 
geneesmiddelen. Anderzxds kunnen bestaande farmaceutische stoffen een 
bestemming krxgen voor een nieuwe indicatie. Bekende voorbeelden hiervan zxn het 
antihypertensivum clonidine, het anticonvulsivum pregabaline, en het tricyclische 
antidepressivum amitriptyline, die tegenwoordig een belangrxke plek innemen in de 
klinische praktxk van pxnbestrxding. Dat de meeste ontwikkelingen plaatsvinden in 
de tweede categorie illustreert de immense uitdagingen waar men voor staat in het 
ontwikkelen van een nieuw type geneesmiddel. 
Nociceptie versus pTn
Pxnsensatie heeft een duidelxke fysiologische functie als waarschuwingssysteem 
voor (potentiele) fysieke schade. Aangezien de dreiging van schade mogelxk directe 
actie noodzakelxk maakt, is de sensatie van pxn onlosmakelxk verbonden met mentale 
processen zoals cognitie en a(ect. De pxncascade wordt geïnitieerd vanuit het 
nociceptieve systeem. Nociceptie bestaat uit vier processen. Een pxnprikkel wordt 
door een nociceptor omgezet in een actiepotentiaal zodra de prikkeldrempel is bereikt 
(transductie). Vervolgens wordt het signaal overgedragen via speci'eke nociceptoren 
(Aɷ zenuwvezels of C-zenuwvezels) van het perifere zenuwstelsel via het ruggenmerg 
naar de hersenen (transmissie). De zenuwbanen lopen uit naar speci'eke gebieden in 
de hersenen die betrokken zxn bx ofwel het versterken dan wel het verzwakken van het 
signaal (modulatie): de hersenstam, het periaqueductaal grxs (/8%), de thalamus, maar 
ook de amygdala, hypothalamus en de cortex cingularis anterior. De totaliteit van het 
sensorisch-discriminatieve en het cognitief-a(ectieve signaal resulteert in de ervaring 
van pxn (perceptie). De overdracht, regulatie en modulatie van het oorspronkelxke 
nociceptieve signaal tot aan de daadwerkelxke perceptie vindt plaats in een cascade 
waarin verscheidene fysiologische (neurotransmitter)systemen zxn betrokken op alle 
betre(ende niveaus. Pxnperceptie is de subjectieve ervaring van het gewaarworden 
van een signaal vanuit het nociceptieve systeem. Deze perceptie is niet alleen het 
resultaat van diverse fysieke en mentale factoren, maar staat ook onder invloed van 
externe factoren waaronder cultuur, opvoeding en situatie.
Het ontwikkelen van behandeling gericht op pTnperceptie
Om de perceptie van chronische pxn te behandelen is het cruciaal om het zenuwstelsel 
in zxn totaliteit te benaderen. Daarom richten de meest e(ectieve farmacologische 
therapieën zich niet op zeer speci'eke receptoren, maar op het moduleren van 
pxnperceptie op verschillende niveaus in de pxncascade. Centrale pxnmodulatie is het 
thema van deze thesis, waarin twee zeer wxdverspreide neurotransmittersystemen 
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en farmacologische aangrxpingspunten in het centrale zenuwstelsel centraal staan. 
Het %898-erge systeem en het endocannabinoïde systeem spelen niet alleen een rol 
in pxnperceptie, maar zxn ook betrokken bx diverse andere functies van het centrale 
zenuwstelsel. Om deze reden is een geïntegreerde benadering van complementaire 
biomarkers noodzakelxk om inzicht te krxgen in het werkingsmechanisme van een 
geneesmiddel dat aangrxpt op een van deze wxdverspreide neurotransmittersystemen. 
Het gebruik van farmacodynamische biomarkers in 
geneesmiddelenontwikkeling 
In het veranderende landschap van geneesmiddelenontwikkeling op het gebied van 
pxn, lxkt het ‘blockbuster’ model, waarbx one size 6ts all geneesmiddelen voor grote 
groepen patiënten worden ontwikkeld,  op zxn einde te lopen. Er ligt een sterkere 
nadruk op het identi'ceren van subpopulaties van patiënten die ofwel meer kans 
hebben om goed te reageren op de behandeling, of juist een groter risico lopen op 
het ontwikkelen van bxwerkingen. In principe zou dit moeten leiden tot een e(ectiever 
ontwikkeltraject, met een kleiner risico op falen ten gevolge van gebrekkige werkzaam-
heid of onaanvaardbare nevenwerkingen. Een elementair onderdeel van e(ectieve 
geneesmiddelenontwikkeling, is het verkrxgen van meer kennis van het complete 
werkingsmechanisme van een nieuwe stof en van de invloed op fysiologie en pathofy-
siologie, in iedere stap van de ontwikkeling. Dit vergt een investering, maar zal uiteindelxk 
leiden tot eNciëntere geneesmiddelenontwikkeling en e(ectievere geneesmiddelen. 
      Om mechanistische kennis te genereren vanaf de vroege fase van het klinisch 
onderzoek, spelen biomarkers een cruciale rol. Een biomarker wordt gede'nieerd als 
een meetbare indicator van een normaal biologisch proces, een pathogeen proces of 
een farmacologische respons op een therapeutische interventie. 
Aangezien chronische pxn vaak leidt tot wxdverspreide verstoringen binnen de 
pxncascade, is het waarschxnlxk dat de meest e(ectieve nieuwe geneesmiddelen 
zich zullen richten op receptoren binnen het perifere en centrale zenuwstelsel. In de 
ontwikkeling van dergelxke geneesmiddelen, is het geïntegreerd meten van zowel de 
analgetische e(ecten, als de e(ecten op het centrale zenuwstelsel van grote waarde 
om inzicht te krxgen in het pro'el van gewenste en ongewenste farmacologische 
e(ecten. Met dit als doel heeft het Centre for Human Drug Research (.-!D) twee 
testbatterxen ontwikkeld, de PainCart en de NeuroCart. 
Multimodale biomarker voor pTn: PainCart 
In het licht van het bovenstaande kan de multimodale testbatterx van opgeroepen 
pxnprikkels, de PainCart, een belangrxke rol spelen in vroege fase klinisch onderzoek. 
Deze kan worden toegepast in zowel gezonde vrxwilligers als in specifieke 
patiëntenpopulaties. Ondanks dat de klinische presentatie van chronische pxn in 
geen enkele model kan worden nagebootst, kan de testbatterx van opgeroepen 
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pxnprikkels waardevolle informatie verscha(en over het werkingsmechanisme en de 
aangrxpingspunten van een geneesmiddel. Wanneer dit instrument wordt toegepast 
in een data-intensief Fase I of II onderzoek, in combinatie met frequente bepalingen 
van farmacokinetiek en veiligheid, is het mogelxk mechanistische kennis te vergaren op 
het gebied van humane farmacologie van een nieuw geneesmiddel. De waarde van de 
toepassing van dit instrument ligt in de handen van de onderzoeker en/of opdrachtgever 
van het onderzoek. Waar de beperkte overeenkomsten tussen chronische pxn, met zeer 
heterogene oorzaken en pathofysiologie, en het oproepen van pxnprikkels in gezonde 
vrxwilligers een tekortkoming lxkt, is dit eigenlxk een pluspunt. Enkele voordelen van 
het laatste zxn: een homogene populatie, gestandaardiseerde stimuli, gecontroleerde 
intensiteit en duur van de stimuli en de kwantitatieve uitkomsten die vergeleken 
kunnen worden over txd en tussen proefpersonen. (Arendt-Nielsen, :??O) Daarom is 
dit instrument uitermate geschikt voor het kwanti'ceren van speci'eke elementen van 
een systeem dat verstoord raakt wanneer er sprake is van pxn.
De PainCart is een multimodale biomarker, die bestaat uit verschillende 
complementaire pxntaken, die individueel uitgebreid zxn beschreven in eerder klinisch 
onderzoek. (Okkerse, :?=>). Oorspronkelxk bestond de PainCart uit vier taken die 
ieder een verschillende modaliteit van pxn vertegenwoordigen: koudepxn, drukpxn, 
elektrische pxn en hittepxn. De PainCart bevatte echter geen pxntaak om hyperalgesie 
te kwanti'ceren, een kenmerkend symptoom van inBammatoire pxn en neuropathische 
pxn. Daarom beschrxft hoofdstuk 1 van dit proefschrift een literatuurstudie naar de 
farmacologische sensitiviteit van hyperalgesiemodellen in gezonde vrxwilligers. Hierin 
zxn drie modellen geselecteerd op basis van frequentie van gebruik en toepasbaarheid. 
Alhoewel het capsaicine model beschreven wordt als een model voor neuropathische 
pxn, lxkt het niet gevoelig voor behandeling met geneesmiddelen uit de klasse die 
worden voorgeschreven in de behandeling van neuropathische pxn (tricyclische 
antidepressiva, calciumkanaal ɲ:-ɷ liganden). Het PH9 model voor inBammatoire pxn 
liet een sterke farmacologische sensitiviteit voor behandeling met &#8$!’s zien. Dit pleit 
voor een onderscheid tussen neuropathische hyperalgesie, die in de klinische praktxk 
nauwelxks op &#8$!’s reageert, en hyperalgesie bx ontstekingen die hiermee wel goed 
behandeld kunnen worden. Op basis van deze literatuurstudie is de PainCart uitgebreid 
met een modaliteit voor ontstekingspxn, het PH9 model.
Wanneer de PainCart wordt toegepast in een klinisch onderzoek, worden de taken 
na elkaar uitgevoerd binnen een meetronde. Voorafgaande aan de toediening van een 
behandeling (actief of placebo) wordt een meetronde uitgevoerd, die wordt herhaald 
na de toediening op txdstippen afhankelxk van het verwachte farmacokinetische 
pro'el. Om de power ten gevolge van inter-individuele variabiliteit te vergroten, wordt 
zo mogelxk een crossover onderzoeksopzet toegepast. Daarnaast wordt variabiliteit als 
gevolg van de a(ectieve componenten van pxnperceptie geminimaliseerd door middel 
van een gestandaardiseerd protocol waarin de proefpersonen zelf verantwoordelxk zxn 
voor het opstarten en afbreken van de taak. Tevens heeft iedere pxntaak een maximale 
veiligheidsgrens waardoor er geen risico is op weefselschade.
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Multimodale biomarker voor het functioneren van het centrale 
zenuwstelsel: NeuroCart
Analoog aan de PainCart wordt in dit proefschrift gebruik gemaakt van de NeuroCart, 
een multimodale cognitieve en neurofysiologische testbatterij. Deze testbatterij bevat 
diverse taken die uitgebreid zijn toegepast om speci'eke, tijd- en dosisafhankelijke 
e(ecten van geneesmiddelen te kwanti'ceren. De volgende functionele domeinen 
worden gemeten met de NeuroCart: hand-oog coördinatie, alertheid, geheugen, subjec-
tieve e(ecten, stemming en neurobiologische hersenactiviteit (elektro encefalogra'e). 
In deze thesis zxn de taken beperkt tot degene die in het verleden zxn aangetoond 
sensitief te zxn voor de e(ecten van de twee geneesmiddelen die centraal staan in 
de thesis: cannabinoïden en ɲ:/ɲ; subtype selectieve %898A receptor modulatoren. 
      In deze thesis zxn de beide testbatterxen gebruikt als biomarkers om de farma-
codynamische e(ecten in relatie tot de farmacokinetiek en veiligheidsmetingen, te 
beschrxven van potentieel nieuwe en bekende analgetica. De nadruk ligt hierbx op 
twee omvangrxke neurotransmittersystemen, het endocannabinoïde systeem en het 
%898-erge systeem. Beide systemen zxn betrokken bx een scala aan fysiologische 
functies, met receptoren verspreid over het gehele centrale en perifere zenuwstelsel. 
De uitdaging ligt in het ontwikkelen van therapieën die aangrxpen op dit systeem, dat 
bx chronische pxn mogelxk verstoord is als gevolg van pathologie, en de balans binnen 
het systeem herstellen. Doordat deze beide systeem zo wxdverspreid zxn binnen 
het zenuwstelsel is er niet alleen een kans dat de behandeling pxn vermindert, maar 
ook een risico op bxwerkingen. Om deze reden is het van grote waarde om binnen 
geneesmiddelenontwikkeling op dit gebied gebruik te maken van een gecombineerde 
benadering, waarbx zowel de farmacodynamische e(ecten op de pxn als op andere 
centraal zenuwstelsel functies, worden geïntegreerd.
Centrale modulatie van pTn: het endocannabinoïde systeem
De twee belangrxkste cannabinoïd (.9) receptoren zxn .9G en .95. De focus in 
dit proefschrift ligt op de .9G receptor die zich bevindt in het gehele zenuwstelsel. 
.9G receptoren worden gevonden in verschillende hersenstructuren waaronder de 
cortex, basale ganglia, hippocampi, cerebellum, thalamus, amygdala, /8% en medulla 
oblongata. Daarnaast worden de .9G receptoren ook gevonden in het ruggenmerg, 
voornamelxk in de interneuronen van de dorsale hoorn. Bovendien zxn .9G receptoren 
in het perifere zenuwstelsel betrokken bx signaaloverdracht van onder andere 
nociceptieve zenuwen. Als gevolg van deze verspreiding van receptoren over het 
gehele zenuwstelsel, is het endocannabinoïde-systeem betrokken bx de regulatie van 
zeer uiteenlopende fysiologische processen, van geheugen tot slaap en van gastro-
intestinale motiliteit tot pxnperceptie. 
In hoofdstuk 3 wordt een onderzoek beschreven naar een nieuwe orale formulering 
van ѐ+-,-., een exogene ligand van de .9G receptor. Hierin werden :@ patiënten 
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met (primaire of secundaire) progressieve Multiple Sclerosis (C#) met spasticiteit 
en pxn placebo-gecontroleerd behandeld gedurende een periode van @ weken. De 
werkzaamheid en secundaire e(ecten werden uitgedrukt in zowel objectieve (o.a. 
elektrofysiologische) als subjectieve uitkomstmaten (alertheid, stemming). Om tot een 
geschikte dosis te komen, werd de behandelfase voorafgegaan door een ‘challenge 
fase’, waarin een individuele e(ectieve en tolereerbare dosis werd geselecteerd. 
De objectieve uitkomstmaten lieten txdens de behandelfase geen signi'cant e(ect 
zien. Subjectieve spasticiteit daarentegen liet een verbetering zien, die statistisch 
signi'cant verschillend was van placebo na twee weken behandeling. Pxnscores 
verbeterden eveneens en lieten een statistisch signi'cante verbetering zien na : en @ 
weken behandeling.
Het farmacokinetische model toonde aan dat er sprake was van een meer variabel 
pro'el ten opzichte van eerder onderzoek dat werd uitgevoerd in gezonde vrxwilligers. 
De geobserveerde variabiliteit heeft mogelxk geleid tot meer variabiliteit in de 
farmacodynamische respons. 
Dezelfde orale formulering van ѐ+-,-. werd onderzocht in hoofdstuk 4, ditmaal in 
gezonde vrxwilligers, gebruikmakend van de PainCart. Dit onderzoek werd uitgevoerd 
in het kader van de eerder uitgevoerde farmacologische validatie van de PainCart. Het 
doel was het in kaart brengen van het analgetische pro'el van een klassiek analgeticum 
(paracetamol) en een centrale modulator van pxn (ѐ+-,-.) in vergelxking met een 
negatieve controle in de vorm van een sedativum (promethazine). Dit onderzoek werd 
placebo-gecontroleerd uitgevoerd in :@ proefpersonen gebruikmakend van een cross-
over onderzoeksopzet. 
Ogenschxnlxk tegen de verwachting in, liet paracetamol geen signi'cant analgetisch 
e(ect zien op de pxntaken van de PainCart. Behandeling met ѐ+-,-. vertoonde 
eveneens geen acuut analgetisch e(ect en er leek zelfs sprake van hyperalgesie op 
twee van de vxf pxnmodaliteiten, elektrische pxn en drukpxn. Na de behandeling 
met promethazine werd eveneens een toename in pxnsensitiviteit geconstateerd: 
gevoeligheid voor koudepxn, drukpxn en inBammatoire pxn nam toe. Naast de PainCart, 
werden ook enkele taken van de NeuroCart uitgevoerd, alwaar behandeling met 
ѐ+-,-. en promethazine duidelxke subjectieve e(ecten lieten zien op alertheid en 
veranderde waarneming. 
Dit onderzoek toonde opnieuw aan hoe complex het werkingsmechanisme van 
paracetamol is en dat het nog steeds niet volledig is ontrafeld, ondanks dat het behoort 
tot de meest gebruikte analgetica wereldwxd. Tevens toonde het onderzoek aan dat 
ѐ+-,-. geen acuut e(ect heeft op pxndrempels van nociceptieve pxndrempels, 
ofschoon het in verschillende situaties een analgetisch e(ect kan bewerkstelligen. In 
combinatie met de bevindingen uit Hoofdstuk 3 onderschrxft dit onderzoek de notie 
dat herhaaldelxk toedienen van ѐ+-,-. leidt tot een geleidelxk farmacodynamisch 
e(ect dat de perceptie van pxn of spasticiteit behandelt, en niet een acuut e(ect 
bewerkstelligt op nociceptie of elektrofysiologisch meetbare uitkomstmaten. 
Bovendien toonde dit onderzoek de speci'citeit van de PainCart aan op het gebied van 
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analgetische interventie, aangezien pxndrempels niet verhoogd werden door sedatie 
zoals geïnduceerd door promethazine.
Centrale modulatie van pTn: het RP#P systeem
Gamma-aminoboterzuur (%898) is de voornaamste remmende neurotransmitter in het 
centrale zenuwstelsel. Er zxn twee types %898 receptoren, en de focus in dit proefschrift 
ligt op het type %898A. Dit zxn pentamerische ionotrope receptoren, waarvan de meer 
dan :? subtypes zxn opgebouwd uit verschillende combinaties van de subeenheden 
ɲ=-A, ɴ=-@, ɶ=-;,ɷ, ɸ,ʍ. Er is sprake van een grote heterogeniteit in functie van de diverse 
subtypes, wat gereBecteerd wordt in de distributie van de verschillende subtypes 
over diverse anatomische locaties binnen het centrale zenuwstelsel. Hierdoor zxn de 
verschillende subtypes geassocieerd met verschillende speci'eke neurofysiologische 
functies. Het ɲ= subtype bxvoorbeeld, is geassocieerd met sedatie en amnesie, waar de 
subtypes ɲ: en ɲ; in grotere mate betrokken zxn bx anxiolyse en de modulatie van pxn, 
en het ɲ< subtype bx geheugenfuncties. 
Hier volgt de beschrxving van twee humane onderzoeken waarin voor het 
eerst de beide biomarkers, NeuroCart en PainCart, werden geïntegreerd om het 
farmacodynamische e(ect van een centraal werkend geneesmiddel te beschrxven. 
Dit betreft /0-12345627, een nieuwe partiële %898A ɲ:/ɲ;/ɲ< subtype-selectieve 
positieve allostere modulator die wordt ontwikkeld voor verschillende indicaties, 
waaronder angststoornissen, neuropathische pxn en epilepsie. In Hoofdstuk 5 wordt 
een tweedelig First-in-Human onderzoek in gezonde vrxwilligers beschreven, dat werd 
uitgevoerd in een partiële cross-over onderzoeksopzet. Het doel van het eerste deel 
was het bestuderen van een groot bereik aan doseringen, om inzicht te krxgen in de 
veiligheid, de farmacodynamiek (/!) en farmacokinetiek (/p). Op basis hiervan werden 
twee doseringen geselecteerd (=< en A< mg) voor een directe vergelxking met de non-
selectieve positieve allostere modulator van de %898A receptor, lorazepam (:mg), in 
het tweede deel van het onderzoek. De vergelxking met zowel placebo als lorazepam 
(: mg), als de combinatie van /0-12345627 met lorazepam, toonde een di(erentieel 
pro'el per receptor subtype van competitieve en non-competitieve receptorinteractie, 
zonder synergie. Afhankelxk van het functionele domein, werden er additieve of infra-
additieve farmacodynamische e(ecten gevonden, in lxn met de voorspelde functionele 
selectiviteit voor de ɲ:/ɲ;/ɲ< subtypes. Zo werd er een additief e(ect gevonden op die 
taken die activiteit op ɲ:/ɲ; receptor subtypes vertegenwoordigen. Daarnaast werd 
het e(ect van lorazepam (:mg) uitgedoofd op taken die %898A ɲ= receptor subtypes 
vertegenwoordigen, mogelxk doordat /0-12345627 werkt als een antagonist ten 
opzichte van het /! e(ect van lorazepam, als gevolg van lage intrinsieke activiteit 
voor het %898A ɲ= receptor subtype. De bevindingen over de wisselwerking tussen 
intrinsieke activiteit en receptoraNniteit illustreren niet alleen de receptorfarmacologie 
van /0-12345627, maar ook die van %898A ɲ:/ɲ;/ɲ< subtype-selectieve positieve 
allostere modulators in het algemeen. 
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Gebaseerd op bovenstaande uitvoerige farmacologische karakterisering, werden 
twee doseringen geselecteerd om het analgetische e(ectpro'el van /0-12345627 in 
kaart te brengen. Hoofdstuk 6 beschrijft een dubbelblind, placebo-gecontroleerd, 
cross-over onderzoek in gezonde vrijwilligers naar de e(ecten van twee enkelvoudige 
doseringen (=< mg en A< mg) van /0-12345627, in vergelijking met pregabaline (;?? 
mg) als positieve controle. Farmacodynamische metingen werden uitgevoerd met de 
biomarker testbatterij van opgewekte pijnprikkels, de PainCart, en /p werd bepaald. 
De behandeling met /0-12345627 resulteerde in een analgetisch e(ect, waarbij 
een dosering van A< mg een statistisch signi'cant e(ect vertoonde op de taak voor 
koudepijn, en beide doseringen op de taak voor drukpijn. Behandeling met pregabaline 
produceerde eveneens een analgetisch e(ect op de taken voor koudepijn en drukpijn. 
Vanuit een mechanistisch perspectief is het lastig om de bevindingen op de pijntaken 
van dit onderzoek te vertalen naar een neuropathische pijnpatiënt. Het onderzoek 
illustreert echter eenduidig dat /0-12345627 het vermogen bezit om analgesie te 
induceren, in doseringen die geen ernstige sedatie of andere bijzondere bijwerkingen 
veroorzaken.
(!).-))!$  $"  .+".3-)!$) 
De sensatie van pijn is een complex en veelzijdig proces waarbij verschillende centrale 
en perifere neurotransmittersystemen betrokken zijn. Deze thesis beschrijft de 
vroege klinische ontwikkeling van twee analgetica die werken op respectievelijk de 
endocannabinoïde .9G receptoren en ɲ:/ɲ;/ɲ< subtypes van %898A . Voor beide zijn 
de neurofysiologische en analgetische e(ecten pro'elen in kaart gebracht om inzicht 
te bieden in de complexe wisselwerking tussen .&# demping, acute nociceptie en 
de ervaring van pijn. De integratie van deze bevindingen helpt bij het bepalen van de 
therapeutische index, mogelijke bijwerkingen en mogelijke indicatiegebieden voor 
toekomstige klinische onderzoeken. 
Op het eerst gezicht lxkt de vertaling van de resultaten van de onderzoeken 
gebruikmakend van de PainCart niet ondubbelzinnig. De schxnbaar incongruente 
bevindingen illustreren echter exact op welke manier de biomarker testbatterx moet 
worden toegepast en geïnterpreteerd. Zoals al eerder beschreven: de vertaling van 
opgewekte pxnprikkels in gezonde vrxwilligers naar speci'eke patiëntenpopulaties is 
niet eenvoudig of eenduidig. Bevindingen kunnen niet direct worden geëxtrapoleerd, 
maar dienen te worden geplaatst in de juiste context, met inachtneming van de waarde 
en de beperkingen van nociceptieve tests. Voor geneesmiddelen die werkzaam zxn in 
het centrale zenuwstelsel zxn twee aspecten hierin van belang: de complexiteit van pxn 
en mogelxke interacties met andere neurofysiologische functies. 
De voordelen van het gebruik van biomarkers voor pxn om mechanistische kennis te 
vergaren ten opzichte van onderzoek in patiënten zxn uiteenlopend: gestandaardiseerde 
eindpunten, minder variabiliteit in pxn en daardoor meer statistische power, meer 
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robuust, betrouwbaar herhaaldelxk te meten, minder bias als gevolg van de a(ectieve 
componenten van de pxncascade en de mogelxkheid om speci'eke elementen van het 
nociceptieve systeem te bestuderen. Daarnaast is in het verleden aangetoond dat de 
pxntestbatterx sensitief is om reductie van pxnperceptie te detecteren, door analgetica 
die niet bekend staan als directe nociceptieve pxnstillers, zoals pregabaline of 
imipramine. Het huidige proefschrift heeft bovendien aangetoond dat deze testbatterx 
geen analgetische e(ecten toont van pure sedativa, zoals promethazine. 
Vanzelfsprekend zxn er ook beperkingen aan het gebruik van humane pxnmodellen. 
Allereerst lxkt het veelvormige klinisch beeld van neuropathische pxn niet na te 
bootsen in een gezonde vrxwilliger. Vanuit ethisch perspectief is het evident dat het 
opwekken van chronische pxn niet mogelxk is. Daarnaast creëert streng gecontroleerd 
onderzoek in een zeer homogene populatie mogelxk een hogere sensitiviteit, waardoor 
subtiele signalen kunnen worden gedetecteerd, die niet waarneembaar zxn in een 
patiëntenpopulatie. Anderzxds kunnen potentiele farmacodynamische e(ecten gemist 
worden, doordat de pathofysiologie samenhangt met dysregulatie in het systeem. 
Hierdoor reageert het gezonde zenuwstelsel niet op dezelfde wxze op farmacologische 
interventie. Mogelxk kunnen aanvullende biomarkers dan een rol spelen om inzicht te 
verscha(en in de farmacodynamiek van een geneesmiddel. 
Wanneer de metingen van de multimodale biomarker voor pxn worden geïntegreerd 
met de karakterisering van neurocognitieve en neurofysiologische e(ecten, ontstaat 
een completer beeld van de farmacodynamiek van een pxngeneesmiddel. Dit inzicht 
in de humane farmacologie vormt het stuk van de puzzel dat nodig is om de andere 
stukken, zoals farmacokinetiek, veiligheid en preklinisch onderzoek, met elkaar te 
verbinden.
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